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Chapter 1 Introduction 
 
This chapter concentrates on the definition and 
importance of naturally occurring cyclotides, the 
biosynthesis of cyclotides, and general aspects of 
serine proteases, including their inhibitors. 
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1.1 What is a Macrocyclic cysteine knot microprotein (Cyclotides)? 
Cyclotides (cyclic peptides), are classified as cyclic microproteins of up to 37 
amino acids (Broussalis et al., 2001; Chen et al., 2005a; Chen et al., 2006; Clark, 
Daly & Craik, 2006). Cyclotides have a unique scaffold comprising of a cyclic 
peptide backbone and three conserved disulfide bonds arranged in the cysteine knot 
topology as shown in Figure 1.1 (Cemazar et al., 2006; Felizmenio-Quimio, Daly 
& Craik, 2001); this conformational rigidity imparts great thermal and proteolytic 
stability (Colgrave & Craik, 2004; Heitz et al., 2008), suggesting that cyclotides 
have the potential to play an important role as protein drug scaffolds in drug 
discovery and pharmaceutical applications (Craik, Simonsen & Daly, 2002). 
Cyclotides have been isolated from plants of the Cucurbitaceae (Felizmenio-
Quimio et al., 2001; Hernandez et al., 2000), Rubiaceae and Violaceae families 
(Craik et al., 1999; Goransson, Broussalis & Claeson, 2003; Gustafson, McKee & 
Bokesch, 2004; Trabi & Craik, 2004), and display diverse and interesting biological 
activities ranging from anti-insecticidal activity to anti-HIV activity and anti-
bacterial activity (Daly, 1999; Gustafson et al., 1994; Lindholm et al., 2002; Tam et 
al., 1999a; Witherup et al., 1994). The sequence of a few representative cyclotides 
is shown in Table 1.1 (page 24). 
 
 
 
Figure 1.1 Cyclic cysteine knot scaffold in cyclotides  
The cyclotide structure features a combination of a head-to-tail cyclic backbone and cysteine knot 
arrangement of three disulfide bonds in which Cys (I) – Cys (IV) and Cys (II) – Cys (V) form a ring 
that is penetrated by the third disulfide bond [Cys (III) – Cys (VI)]. Picture is adapted from 
www.cyclotides.com. 
I
IV
III
II
V
VI
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Cyclotides have also been shown to be important in some traditional medicines. An 
extract from the plant Oldenlandia affinis has been used widely as an utereonic 
agent to accelerate child birth (Gran, Sandberg & Sletten, 2000). The active 
ingredient was later characterised as the 29-amino acid cyclic peptide, Kalata B1 
(Saether et al., 1995; Trabi & Craik, 2002)  
 
To date, more than 50 cyclotides have been discovered by characterising their head-
to-tail cyclisation and cysteine knot motifs (Craik et al., 1999; Simonsen et al., 
2005; Trabi & Craik, 2002). Interestingly, cyclotides comprised of fewer than 15 
amino acids generally lack the disulfide bond, which leads to a lack of well-defined 
three dimensional structure, meaning that a only cyclic motif is observed (Craik et 
al., 2003; Luckett et al., 1999). Examples of cyclotide sequences from Violaceae 
and Rubiaceae families are shown in Figure 1.2.  
 
A) 
   I 
 
II 
 
III 
 
IV 
 
V 
 
VI  
Violaceae 
 
Cycloviolin C 
(Leonia cymosa) 
 
GIP·· C GES C VFIP· C LTTVA·G C S C ···KNKV C YRN 
Varv A 
(Viola arvensis) GLPV· C GET C VGGT· C N·T··PG C S C ···SWPV C TRN 
 
Hypa A 
(Hybanthus parviflorus) 
 
GIP·· C AES C VYIP· C TITALLG C S C ···KNKV C Y·N 
Rubiaceae 
 
Cyclopsychotride 
(Psychotria longipes) 
 
SIP·· C GES C VFIP· C TVTALLG C S C ···KSKV C YKN 
 
Circulin A 
(Chassalia parviflora) 
 
GIP·· C GES C VWIP· C I·SAALG C S C ···KNKV C YRN 
 
Palicourein  
(Palicourea condensate) 
 
GDPTF C GET C RVIPV C TYSAALG C T C DDRSDGL C KRN 
 
Kalata B1 
(Oldenlandia affinis) 
 
GLPV· C GET C VGGT· C N·T··PG C T C ···SWPV C TRN 
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Figure 1.2 The cyclotide sequences from Violaceae and Rubiaceae (A) and the structure of Kalata 
B1 (B).  
 
Peptides displayed in Table (A) are head-to-tail cyclised peptides in which the sequences are written 
starting from the presumed N-terminal cleavage point in the linear precursors. A ribbon diagram (B) 
represents the cyclotide framework based on the structure of Kalata B1 with the cysteine knot core 
(Yellow), and a connecting point (Gly-Asn) is shown. Picture is adapted from  (Simonsen et al., 
2005).  
 
 
 
Most plant cyclotides shown in Figure 1.2 exhibit the distinctive cysteine knot 
scaffold together with the cyclic motif, which contributes to their great thermal and 
proteolytic stability (Colgrave & Craik, 2004). Plant cyclotides tend to be markedly 
different relative to circular proteins found in microorganisms (Craik et al., 2003) 
and animals in terms of their structures. Some examples of circular proteins found 
in microorganisms and animals are shown in Figure 1.3. 
 
  
B) 
G 
N 
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Figure 1.3 Three-dimentional structure of naturally occurring proteins.  
Clockwise from the upper left proteins are: bacteriocin AS-48 (A) from Enterococcus faecalis, 
Microcin J25 (B) from Escherichia coli, MCoTI-II (C) from bitter melon seeds, RTD-1 (D) from the 
leukocytes of Rhesus macaques, Kalata B1 (E) from several plants of the Rubiaceae and Violaceae 
plant families, and SFTI-1 (F) from the seeds of the sunflower. Disulfide bonds are shown in yellow. 
Picture is adapted from (Trabi & Craik, 2002) 
 
Bacteriocin AS-48, Microcin J25 and RTD-1 are naturally occurring circular 
proteins found in microorganisms and animals. Bacteriocin AS-48 from 
Enterococcus faecalis consists of 70 amino acids, and has shown potent anti-
microbial activity (Martinezbueno et al., 1994). Its three-dimensional structure 
contains five α-helices linked by five short turns, and the head-to-tail linkage as 
seen in Figure 1.3, rendering it considerably stable against thermal denaturation 
(Trabi & Craik, 2002). Microcin J25 from E.coli is a highly hydrophobic, circular 
protein with 21 residues, showing a broad spectrum of anti-microbial activity 
(Blond et al., 1999). Its circular backbone is critical for this activity, proven by 
studies that show the linear form of microcin J25 has no measurable anti-microbial 
activity (Blond et al., 1999).  
D 
C 
B 
A 
F 
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A distorted antiparallel β-sheet is a distinct characteristic of the three dimensional 
structure. Rhesus theta defensin-1 (RTD-1) from leukocytes of rhesus macaques is 
composed of 18 amino acids, with six cysteine residues (Tang et al., 1999). The 
three dimensional structure of RTD-1 indicates that two β-strands and two turns are 
the major element of RTD-1 scaffold (Trabi & Craik, 2002). The three disulfide 
bonds are arranged in a ladder-like structure, contrary to those observed in the 
cyclotides, which form the so-called “cysteine knot” scaffold. This ladder-like 
structure seems to be relatively flexible compared to that observed in cyclotides 
(Trabi, Schirra & Craik, 2001).  
 
Naturally occurring circular proteins in plants were first discovered in the mid-
1990s. Circulins A and B are an example of circular proteins in plants, initially 
discovered in the screening of anti-HIV activity (Gustafson et al., 1994). It has been 
observed that the size of circular proteins in plants varies according to their species 
and family. Sunflower trypsin inhibitor-1 (SFTI-1) is a small inhibitor with 14 
amino acids, and is also classified as a Bowman-Birk family inhibitor, a family of 
small serine protease inhibitors found in several plants (Luckett et al., 1999). Its 
three dimensional structure shows that SFTI-1 is comprised of two antiparallel β-
strands and one disulfide bond (Trabi & Craik, 2002) as seen in Figure 1.3. 
 
Kalata B1 was the first cyclotide containing a cyclic cysteine knot (CCK) scaffold 
to have its three dimensional structure determined. This CCK motif consists of a 
small embedded ring generated by two disulfide bonds that is penetrated by the 
third disulfide bond together with a cyclic backbone motif (Saether et al., 1995). A 
small triple-stranded β-sheet has been found in this CCK motif, rendering Kalata 
B1 extremely resistant to thermal denaturation and enzymatic hydrolysis (Craik et 
al., 1999). In addition, Kalata B1 was found to have insecticidal activity (Jennings 
et al., 2001; Wang et al., 2009). 
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It is interesting to note that the CCK scaffold is distributed extensively within 
Cucurbitaceae, Rubiaceae and Violaceae families. Recently, two cyclotides from 
the Cucurbitaceae plant family have been reported, known as Momordica 
cochinchinensis trypsin inhibitor I (MCoTI-I) and Momordica cochinchinensis 
trypsin inhibitor II (MCoTI-II) (Hernandez et al., 2000). These two disulfide-rich 
proteins are among the most potent trypsin inhibitors to date, with an inhibition 
constant in the low-picomolar range. This is described in detail in the next section.  
 
1.2 The MCoTI family cyclotides 
MCoTI-I and MCoTI-II are naturally occurring polypeptides, extracted from the 
seeds of Momordica cochinchinensis (see Figure 1.4), a member of the 
Cucurbitaceae plant family found widely in tropical regions. These are the only 
known cyclotides of the squash trypsin inhibitor family, comprising of 34 amino 
acids (Felizmenio-Quimio et al., 2001; Heitz et al., 2001). This plant polypeptide is 
composed of a cyclic backbone and a knotted arrangement of three disulfide bonds, 
providing well-defined architecture and exceptional stability. MCoTI-I and MCoTI-
II exhibit very potent trypsin inhibition (Ki = 30 – 100 pM). 
 
 
 
 
Figure 1.4 Image of the Momordica cochinchinensis plant 
(Source: www.stuartxchange.org). 
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The NMR structure of MCoTI-II has been elucidated, comprising of a well defined 
β-hairpin (Felizmenio-Quimio et al., 2001), with three disulfide bonds arranged in a 
cysteine knot. The structure and sequence of MCoTI-II is shown in Figure 1.5 
(Avrutina et al., 2005); the embedded ring formed by two disulfide bonds that is 
penetrated by the third disulfide bond altogether with cyclic motif (Felizmenio-
Quimio et al., 2001; Heitz et al., 2001). A list of known cyclotides and their amino 
acid sequence is shown in Table 1.1. 
 
 
 
Figure 1.5 Structure and sequences of MCoTI-I, II and III 
 
(A) Schematic representation of three dimensional structure of MCoTI-II: cyclic cysteine knot 
scaffold found in MCoTI-II cyclotide is formed by two disulfide bonds that are penetrated by the 
third disulfide bond. (B) Amino acid sequences of the naturally occurring microproteins MCoTI-I, II 
and III, <E refers to the amino-terminal pyro-Glu of MCoTI-III. 
A 
MCoTI-I: cyc. -SGSDGGVCIPKILQRCIIRRDSDCIIIPGACIVICVRGNGYCVIG 
MCoTI-II: cyc. -SGSDGGVCIPKILKKCIIRRDSDCIIIPGACIVICVRGNGYCVIG 
MCoTI-III:          <ERACIPRILKKCIIRRDSDCIIIPGECIVICVKENGYCVIG 
 
B 
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Table 1.1 Examples of discovered cyclotides and their sequences 
 
 I Loop 1 II Loop 2 III Loop 3 IV * V Loop 5 VI Loop 6 
Cycloviolacin O1 
· C A E S C V Y I P C T V T A L L G C S C · S N R V C Y · N G · I P 
Cycloviolacin O2 
· C G E S C V W I P C I S S A · I G C S C · K S K V C Y R N G · I P 
Cycloviolacin O3 
· C G E S C V W I P C L T S · · I G C S C · K S K V C Y R N G · I P 
Cycloviolacin O4 
· C G E S C V W I P C I S S A · I G C S C · K N K V C Y R N G · I P 
Cycloviolacin O5 
· 
C G E S C V W I P C I S S · · V G C S C · K N K V C Y K N G T · P 
Cycloviolacin O6 
· 
C G E S C V W I P C I · S A · V G C S C · K S K V C Y K N G T L P 
Cycloviolacin O7 
· C G E S C V W I P C T I T A · A G C K C · K S K V C Y · N G · I P 
Cycloviolacin O8 
· C · E S C V W I P C I S S · · V G C S C · K S K V C Y K N G T L P 
Cycloviolacin O9 
· C G E S C V W I P C L T S A · · G C S C · K S K V C Y R N G · I P 
Cycloviolacin O10 
· C G E S C V Y I P C L T S A V · G C S C · K S K V C Y R N G · I P 
Cycloviolacin O11 
· C G E S C V W I P C I · S A V V G C S C · K S K V C Y K N G T L P 
Cycloviolacin H1 
· C G E S C V Y I P C L T S A V I G C S C · K S K V C Y R N G · I P 
Kalata B5 
· C G E S C V Y I P C I S G V I · G C S C · T D K V C Y L N G T · P 
Circulin A 
· C G E S C V W I P C I · S A A L G C S C · K N K V C Y R N G · I P 
Circulin B 
· 
C G E S C V F I P C I S T 
· 
L L G C S C 
· 
K N K V C Y R N G V I P 
Cyclopsychotride A 
· 
C G E S C V F I P C 
· 
V T A L L G C S C 
· 
K S K V C Y K N S 
· 
I P 
Violapeptide 1 V C G E T C V G G T C · · · N T P G C S C · S R P V C T X N G · L P 
Cycloviolacin I C G E T C V G G T C · · · N T P G C S C · S W P V C T R N G · L P 
Kalata B1 V C G E T C V G G T C · · · N T P G C T C · S W P V C T R N G · L P 
Kalata B2 V C G E T C F G G T C · · · N T P G C S C · T W P I C T R D G · L P 
Kalata B3 T C G E T C F G G T C · · · N T P G C T C D P W P I C T R D G · L P 
Kalata B4 V C G E T C V G G T C · · · N T P G C T C · S W P V C T R D G · L P 
Kalata S V C G E T C V G G T C · · · N T P G C S C · S W P V C T R N G · L P 
Varv peptide A V C G E T C V G G T C · · · N T P G C S C · S W P V C T R N G · L P 
Varv peptide B V C G E T C F G G T C 
· · · 
N T P G C S C D P W P M C T R N G 
· 
L P 
 
This table displays some of discovered cyclotides, and their sequences consisting of three disulfide bonds arranged as following, Cys (I)-Cys (IV), Cys (II)-Cys (V) and 
Cys (III)-Cys (VI). Table is adapted from www.cyclotides.com. *: loop 4 
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The inhibitory activity of MCoTI-II against trypsin is not only governed by the 
cysteine knot scaffold, but also by the cyclic motif. It was shown by Avrutina et al. 
(Avrutina et al., 2005) that the cyclic motif of MCoTI-II makes a significant 
contribution to trypsin inhibitory activity. This was indicated by the open chain 
MCoTI-II synthesised also exhibiting trypsin inhibition, but with an inhibition 
constant approximately 10-fold lower compared to wild-type MCoTI-II. This 
contribution of the cyclic motif to biological activity has also been studied 
extensively with other peptides, such as Kalata B1, which shows anti-HIV activity 
if the cyclic motif is present within the molecule, whilst acyclic Kalata B1 is 
inactive (Avrutina et al., 2005). 
 
Additionally, the contribution of basic residues within the inhibitory loop was also 
investigated by the replacement of Lys14 (P4’ residue) with Arg or Ala, and it was 
discovered that the replacement of Arg and Ala at Lys13 (P3’ residue) and Lys14 
(P4’ residue) slightly affected trypsin inhibition. However, it was observed that the 
substitution of Lys10 (P1 residue) by Ala completely abolished the trypsin 
inhibition activity (Avrutina et al., 2005). This is described further in the section on 
protease inhibition (Chapter 4). 
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1.3 The Biosynthesis of Cyclotides 
To date, relatively little is known about the biosynthesis of cyclotides, and precisely 
how cyclotides are produced in vivo remains an unanswered question. Nevertheless, 
it has long been known that cyclotides are true gene-products and the presence of 
cyclotides in plants has led to the question of what biological functions they 
perform. It is important to note that isolated plant cyclotides are fundamentally 
distinct from the small cyclic proteins commonly found in microorganisms in that 
the latter are much smaller (typically composed of 5-10 amino acids in length with 
no disulfide bonds) and are normally synthesised by multienzyme complexes 
(Bordusa, 2001).  
 
 
 
 
Figure 1.6 The schematic representation of Kalata B1 biosynthesis  
 
(A) The schematic organisation of O. affinis gene Oak 1, consisting of the endoplasmic reticulum 
signal (ER signal) labelled in pink, N-terminal precursor domain (NTPD) labelled in green, N-
terminal repeat (NT) labelled in red, cyclotide domain labelled in orange and a short C-terminal tail 
region labelled in blue. (B) The schematic representation of amino acid sequences of the protein 
encoded by Oak1 clone, and G and N residues at N- and C-terminus in cyclotide domain where the 
cyclisation occurs. Pictures are adapted from (Jennings et al., 2001; Saska et al., 2007). 
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In contrast, cyclotides found in plants are true gene proteins that are ribosomally 
synthesised (Daly et al., 2006). The precise biosynthesis mechanism of cyclotides 
in higher organisms is not yet clear, but it is thought that plant cyclotides are 
produced by the excision of larger linear precursors encoded by gene sequences 
(Gustafson et al., 2004; Jennings et al., 2001).  
 
Recently, genes encoding Kalata B1 cyclotides from Oldenlandia affinis, named 
Oak1, have been discovered, encoding a precursor protein of Kalata B1 as shown in 
Figure 1.6 (Jennings et al., 2001). Kalata B1, a cyclotide of 29 amino acids, 
displays a wide range of biological activity, ranging from anti-insecticidal activity 
to anti-HIV activity.   
 
The function of the N-terminal precursor domain (NTPD) and N-terminal repeat 
(NTD) within Oak1 (Figure 1.6) is not clear, but it has been suggested that it 
displays an essential role in excision and ligation of the cyclotide domain. Notably, 
comparison between cyclotide sequences and cyclotide precursors has led the N- 
and C-terminal side of the cyclotide domains within the precursor to be identified 
(Daly et al., 2006; Jennings et al., 2001). The Kalata B1 precursor shown in Figure 
1.6 is an example, suggesting that the cyclisation involves ligation at the Asn-Gly 
peptide bond to form a loop.  
 
The processing steps involved in producing cyclotides indicate that cyclotides must 
be excised from the linear precursor proteins, but whether the excision and 
cyclisation occur together or sequentially remains unclear (Jennings et al., 2001; 
Trabi & Craik, 2002). Also, it is important to note that the function of cyclotides in 
plants appears to be as defence molecules since they exhibit potent insecticidal 
activity in some cases, such as Kalata B1, which prevents the growth and 
development of larvae from the Lepidopteran species H.punctigera (Jennings et al., 
2001). Defence molecules in plants are commonly found to be cysteine-rich 
proteins (Craik et al., 1999). 
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The production of cyclotides in plants has inspired the production of cyclotides by 
non-enzymatic process. The molecular biology technique of DNA expression may 
also be applied to cyclotide synthesis, which is described in the following section. 
 
1.4 The Biosynthesis of Cyclotides in Living Bacterial Cells   
Recently, the biosynthesis of cyclotides inside living bacterial cells has been 
published by Camarero et.al. utilising recombinant DNA expression techniques, 
with the use of engineered protein-splicing units called inteins (Camarero et al., 
2007). This approach involves intramolecular native chemical ligation (NCL) of a 
linear cyclotide precursor to produce the head-to-tail or backbone cyclisation as 
shown in Figure 1.7. NCL is a technique that may be employed in synthesising 
large proteins, involving a chemoselective reaction between a C-terminal thioester 
and an N-terminal cysteine. In the case of cyclotide synthesis, an N-terminal 
cysteine residue and a C-terminal thioester in the same linear precursor are 
required. The details of NCL are further described in Chapter 2.  
  
  
Chapter 1 Introduction 
29 
 
 
 
Figure 1.7 The biosynthetic approach for the production of cyclotide MCoTI-II inside E.coli cells  
 
All reactions occur in E.coli. The backbone cyclisation is mediated by a modified protein-splicing 
unit (or intein) upon cleaving Met by endogeneous Met aminopeptidase, and the cyclised product 
subsequently folds in the bacterial cytoplasm. Picture is adapted from (Camarero et al., 2007) 
 
As seen in Figure 1.7, a recombinant protein is initially expressed in which the 
linear cyclotide precursor is fused in-frame at its C- and N-termini to a modified 
intein and a Met residue respectively. The presence of Met at the N-terminal of the 
cyclotide linear precursor allows a free N-terminal Cys residue to be generated after 
cleavage by endogenous Met amino peptide (MAP). This is followed by backbone  
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cyclisation and oxidative folding. This approach can be applied to the biosyntheses 
of Kalata B1 and MCoTI-II cyclotides (Camarero et al., 2007). Following cell lysis, 
folded MCoTI-II is isolated from the soluble cellular fraction by affinity 
chromatography using trypsin-agarose beads. However, binding partners for 
affinity chromatography for Kalata B1 have not yet been established, which makes 
the isolation step of this cyclotide difficult (Camarero et al., 2007).  
 
The main drawback of this biosynthesis approach is the low overall yield of the 
cyclisation and refolding processes (Camarero et al., 2007). Therefore, chemical 
syntheses, for example solid phase peptide syntheses (SPPS) together with thia-zip 
native chemical ligation (NCL), may be a more efficient approach that can be 
applied to the syntheses of macrocyclic cysteine rich proteins such as MCoTI-I and 
MCoTI-II. 
 
In this thesis, the syntheses of MCoTIs cyclotides are studied with the aim to 
broaden their biological activities against a variety of proteases. Thus, the following 
section will discuss some serine proteases addressing this work, including some 
examples of serine protease inhibitors and their mechanisms of action.  
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1.5 Proteases 
Proteases (also called proteinases, or proteolytic enzymes), are found widely in all 
organisms and are known to play a vital role in diverse physiological functions, 
ranging from the simple digestion of food protein (via the cleavage of the peptidic 
bond) to highly-regulated cascade reactions in living organism, such inflammation, 
complement phenomena, cell fusion, cell proliferation, immunity, tumorgenesis and 
metastasis (Barrett, Rawlings & Woessner, 1998; Hedstrom, 2002). 
 
Proteases are classified into two main types, exopeptidases and endopeptidases, 
according to their action of cleaving an amino acid in a polypeptide chain (Beynon, 
2000): 
 
 Exopeptidases are proteolytic enzymes that catalyse the hydrolysis of an amino 
acid from the end of a polypeptide chain; aminopeptidases and 
carboxypeptidases are the main examples of exoproteases, which cleave from 
the N-amino terminal and C-carboxylic terminal of peptide bonds respectively. 
 
 Endopeptidases are proteolytic enzymes that catalyse the cleavage of non-
terminal amino acids within protein molecules. Examples of endopeptidases 
include trypsin, chymotrypsin, caspase and elastase.  
 
Typically, proteolytic enzymes are classified according to the chemical nature of 
these catalytic sites in which the substrate specificity is largely governed by the 
properties of binding sites responsible for the hydrolysis of peptidic bonds. There 
are currently six distinct categories, namely serine protease, cysteine (thio) 
proteases, aspartic proteases, metallo proteases, threonine proteases and glutamic 
proteases (Barrett et al., 1998). This work in this thesis focusses on the serine 
proteases.  
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The catalytic mechanisms of each protease varies greatly (Beynon, 2000). Serine 
and cysteine proteases display similar catalytic mechanisms, with the hydroxy and 
thiol groups of a serine or cysteine side chain forming a covalent complex with the 
enzyme (known as an acyl-enzyme intermediate). However, for aspartic and 
metallo proteases, covalent enzyme complexes are not observed.  
 
In addition, serine and cysteine proteases possess a strongly nucleophilic oxygen or 
sulphur at their catalytic sites that align with a hydrogen bond acceptor. This is 
thought to increase oxygen and sulphur nucleophilicities (Beynon, 2000). 
Therefore, serine and cysteine protease inhibitors can involve the introduction of 
electrophilic groups, such as Michael acceptors, carbonyls, or alkyl halides in order 
to form a covalent bond with the oxygen or sulphur nucleophiles (Powers et al., 
2002).  
 
1.5.1 Serine Proteases 
Serine proteases are the most widely studied proteases so far, and are involved in 
many critical physiological processes, such as blood coagulation, fribrinolysis, 
kinin formation, immunity and metastasis (Barros, Crosby & Moreno, 1996; 
Coughlin, 2000; Dodson & Wlodawer, 1998; Hedstrom, 2002; Johnson, 2000; 
Joseph, Ghebrehiwet & Kaplan, 2001; Neurath, 1984). Currently, a third of all 
documented proteases are serine proteases.     
 
Serine proteases can be catagorized into four main clans according to their topology 
(Barrett et al., 1998).  
 
• Chymotrypsin-like 
• Subtilisin-like 
• Carboxypeptidases  
• Clp proteases 
 
Chymotrypsin-like serine proteases are among the most abundant serine proteases 
with over 240 chymotrypsin-like serine proteases documented to date (Barrett et al., 
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1998). These contribute to physiological processes, including digestion, 
homeostasis, apoptosis, signal transduction, reproduction and the immune response 
(Barros et al., 1996; Coughlin, 2000; Hedstrom, 2002; Johnson, 2000; Joseph et al., 
2001; Neurath, 1984). 
 
In this thesis, chymotrypsin-like serine proteases are the main proteases targeted, 
including trypsin, chymotrypsin, pancreatic elastase, tryptase, leukocyte elastase, 
thrombin and matriptase. However, some of MCoTI inhibitors studied in this thesis 
will also be designed in order to target subtilisin. 
1.5.2 The Structure of Chymotrypsin-like Serine Proteases 
Typically, the overall structure of chymotrypsin-like serine proteases is comprised 
of three main auxiliary domains that are all involved in the mechanistic inhibition 
pathways. These are described as follows: (Hedstrom, 2002) 
 
• The catalytic triad 
• The oxyanion hole 
• The substrate recognition component 
 
The catalytic triad 
The catalytic triad is part of an extensive hydrogen bonding network formed within 
the protease active site (Gandour, 1981; Gandour, Nabulsi & Fronczek, 1990), and 
refers to the three key amino acid residues observed inside the enzyme active site. 
These are His57, Asp102 and Ser195. Typically, a hydrogen bond network is 
formed between His57 and Asp102, and between His57 and Ser195, that function 
cooperatively in the catalysis of peptide bond hydrolysis.  
 
Each of these amino acids has a specific role in the catalytic processes, as follows: 
 
• The OH of Ser195 acts as the nucleophilic oxygen which attacks the 
carbonyl carbon of the substrate to generate an intermediate, the so-called 
acyl-enzyme intermediate.  
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• The NH of His57 is able to accept the hydrogen from the OH of Ser195, 
which in turn increases the nucleophilicity of OH in hydrolysing the peptide 
bond. 
• The CO2H of Asp102 forms the hydrogen bond with the NH of His57, 
which subsequently promote the nucleophilicity of adjacent NH within 
imidazole ring of His57 as seen in Figure 1.8. 
 
The catalytic mechanism of serine protease inhibition has been described, involving 
the fragment transfer of an acyl motif, which leads to the formation of an acyl-
enzyme intermediate that is a key intermediate in the catalytic mechanism of all 
serine proteases. This then undergoes a deacylation process. The mechanism may 
be summarised as follows. 
 
Acylation steps: 
 
• The substrate enters and binds tightly to the protease active site via the 
assistance of hydrogen bonds formed between the carbonyl oxygen of the 
P1 residue and an amino group of Ser195, resulting in the formation of a 
non-covalent substrate-enzyme complex, known as the Michaelis complex. 
• Subsequently, this Michaelis complex is attacked by the nucleophilic 
oxygen of Ser195 to generate a tetrahedral intermediate. The scissile peptide 
bond between carbon and nitrogen bond of substrate at the P1 residue is 
cleaved, and an amine product is released. As a result, an acyl-enzyme 
intermediate is formed between Ser195 and the N-terminal of the substrate. 
 
Deacylation steps: 
 
• The acyl-enzyme intermediate is attacked by water to generate another 
tetrahedral intermediate, which subsequently collapses to re-create the 
catalytic triad, and the carboxylic acid is simultaneously ejected.  
 
The detail of this catalytic mechanism is represented in Figure 1.8.  
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Figure 1.8 The catalytic mechanism of serine protease hydrolysis 
 
The acylation step (rate controlling 
step): an acyl-enzyme intermediate 
is formed by the nucleophilic attack 
of hydroxyl oxygen of Ser195 to 
form a tetrahedral intermediate, 
releasing an amine product. 
The deacylation step: an acyl-enzyme 
intermediate is attacked by water to 
generate a tetrahedral intermediate, and 
release a carboxylic acid product.  
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The oxyanion hole 
The oxyanion hole of serine proteases is formed by the NHs backbone of Gly193 
and Ser195 (trypsin and chymotrypsin), and is known to play a vital role in 
activating the cleavage at the scissile peptide bond (Hedstrom, 2002). It stabilises 
the negatively charged oxyanion of the tetrahedral intermediate generated by 
nucleophilic attack of the OH of Ser195 to the carbonyl carbon. As a result, the 
carbonyl oxygen becomes negatively charged, subsequently migrating to the 
oxyanion hole structurally linked to the catalytic triad as depicted above. 
 
The substrate recognition site 
A system for describing the interaction of proteases and their substrates was first 
introduced by Schechter and Berger in which the protease specificity was 
thoroughly analysed by focusing on the P1-S1 interaction between protease and 
their substrates in which P1-P1’ denotes as the peptidic residues on the acyl and 
leaving group site of the scissile bond, while S1-S1’ denotes as the corresponding 
enzyme binding site (Schechter & Berger, 1967) as shown in Figure 1.9.  
 
Figure 1.9 Schechter and Berger Notation (Schechter & Berger, 1967) 
This notation represents the relation between the substrate subsites (denoted as “P”) and the protease 
subsites (denoted as “S”). The peptide bond between P1 and P1’ is the scissile bond, and “prime” 
subsites are refered to the carboxy terminal side of both the substrate and the enzyme. 
Amino  terminus 
SUBSTRATE 
scissile bond 
P3 P2 P1 P1’ P2’ P3’ 
S3 S2 S1 S1’ S2’ S3’ 
carboxy terminus 
ENZYME 
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The primary binding pocket (the S1 Site) 
Typically, the specificity of chymotrypsin-like serine proteases is determined by the 
P1-S1 interaction and this is governed by the residues at Asp189, Gly216 and 
Gly226. These residues form a binding pocket (the S1 pocket) that is necessary for 
protease specificity. 
 
The specificity of individual serine proteases is markedly governed by the 
characteristics of the S1 site, which vary across chymotrypsin-like serine proteases, 
such as chymotrypsin preferring Phe, Tyr and Trp at the P1 residue (Knowles, 
1965).  
 
However, in the case of trypsin the negatively charged S1 pocket formed by the 
combination of Asp189, Gly216 and Gly226, strongly favours positively-charged 
residues, such as Arg or Lys at the P1 position (Huber et al., 1974; Krieger, Kay & 
Stroud, 1974). Elastase specificity deviates from that of trypsin and chymotrypsin, 
as the key residues Val216 and Thr226 form a small hydrophobic hole, meaning 
only small aliphatic residues such as Val or Ala at the P1 residues are able to fit 
correctly (Shotton & Hartley, 1970; Shotton & Watson, 1970). 
 
The polypeptide binding site and the S2-Sn site 
Apart from the S1 site, the polypeptide binding site and the S2-Sn sites are also 
vital for protease-substrate interaction (Hedstrom, 2002). Notably, the hydrogen 
bonds observed between the carbonyl oxygen of Ser214 and the NH of the P1 
residue, the NH of Trp215 and the carbonyl of P3, and the carbonyl of Gly216 and 
the NH of P3 are important in substrate hydrolysis efficacy, but to a lesser degree 
compared to the S1 site as shown in Figure 1.10B.  
 
In summary, the binding specificity of a serine protease with its substrate is 
markedly dependent on the binding site, the S1 site, and the catalytic triad.  
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Figure 1.10 Illustration of interaction between substrate and trypsin 
A represents the S1 pocket of trypsin complexed with EETI-II (PDB ID 1H9I). Lys side chain 
residues at the P1 position of EETI-II (gray) is buried in the S1 pocket of trypsin (green). B displays 
the schematic representation of interactions between substrate and trypsin, comprising of the 
catalytic triad (blue), oxyanion hole (violet), the substrate recognition site (green and orange). The 
amino acid side chain at the P1 position fits into the S1 site, with the assistance of interaction 
between Asp189 (at the bottom of the S1 site) and the positively charged side chain (the P1 residue). 
B 
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Among the proteases studied in this thesis are chymotrypsin-like serine proteases 
and subtilisin-like serine proteases. The former is examined, ranging across bovine-
β-trypsin and α-chymotrypsin to human leukocyte elastase, human-β-tryptase, 
thrombin and matriptase, whilst subtilisin is the only subtilisin-like serine protease 
discussed in this thesis. General aspects of these individual trypsin-like serine 
proteases are described in the following section. 
1.5.3 Chymotrypsin (EC 3.4.21.1) and Trypsin (EC 3.4.21.4) 
Bovine-β-trypsin and α-chymotrypsin (shown in Figure 1.11) are well-studied 
chymotrypsin-like serine proteases, and are proteolytic enzymes that break down 
dietary protein molecules (Rawlings & Barrett, 1994). They are structurally related 
serine proteases and are initially produced as proenzymes (an inactive from), which 
is subsequently activated to yield the active enzyme (Ma, Tang & Lai, 2005). 
 
Trypsin is known as proteolytic enzyme from pancreatic secretion and originally 
synthesised in an inactive proenzyme (trypsinogen) by the pancreas (Stroud, Kay & 
Dickerson, 1974). The activation process of trypsin begins in the gut in which an 
alkali environment (pH 8) is required to activate the proenzyme by the cleavage of 
the peptidic bond (Lys15-Ile16) on the trypsin molecules (Stroud et al., 1974). 
Chymotrypsin is also synthesised in the pancreas, and is found in the gut together 
with trypsin. Chymotrypsin is initially synthesised as a proenzyme, called 
chymotrypsinogen, which is enzymatically inactive, but it is activated upon tryptic 
cleavage and autolysis by chymotrypsin itself (Barrett et al., 1998).  
 
Trypsin and chymotrypsin display high sequence and significant tertiary structural 
homology, including similarity of their catalytic mechanisms (Hedstrom, 2002). 
Residues His57, Asp102 and Ser195 form the catalytic triads in both trypsin and 
chymotrypsin, but the substrate specificities vary. The substrate binding pocket (S1) 
of trypsin favours basic residues, such as lysine and arginine, but that of 
chymotrypsin prefers hydrophobic residues like phenylalanine, tyrosine and 
tryptophan (Knowles, 1965; Ma et al., 2005). It was reported that enzyme 
specificity can be exchanged by mutagenesis (Hedstrom, 2002; Ma et al., 2005).   
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Figure 1.11 The crystal structure of bovine-β-trypsin and bovine-α-chymotrypsin   
 
Figure A and B display the crystal structure of bovine-β-trypsin (A, PDB ID 2BZA) (Ota et al., 
1999) and bovine-α-chymotrypsin (B, PDB ID 1YPH). The catalytic triad is included. 
A 
B 
  
Chapter 1 Introduction 
41 
 
 
1.5.4 Pancreatic Elastase (PE: EC 3.4.21.36) and Leukocyte Elastase (LE: 
3.4.21.37) 
 
Pancreatic elastase (first reported by Baló and Banga) is a serine protease that 
belongs to the chymotrypsin family (Balo & Banga, 1949) and is so named due to 
its ability to degrade elastin, an important component of connective tissues (Bode, 
Meyer & Powers, 1989b). Excessive elastin proteolysis occurs in a number of 
pathological diseases, ranging from emphysema to atherosclerosis (Edwards & 
Bernstein, 1994; McBride, Freeman & Leatherbarrow, 1999). This unique activity 
is significantly different from that of other proteolytic enzymes, such as trypsin and 
chymotrypsin (Balo & Banga, 1949). 
 
Porcine pancreatic elastase (PPE) is categorised into two main types; pancreatic 
elastase I and II, both of which exhibit specificity in hydrolysing elastin, fibrous 
and insoluble protein (Gertler, Weiss & Burstein, 1977; Gestin et al., 1997; 
Largman, Brodrick & Geokas, 1976). However, they are significantly different in 
terms of the type of their substrates (Renaud et al., 1983). Pancreatic elastase I is 
restricted to hydrolysis of non-bulky residues, such as Ala and Val at the P1 
residue. However, pancreatic elastase II prefers a wide variety of amino acids at the 
P1 position ranging from aromatic to large hydrophobic, including phenylalanine, 
tyrosine and leucine (Gestin et al., 1997).  
 
The catalytic sites of both pancreatic elastase I and II are composed of three amino 
acids; Asp102, His57 and Ser195, similar to those of trypsin and chymotrypsin, 
which contain three hydrogen bonds (Barrett et al., 1998). The specificity of 
individual porcine pancreatic elastase subsites has been investigated, and found to 
have the following specificities; the S1’ subsite favours Lys, Ala or Gly, while the 
S2’ subsite has a marked specificity for Ala and some more bulky residues. The S3’ 
subsite has high aromatic specificity (Renaud et al., 1983).  
 
Human leukocyte elastase (HLE) is widely known for its pathological role in lung 
emphysema, cystic fibrosis, adult respiratory distress syndrome (ARDS), 
rheumatoid arthritis, tumor invasion and infectious diseases (Shamamian et al., 
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2001). Human LE is a glycoprotein, composed of a peptide chain of about 218 
amino acid residues, including four disulfide bonds (Barrett et al., 1998; Takahashi 
et al., 1988), with sugar chains attached to Asn 109 and 159 (Navia et al., 1989). 
Human LE is homologous to other elastolytic serine proteases, and its tertiary 
structure is similar to porcine PE (Bode et al., 1989b). The specificity of human LE 
is largely contributed by the substrate binding site (S1) in which small alkyl side 
chains at the P1 position are preferred, such as Val and Ala (McBride et al., 1999). 
 
The calcium binding site observed in both porcine PE and human LE acts to 
stabilise elastase molecules, but plays no role in any catalytic processes (Bode et 
al., 1989b). The calcium binding sites of porcine PE and human LE differ slightly 
in terms of the peptide segments composing in the calcium binding site region, with 
the peptide segment Glu70-Glu80, acting as the calcium binding loop. The structure 
of human LE is shown in Figure 1.12. 
 
Figure 1.12 The crystal structure of human leukocyte elastase  
This figure displays human leukocyte elastase structure (chymotrypsin-like fold, PDB ID 1EAS). 
The calcium binding site and catalytic triad are included (Bernstein et al., 1994). 
Ca2+ 
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1.5.5 Human β-Tryptase (EC 3.4.21.59) 
Human β-tryptase, a mast-cell specific serine protease, was first introduced in 1963 
by Lagunoff (Lagunoff & Benditt, 1963). β-tryptase is among the most abundant 
secretory granule-derived serine (trypsin-like) proteases found in mast cells (Sakai 
et al., 1996a). Its structure is composed of four equivalent monomers arranged in a 
square ring. Typically, human β-tryptase is stored in secretory granules and is 
subsequently excreted upon mast cell stimulation, mainly as a result of certain 
allergic and inflammatory disorders (Schwartz, 1994; Schwartz et al., 1981). 
 
The crystal structure of human β-tryptase complexed to 4-amidinophenyl pyruvic 
acid has been published (Pereira et al., 1998; Sturzebecher, Prasa & Sommerhoff, 
1992), and clearly reveals that an enzymatically active human β-tryptase structure is 
composed of four monomers A, B, C and D as shown in Figure 1.13. Monomer A 
is exactly identical to C, and B is identical to D. Each tryptase monomer is 
comprised of two six-stranded β-barrels, attached by three trans-domain segments, 
two helices as well as polypeptide loops on their surfaces (Barrett et al., 1998). Its 
catalytic triad is similar to those of serine proteases (trypsin-like), consisting of 
Ser195, His57 and Asp102 residues that are localised at the junction between the 
two barrels.  
 
Human tryptase can be categorised into four main types (Barrett et al., 1998), 
named as α, β, γ and δ-tryptases in which α-tryptase and β-tryptase are considerably 
different in terms of proteolytic ability; α-tryptase is proteolytically inactive (Sakai 
et al., 1996a; Sakai, Ren & Schwartz, 1996b), while β-tryptase is enzymatically 
active after activation. δ and γ-tryptases are of insignificant importance in terms of 
proteolytic ability, but are also expressed in mast cells upon activation (Caughey et 
al., 2000; Wang et al., 2009; Wang et al., 2002; Wong et al., 1999).  
 
β-tryptases are initially synthesised as an inactive form, the so-called proenzyme 
which is subsequently activated to give an enzymatically active form by two 
processes: autolytic cleavage, and proteolytic cleavage in the presence of 
dipeptidyl-peptidase I and other enzymes (Sakai et al., 1996b).  
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Interestingly, it has been reported that mutation of residues D216G and K192Q (in 
β-tryptase) situated at the entrance of the specificity pocket accounts for the loss of 
activity in α-tryptase (Barrett et al., 1998; Selwood et al., 2002). 
 
According to the crystal structure of human β-tryptase, each of the active sites faces 
a central pore, restricting access to substrates (and inhibitors) as each β-tryptase 
monomer is situated between two adjacent monomers, linked by contacting loops 
(Pereira et al., 1998). This is a distinct feature of β-tryptase, but is not observed in 
other serine proteases. However, the active site of each monomer is almost 
structurally identical to that of trypsin, contributing to its specificity similar to that 
of trypsin. 
 
The substrate specificity of β-tryptase prefers positively charged P1 residue amino 
acids, such as Lys or Arg (Kam et al., 1995). Furthermore, the subsite specificity of 
β-tryptase at the S2 site also prefers Lys and Arg, and these appear to be among the 
most favourable amino acids at P2 (Kam et al., 1995). 
 
It has been found that β-tryptase activities are strongly dependent on pH, reaching 
maximum activity at neutral, or alkaline pH, but rapidly dropping below pH 7 
(Barrett et al., 1998). Also, β-tryptase shows proteolytic activity in hydrolyzing a 
small number of proteins, such as inactivating fibrinogen, fibronectin and high-
molecular-weight kininogen, and activating zymogen of stromelysin-1 and 
urokinase-type plasminogen activator (Pereira et al., 1998). 
 
The proteolytic activity of β-tryptase relies largely on the presence of the heparin 
chain, which stabilizes the tetramer of β-tryptases via ternary complex formation 
between β-tryptase and heparin (Pereira et al., 1998). β-tryptase activity rapidly 
drops in the absence of heparin due to the dissociation of the β-tetramer, which 
leads to an inactive form (Hallgren, Spillmann & Pejler, 2001; Selwood, McCaslin 
& Schechter, 1998).  
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Figure 1.13  The crystal structure of human β-tryptase (PDB ID 2BM2)  
Figure A displays tetramer of human β-tryptase molecule, consisting of monomer A, B, C, D and 
two identical pairs of monomer are indicated, A-C and B-D. Figure B represents one tryptase 
monomer, possessing chymotrypsin-like fold (Levell et al., 2005) and catalytic triad is shown. 
  
A 
B 
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D 
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1.5.6 Thrombin (EC 3.4.21.5)  
Thrombin (also known as factor IIa) is a serine “trypsin-like” protease capable of 
producing a blood clot. It is the coagulation protein that catalyses the coagulation-
related cascade reaction (Barrett et al., 1998). The active form is known as α-
thrombin, and differs from β- and γ-thrombin in terms of proteolytic function. 
Indeed, β- and γ-thrombin are generated by the autolytic degradation of α-thrombin 
and do not exhibit any function in coagulation processes (Boissel et al., 1984; 
Fenton et al., 1977; Hofsteenge, Braun & Stone, 1988).  
 
α-Thrombin consists of two main chains as seen in Figure 1.14, the A and B 
domains, which differ in terms of  their structures and proteolytic abilities. The A 
domain is composed of 36 amino acids (in human), while, the B domain has 259 
amino acids. The domains are connected by a single disulfide bond. Furthermore, 
the B chain domain contains three disulfide bonds and is glycosylated on Asn60 
(Barrett et al., 1998). It has also been suggested that a sodium ion binding site 
observed in α-thrombin plays a vital role in catalysis (Barrett et al., 1998; Dicera et 
al., 1995; Guinto et al., 1999). 
 
Typically, α-thrombin is produced by the enzymatic cleavage of prothrombin by 
active Factor Xa. Subsequently, thrombin activates clot formation events via 
cleavage of two oligopeptides (fibrinopeptide A and fibrinopeptide B) from the N-
termini of the fibrinogen chains (Barrett et al., 1998; Higgins, Lewis & Shafer, 
1983). In the presence of Ca2+, thrombin also affects the formation of a fibrin clot 
by activating blood coagulation factor XIII (or fibrin-stabilizing factor), which in 
turn strengthens the clot network, making it resistant to lysis. It has been suggested 
that Factor Va participates as a co-factor in the prothrombin activation step to yield 
thrombin, which subsequently activates both co-factors V and VIII, essential in 
coagulation cascade processes (Esmon, 1993).  
 
The specificity of thrombin is similar to trypsin, with Lys and Arg preference at the 
P1 position (Barrett et al., 1998). However, it has been reported that thrombin is 
more selective than other serine proteases.  
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The subsite preference of thrombin has been elucidated, and it was found that Pro is 
favoured at the S2 position, while Val and Met, or D-Phe in synthetic substrates, are 
preferred at the S3 position (Barrett et al., 1998; Bode et al., 1989a). 
 
 
 
Figure 1.14 The crystal structure of thrombin  
This figure shows the crystal structure of thrombin (PDB ID 2BVR), possessing two chains; chain A 
(pale orange) and chain B (grey). The catalytic triad is located within chain B (Neumann et al., 
2005). 
  
Chain A 
Chain B 
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1.5.7 Subtilisin (EC 3.4.21.62) 
Subtilisin is serine protease first isolated from Bacillus subtilis (Barrett et al., 
1998). Monomeric proteins composed of 268-275 amino acid residues with 
molecular weight 26.9-27.5 kDa. The structure of subtilisin is shown in Figure 
1.15. The catalytic site of subtilisin is composed of Asp32, His64 and Ser221, 
where His64 and Ser221 are located near the ends of two α-helices, and Asp32 lies 
at the end of a strand of the central β-sheet (Barrett et al., 1998; Poulos et al., 1976; 
Robertus et al., 1972). The oxyanion hole which stabilises the negative charge of 
the tetrahedral intermediate is made up of Asn155, Ser221 and Thr220 residues. 
The structure of subtilisin contains a high-affinity calcium binding site, which 
stabilises its structure (Barrett et al., 1998; Pantoliano et al., 1988).   
 
Crystallographic data (Gron & Breddam, 1992; Gron, Meldal & Breddam, 1992) 
show that the subtilisin fold is markedly dictinct from other pancreatic serine 
proteases (chymotrypsin-like) in that subtilisin consists of a central seven-stranded 
parallel β-sheet surrounded by nine α-helices, with two strands of antiparallel β-
sheet close to the C-terminus. The S1 subsite favours large hydrophobic side chain 
residues, such as Phe, while the S2 subsite prefers the small side chain residues, 
such as Ala. The S4 subsite also shows a preference for hydrophobic residues. 
 
The mutation of subtilisin has been shown to alter substrate specificity. For 
example, replacement of Ser221 with Cys resulted in aminolysis occurring instead 
of hydrolysis (Nakatsuka, Sasaki & Kaiser, 1987), while the double alteration of 
both Ser221Cys and Pro225Ala, the so-called “subtiligase”, enables certain 
peptides to be ligated in aqueous solution with high yield (Abrahmsen et al., 1991). 
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Figure 1.15 The crystal structure of subtilisin  
This figure displays the crystal structure of subtilisin (PDB ID 1BH6), possessing subtilisin fold 
(Eschenburg et al., 1998). 
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1.5.8 Matriptase 
The first enzyme in the Matriptase type II transmembrane serine protease family, 
was isolated by Shi (Shi et al., 1993) from breast cancer cells and also found in 
other epithelial derived cancer cells, such as breast, colorectal, prostate, cervical 
and ovarian. They display gelatinolytic activity in human breast cancer cells, which 
is involved in extracellular matrix (ECM) degradation, a significant process for 
tissue remodelling and cancer invasion, as well as metastasis. Matriptases, typically 
comprised of around 850 amino acids (Friedrich et al., 2002), are cell surface 
proteolytic enzymes expressed in a broad spectrum of epithelium-rich tissues, with 
molecular weigth between 80 to 90 kDa. The name “Matriptase” (Matrix, trypsin 
and proteinase) was given to show their matrix degrading abilities and trypsin like 
specificity.  
 
To date, two matriptases have been identified; matriptase-1 and matriptase-2 (Parr 
et al., 2007; Uhland, 2006). Comparison between matriptase-1 and matriptase-2 has 
shown that both are considerably different in terms of their biological activity in 
breast cancer (Velasco et al., 2002). Matriptase-1 is known to play a role relating to 
cancer invasion and metastasis, while matriptase-2 may act in breast tumor growth 
suppression (Velasco et al., 2002).  
 
Matriptases may also activate growth and angiogenic factors, such as hepatocyte 
growth factor, urokinase-type plasminogen activator, protease-activated receptor-2 
as well as extracellular matrix degradation (Lee, Dickson & Lin, 2000; Takeuchi et 
al., 2000), therefore potentially affecting a great number of physiological and 
pathophysiological processes. 
 
The reduction of matriptase-1 levels leads to the suppression of prostate and 
ovarian primary tumour growth, as well as metastasis (Parr et al., 2007). However, 
the overexpression of matriptase-1 leads to epidermal tumour formation, and 
initiates multistage squamous cell carcinogenesis (List et al., 2005). 
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Matriptase-2, the most recently-identified member of the family, is structurally 
related to matriptase-1, with significant sequence homology over 30% (Parr et al., 
2007; Velasco et al., 2002) and displays functions in association with cancer cells 
such as suppressing the breast tumour growth (in vivo), and reducing breast cancer 
cell motility and invasion (in vitro). 
 
The X-ray structure of matriptase-1 complexed with a small molecule 
(benzamidine) shows a trypsin-like serine protease fold, and also displays two 
adjacent six-stranded β-barrels strapped together by three trans-domain segments, 
and large 60-residue loop insertions, which directly interact with the substrate 
(Velasco et al., 2002). 
 
The catalytic domain of matriptase-1 has been studied, and reveals that preferred 
cleavage site of synthetic peptide substrates contains Arg or Lys at P1 and P4 
positions, basic residues or Gln at P3, small residues Ala, Gly at P2 and Ala at P1’. 
An aspartic residue located at the bottom of the S1 pocket mediates the binding 
efficacy (Friedrich et al., 2002). The catalytic triad consists of Ser195, His57 and 
Asp102 similar to that of trypsin-like serine proteases, and also the oxyanion hole is 
generated by the main chain nitrogen atoms of Gly193 and Ser195. The structure of 
matriptase-1 is shown in Figure 1.16. 
 
It is clear that the suppression of matriptase-1 activity could potentially be an 
important strategy to decelerate the proteolytic activation of cancer progression 
(Friedrich et al., 2002).  
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Figure 1.16 Illustration of matriptase-1 crystal structure  
This figure represents a view from the crystal structure of matriptase-1 (PDB ID 1EAW), which 
possesses the chymotrypsin-like fold (Friedrich et al., 2002). 
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1.5.9 Hepatitis C virus 
Hepatitis C, a blood-borne infectious disease, is caused by the hepatitis C virus 
(HCV), resulting in fibrosis, cirrhosis including liver cancer (Di Bisceglie, 1998). 
Hepatitis C infection is one of the most significant global health problems, affecting 
approximately 170 million people worldwide.  
 
HCV belongs to the family “Flaviviridae” first identified in 1989 (Choo et al., 
1989). HCV is an enveloped, positive-strand RNA virus with approximately 9.6 
kilobases, which acts as a template for cap-independent translation through an 
internal ribosome entry site (IRES) (Kolykhalov et al., 2000; Lindenbach & Rice, 
2005). The resulting protein then undergoes co- and post-translational proteolytic 
processess via host and virally encoded proteases. The virally encoded proteases 
NS2-3 and NS3 are responsible for cleavage between non-structural proteins 2 and 
3 (NS2 and NS3) and the remaining downstream non-structural protein of the 
hepatitis C virus polyprotein, respectively. 
 
X-ray structures of NS3 proteinase reveal that it is composed of 180 amino acids 
(Llinas-Brunet et al., 2004), comprised of two β-barrels and a catalytic triad similar 
to that of serine trypsin-like proteases, located at the N-terminus of NS3 protein 
(Love et al., 1996; Njoroge et al., 2008). Analysis of the sequence of HCV (NS3 
region) suggests that residues His57, Asp81 and Ser139 form the catalytic triad, and 
the S1 pocket is shallow compared to other chymotrypsin-like serine proteases (as 
shown in Figure 1.17B), meaning only smaller amino acids, such as norvaline or 
norisoleucine (Prongay et al., 2007) and cysteine (Slater et al., 2002) can occupy 
the S1 site (Kim et al., 1996). The structure of HCV NS3/4A is shown in Figure 
1.17A. 
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Figure 1.17 The crystal structure of HCV NS3/4A  
Figure A represents a view from the crystal structure of HCV NS3-4A (PDB ID 2FM2) (Yi et al., 
2006), possessing chymotrypsin-like fold. Figure B displays the X-ray structure of a macrocyclic α-
ketoamide inhibitor (green) bound to HCV NS3/4A protease (PDB ID 2A4Q). The distinct 
characteristic of HCV NS3/4A active site appears to be surface exposed and shallow (Chen et al., 
2005b). 
A 
B 
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1.5.10 Foot-and-Mouth Disease Virus (FMDV) 
Foot-and-Mouth Disease is a major problem in agriculture, causing a highly 
contagious disease which affects many cloven-hoofed animals, including cattle, 
sheep, pig and goats (Jaulent et al., 2007). Foot-and-Mouth Disease Virus 3C 
protease (FMDV 3Cpro) is a chymotrypsin-like cysteine protease, and belongs to the 
Apthtovirus genus of the Picornaviridae (or picornavirus) family, possessing an 
overall fold similar to that of chymotrypsin-like serine proteases (Allaire et al., 
1994; Mosimann et al., 1997). 
 
FMDV is composed of a single stranded positive-sense RNA genome that is 
subsequently translated as a single open reading frame. The receiving polyprotein 
precursor is then cleaved by virally encoded proteases to yield the proteins that are 
necessary for capsid assembly and viral RNA replication (Jaulent et al., 2007), and 
FMDV 3C protease digests 10 of the 13 cleavages (Grubman & Baxt, 2004). 
 
The FMDV 3Cpro structure adopts a chymotrypsin fold, with the catalytic triad 
consisting of Cys-His-Asp, analogous to the Ser-His-Asp triad typically conserved 
in chymotrypsin-like serine proteases (Birtley & Curry, 2005; Birtley et al., 2005). 
The FMDV 3Cpro structure consists of two strand β-ribbons located over the 
cleavage site of enzyme that is conserved in all chymotrypsin-like folds (Birtley et 
al., 2005; Sweeney et al., 2007). These β-ribbons are disordered compared to other 
chymotrypsin-like folds, and they appear to be vital for substrate specificity, since 
the mutagenesis of Cys142 at the apical tip of the β-ribbon strongly affects the 
catalytic activity of FMDV (Sweeney et al., 2007). The substrate preference in 
FMDV 3Cpro favours Gln at the P1 residue and Lys at the P2 residue (Blom et al., 
1996; Curry et al., 2007; Seipelt et al., 1999). The structure of FMDV 3Cpro is 
shown in Figure 1.18.   
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Figure 1.18 The FMDV 3Cpro crystal structure  
This figure shows the crystal structure of FMDV 3Cpro (PDB ID 2BHG) and catalytic triad is 
included (Birtley & Curry, 2005). 
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1.6 Protease inhibitors   
Proteases are found naturally in all organisms, and play an essential role in most 
physiological processes (Laskowski & Kato, 1980). According to their ability in 
hydrolysing peptidic bonds as previously described, proteases can potentially be 
vulnerable to their proteogenic environments once activated by endogenous 
proteases. Most proteases are initially synthesised in an inactive form (known as a 
zymogen) that is liberated to the active form upon site-specific and timely 
activation. The design of novel protease inhibitors is the main objective of this 
thesis.   
 
Protease inhibitors are important molecules capable of regulating the proteolytic 
activity of their target proteases, and are widely found in plants, microorganisms 
and animals (Laskowski & Kato, 1980). A large number of proteinaceous protease 
inhibitors have been isolated, and identified to date. Notably, newly discovered 
protease inhibitors have been increasingly isolated, ranging across cysteine, serine, 
aspartyl and metallo protease inhibitors (Bode & Huber, 1992). Further information 
on discovered protease inhibitors can be found in this reference (Bode & Huber, 
1992). 
1.6.1 Protease Inhibitor of Serine Protease 
Serine protease inhibitors compose the great majority of protein-based inhibitors 
known and characterised to date. They are distinguished according to sequence 
similarities, mechanisms of binding and topological similarities, disulfide pattern 
and three dimensional structure (Laskowski & Kato, 1980). Presently, at least 
eighteen different families have been categorised, fifteen of which are represented 
in Table 1.2. These serine protease inhibitors usually interact with enzymes 
according to the substrate-like standard mechanism. Of particular interest to the 
work in this thesis, the squash seed inhibitor family comprises Cucurbita maxima 
trypsin inhibitor-I (CMTI-I) and Ecballium elaterium trypsin inhibitor II (EETI-II) 
(Bode & Huber, 1992), and Momordica cochinchinensis trypsin inhibitors 
(MCoTIs). 
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Table 1.2 Serine Protease Inhibitor Families 
 
This table (adapted from (Apostoluk & Otlewski, 1998; Bode & Huber, 1992)) represents all fifteen 
known families of serine protease inhibitor. The inhibitors have been extracted from plants, animals 
and microorganisms, and the molecular mass of the example given is indicated.  
Family Example of Structure M.W. 
BPTI (Kunitz family)  
extracted from animal 
BPTI 6.5 kDa 
Kazal family 
 extracted from animal 
OMTKY-3 6.0 kDa 
STI (STI-Kunitz) family 
extracted from plant 
Soybean trypsin inhibitor: porcine 
trypsin 
24 kDa 
SSI family  
extracted from microorganism 
Streptomyces subtilisin inhibitor 10.9 kDa 
Potato inhibitor-1 (PI-1) family 
extracted from plant 
CI-2 9.1 kDa 
Potato inhibitor-2 (PI-2) family  
extracted from plant 
CI-1 5.5 kDa 
Chelonianin family  
extracted from animal 
Elafin 6.0 kDa 
Bowman-Birk inhibitor  
extracted from plant 
Soybean BBI 6.4 kDa 
Squash seed inhibitor,  
extracted from plant 
Ecballium elaterium trypsin inhibitor II 2.9 kDa 
Hirudin   
extracted from animal 
Hirustatin 9.1 kDa 
Ecotin  
extracted from microorganism 
Ecotin trypsin inhibitor 6.5 kDa 
Ascaris family 
extracted from animal 
Ascaris trypsin inhibitor 6.8 kDa 
Antistatin family  
extracted from animal 
Antistatin 13.3 kDa 
Bifunctional α-amylase/trypsin 
inhibitor family 
extracted from plant 
Ragi seed 13.1 kDa 
Bombyx family extracted from 
animal 
(Pham et al., 1996a; Pham et 
al., 1996b) 
Fungal protease inhibitor F (FPI-F) 6.1 kDa 
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1.6.2 The Canonical Structure of Serine Protease Protein Inhibitors           
Serine protease inhibitors are the most important example of peptidic protease 
inhibitors, and are studied widely in protein-protein recognition. They comprise of 
small proteins ranging from 29 to 190 amino acid residues (Apostoluk & Otlewski, 
1998; Bode & Huber, 1992), and it is likely that a significant number of serine 
protease inhibitors still await discovery. The distinguishing features of serine 
protease inhibitors depend largely on their reactive (binding) loops, and their 
scaffolds (Bode & Huber, 1992), described as follows.  
 
The Reactive loop           
Typically, the canonical loop of serine protease inhibitors, also termed the binding 
loop, can be recognised by its highly exposed surface, and flat shape (Apostoluk & 
Otlewski, 1998; Bode & Huber, 1992). This main characteristic is observed 
extensively across serine protease inhibitor families (Apostoluk & Otlewski, 1998). 
The exposed canonical loop of serine protease inhibitors plays an important role in 
inhibitory activity, in which specificity is restricted by the nature of the P1 residue 
(Bode & Huber, 1992). The canonical loop is typically situated away from the main 
scaffold connected with conserved space residues as shown in  
Figure 1.19. Notably, serine protease inhibition specificity can often be re-directed 
towards a panel of different serine proteases via substitution of the P1 residue. The 
complementarity between a canonical loop and the enzyme active site is observed, 
as the P1 residue fits into the specific pocket at the S1 subsite with the assistance of 
conserved hydrogen bonds (Beckmann et al., 1988; Bode & Huber, 1992; 
Longstaff, Campbell & Fersht, 1990) .  
 
The Scaffold 
The scaffold found in serine protease inhibitors depends largely on the arrangement 
of the exposed canonical loop, the conserved space residues, disulfide bonds, and 
the conserved hydrogen bond framework within inhibitor molecules (Bode & 
Huber, 1992; Goldenberg & Creighton, 1984). The exposed binding loop of serine 
protease inhibitors is strongly stabilised not only by interactions between residues 
in the inhibitory loop and the inhibitor core (disulfide bonds connected to the 
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hydrophobic core, or hydrogen bonds clamping an exposed loop to the main core), 
but also by the secondary contact region which consists of residues in the sequential 
remote region. It should be noted that this characteristic has been found widely 
across the different inhibitor families as depicted in Figure 1.19.  
 
The high stability of the serine protease inhibitor scaffold seen in Figure 1.19 has 
mainly been attributed to the contributions of disulfide bonds (Goldenberg & 
Creighton, 1984), together with the hydrogen bond network within the inhibitory 
loop (in the S1 pocket). The scaffold and binding loop have been observed to be 
cooperatively related, since amino acids replaced within conserved spacer residues 
result in reduced rigidity of the scaffold, which in turn decreases its stability. 
Moreover, the complexation between an enzyme and the canonical loop of serine 
protease inhibitors is observed to be tightly packed, leading to favourable 
interactions between the protease subsites and canonical loop of inhibitors 
(Laskowski & Kato, 1980). 
 
Although conformational changes have been observed across different serine 
protease inhibitors, the change of loop conformations in the complexes between 
inhibitor and enzyme is rather limited, since an insignificant difference in the 
Ramachandran angles in the corresponding residues is observed (Apostoluk & 
Otlewski, 1998; Bode & Huber, 1992).  
 
 
  
  
Chapter 1 Introduction 
61 
 
 
The interaction between a protease and its inhibitor 
A significant number of complexes between serine proteases and serine protease 
inhibitors have been elucidated via X-ray crystallography (Bode & Huber, 1992; 
Rcad & James, 1986). Most of the given X-ray structures clearly show that a 
complex of canonical serine protease inhibitors and serine protease are formed 
according to a substrate-like mechanism (Bode & Huber, 1992). Complexes tend to 
be formed rapidly (Radisky & Koshland, 2002), and appear to be relatively stable, 
as no hydrolysis is observed (Bode & Huber, 1992).  
 
It has been also found that interactions between inhibitor and enzyme leads to the 
reactive loop of the inhibitor being in close contact with the catalytic residues of the 
proteases, where the P1 residue fits into a specific pocket at the S1 subsite, with the 
assistance of sub-van der Waals contacts, resulting in energetically favourable 
complexes (Bode & Huber, 1992). The contact surfaces between inhibitors and 
enzymes are typically highly complementary, assisted by the conserved hydrogen 
bonds formed between the P1 carbonyl oxygen and Gly193/Ser195. Examples of 
two canonical serine protease inhibitors are shown in Figure 1.19, showing the 
three dimensional structure of soybean Bowman-Birk inhibitor (BBI) (Werner & 
Wemmer, 1991), and Ecballium elaterium trypsin inhibitor (EETI-II) (Chiche et al., 
1989).  
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Figure 1.19 Illustrations of Serine Protease Inhibitor Structure 
This figure shows two examples of serine protease inhibitor families. The main backbone is shown 
in green, the disulfide bridge is displayed in yellow, and the canonical reactive loop is shown in red: 
(A). Soybean BBI from Bowman-Birk family (PDB ID 1D6R) (Koepke et al., 2000), (B). Ecballium 
elaterium trypsin inhibitor II (EETI-II) from squash seed inhibitor family (PDB ID 2IT7).  
  
B 
A 
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1.7 Aims of This Study 
 
The aim of this project is to explore synthetic approaches to both naturally 
occurring and non-naturally occurring MCoTI-II cyclotides via two synthetic 
strategies, namely thia-zip native chemical ligation (NCL) and protease-mediated 
cyclisation strategies. The former has been applied previously for the synthesis of 
Kalata B1 (Daly, 1999), a 29 amino acid cyclic peptide displaying anti-HIV 
activity. The great advantage of this strategy is that unprotected cysteine residues 
and mild condition are used. Therefore, thia-zip NCL strategy might potentially be 
the most convenient approach for the synthesis of cyclotides.  
 
While, protease-mediated cyclisation approach lies on the use of serine protease in 
the cyclotide synthesis. As it has long been known that certain proteases (trypsin, 
chymotrypsin and subtiligase) have been applied in linear peptide syntheses 
(Bordusa, 2001; Bordusa, 2002; Jackson, Burnier & Wells, 1995). As a result, it is 
hypothesized that acyclic microprotein in which its structure is opened at its scissile 
bond (P1 and P1’) could also be cyclised by trypsin, in a manner analogous to 
SFTI-I (sunflower trypsin inhibitor-I) synthesis (Marx et al., 2003).  
 
The re-engineering of its inhibitory loop with replacement of the P1 residue of 
MCoTI-II scaffold altogether with minimisation of mobile loop size via truncating 
some amino acids within mobile loop are of our great interest. This is believed not 
only to broaden their biological activities, but also to increase inhibitory potency in 
some target enzymes, such as β-tryptase. Subsequently, both wild-type and re-
engineered MCoTI-II cyclotides will be evaluated their biological activities against 
a panel of trypsin-like serine proteases, ranging from trypsin, chymotrypsin, 
leukocyte elastase, β-tryptase, HCV NS3/4A, thrombin to matriptase, including 
chymotrypsin-like cysteine protease (FMDV 3Cpro). Prior to this study there had 
been no report of the total synthesis of any MCoTI cyclotides.  
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1.7.1 Overview of This Thesis 
 
 Chapter 2 focuses on the synthetic strategy of naturally occurring MCoTI-I, 
II and re-engineered MCoTI-IIs via thia zip native chemical ligation 
strategy. The general definition of native chemical ligation (NCL), an 
appropriate disconnection point determination and the assembly of peptidyl 
thioester strategy are included. 
 Chapter 3 is concerned about two synthetic routes of MCoTI-I and II 
syntheses with immobilised protease-mediated cyclisation strategy. This is 
further applied to MCoTI-II analogue syntheses. The proposed mechanism 
of proteases mediated cyclisation and comparison between thia-zip assisted 
NCL and protease mediated cyclisation strategies in MCoTI-II syntheses are 
discussed.    
 Chapter 4 concentrates on their protease inhibition activities of MCoTI-I, II 
and analogues against a panel of trypsin-like serine proteases, ranging from 
trypsin, chymotrypsin, elastases, thrombin, β-tryptase to matriptase, 
including cysteine (trypsin-like) protease, FMDV 3Cpro. 
 Chapter 5 focuses on the re-engineering of MCoTI-II scaffold via 
truncating some amino acid residues in mobile loop followed by the 
inhibitory activity examination. The synthesis of hybrid inhibitor named 
MCoEeTI and MCoEeTI analogues and the inhibitory activity against a 
panel of serine protease are also described. The NMR structure of both 
naturally occurring MCoTI-II and truncated MCoTI-II are elucidated. 
 Chapter 6 presents general conclusions from the work presented, including 
perspectives. 
 Chapter 7 describes the general experiment used throughout the thesis.  
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Chapter 2 Thia-zip Assisted Native Chemical 
Ligation (NCL) for MCoTI-IIs Syntheses 
 
Thia-zip assisted Native Chemical Ligation (NCL) strategy 
for the synthesis of MCoTI-II and its analogues will be 
discussed. 
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In this thesis, the syntheses of naturally-occurring MCoTI-I and MCoTI-II were 
carried out using two different strategies:  chemical synthesis and chemoenzymatic 
synthesis. The former, involving a thia-zip native chemical ligation (NCL) 
approach, is illustrated in this chapter, and the latter, principally concentrating on 
the use of immobilised protease to mediate macrocyclisation in the synthesis of 
cyclotides, is described in Chapter 3. 
 
2.1 Native Chemical Ligation (NCL) 
NCL is a prominent technique generally applied to the synthesis of large proteins  
(> 60 residues) (Alves et al., 2003; Lu, Starovasnik & Kent, 1998; Shin & Bertozzi, 
1999) where conventional peptide synthesis is unfavourable. NCL is a 
chemoselective reaction that involves the condensation of two unprotected peptide 
segments, one of which bears a C-terminal thioester and the other an N-terminal 
cysteine residue (Alves et al., 2003). The reversible transthioesterification and 
irreversible intramolecular rearrangement of neighbouring amine nucleophile occur 
at the cysteine residue to form a native amide (peptide) bond.  
 
The reaction mechanism is as follows: firstly, the free thiol of an N-terminal Cys 
undergoes trans-thioesterification, with a C-terminal thioester, followed by 
nucleophilic attack of the α-amine of the Cys residue to regenerate a new peptide 
bond, with concurrent regeneration of the free cysteine thiol (Dawson & Kent, 
2000; Dawson et al., 1994; Lu et al., 1998; Tam & Lu, 1998; Tam et al., 1999a; 
Tam, Lu & Yu, 1999b) as shown in Figure 2.1.  
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Figure 2.1 Schematic representation of NCL (Alves et al., 2003) 
This figure shows the mechanism for NCL; C-terminal thioester and N-terminal cysteine are 
required for NCL. C-terminal thioester reacts with N-terminal cysteine to form thioester 
intermediate (A), which subsequently rearranges to generate a native peptide bond.  
 
The highly chemoselective ligation of NCL was further applied to the total 
synthesis of glycosylated proteins which display a wide range of biological 
activities (Shin & Bertozzi, 1999). Although, a necessary requirement of NCL is 
that the target protein must possess at least one internal Cys residue, many 
ingenious methods have been developed successfully for NCL-mediated synthesis 
of cysteine-free proteins, for example via the use of a removable auxillary group, 
oxyethanethiol, to mimic N-terminal cysteine side chains (Shao, Lu & Kent, 1998; 
Wu et al., 2006). This approach has been applied to the synthesis of head-to-tail 
cyclic peptides. As displayed in Figure 2.2, the cyclic thioester intermediate is 
generated by intramolecular trans-thioesterification between the C-terminal 
thioester and Nα (oxyethanethiol) glycine, allowing spontaneous S-to-N acyl 
rearrangement to render the amide-linked cyclic peptides. The removable auxillary 
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group, the N-α-oxyethanethiol, is subsequently eliminated by Zn dust reduction to 
yield the cyclic peptide (Shao et al., 1998).  
 
 
Figure 2.2 Schematic representation of an extended NCL assisted cyclic pepide synthesis  
This figure represents an extended NCL in macrocyclic peptide syntheses; N-α-oxyethanethiol 
auxillary group is used to mimic the side chain of N-terminal cysteine, which subsequently reacts 
with C-terminal thioester to form cyclic intermediate [A] followed by S, N acyl rearrangement. The 
N-α-oxyethanethiol is removed by zinc reduction. (Z = Gly, Ala and Phe)(Shao et al., 1998) 
 
The N-α-oxyethanethiol removable auxillary group has also been applied to amino 
acids other than glycine, namely alanine and phenylalanine (Shao et al., 1998).  
 
2.2 Thia-Zip Native Chemical Ligation (thia-zip NCL) in Cyclotide syntheses 
Large end-to-end macrocyclic microproteins such as Circulin A and Circulin B, 
Cyclopsychotride (CPT) and Kalata B1 are members of a novel plant-derived 
macrocyclic peptide family (Tam, 1997; Tam et al., 1999a; Tam et al., 1999b). 
They display a panel of biological activities ranging from antibacterial to anti-HIV 
O
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and are 28-31 amino acids long, with six cysteine residues and a high degree of 
homology (Tam et al., 1999a). Examples of chemically synthesised cyclotides are 
shown in Table 2.1. 
 
Table 2.1 Amino acid sequences of Kalata B1, Circulin A and B, CPT, MCoTI-I and MCoTI-II 
 
 
Examples of chemically synthesised cyclotide sequences, Circulin A and B, Cyclopsychotride A and 
Kalata B1 that were previously synthesised and the cyclotide sequences studied in this thesis, 
MCoTI-I and II (34 amino acids long) are shown. 
 
An intramolecular orthogonal coupling strategy using unprotected peptides was 
initially established for the synthesis of both Circulin A and Circulin B, and 
subsequently applied to other macrocyclic peptides (CPT and Kalata) (Tam, 1997; 
Tam et al., 1999a; Tam et al., 1999b).  
 
Thia-zip assisted NCL has been categorised as a ring-enlargement type reaction, 
involving a series of intramolecular rearrangements of the cysteine-rich proteins, 
with cyclisation mediated by intramolecular acyl transfer reactions, followed by a 
series of thiol-thiolactone exchanges as shown in Fig. 2.6. The α-amino thiolactone 
intermediate is formed, and subsequently undergoes S, N acyl-migration to afford 
the end-to-end macrocyclic peptide. An N-terminal cysteine and a (usually C-
terminal) thioester as well as at least one internal free thiol in the peptide chain are 
necessary for thia-zip assisted NCL (Tam et al., 1999b). This methodology has been 
applied for the total synthesis of head-to-tail macrocyclic proteins, such as Kalata 
B1, Circulin A, B and CPT with the use of a Boc/tBu strategy (Tam, 1997; Tam et 
al., 1999a; Tam et al., 1999b). 
 
 
I 
 
II 
 
III 
 
IV 
 
V 
 
VI 
 
Circulin A · C ···GES C ·VWIP C I·SAALG C S C ···KNKV C YRNG·IP 
Circulin B · C ···GES C ·VFIP C IST·LLG C S C ···KNKV C YRNGVIP 
Cyclopsychotride A · C ···GES C ·VFIP C ·VTALLG C S C ···KSKV C YKNS·IP 
Kalata B1 V C ···GET C ·VGGT C ···NTPG C T C ···SWPV C TRNG·LP 
MCoTI-I V C PKILQR C RRDSD C ····PGA C I C ··RGNGY C GSGSDGG 
MCoTI-II V C PKILKK C RRDSD C ····PGA C I C ··RGNGY C GSGSDGG 
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2.3 Synthesis of the naturally-occurring cyclotides MCoTI-I and II 
Our aim was to synthesise the recently-discovered naturally occurring cyclotides 
MCoTI-I and MCoTI-II. These are plant-derived cyclotides 34 amino acids long, 
with three disulfide bonds arranged into a knot topology (Felizmenio-Quimio et al., 
2001; Heitz et al., 2001). MCoTI-I and MCoTI-II sequences are shown in Table 
2.1.  
 
The MCoTI-IIs studied in this thesis are some of the largest naturally occurring 
cyclotides that have been chemically synthesised (Thongyoo, Tate & 
Leatherbarrow, 2006). The MCoTI familly is structurally different from other 
cyclotides in terms of both amino acid sequences, as shown in Table 2.1, and 
biological activity. However, as mentioned previously, they are topologically 
similar, with three disulfide bonds arranged in the cysteine knot scaffold 
(Felizmenio-Quimio et al., 2001; Heitz et al., 2001). Thia-zip NCL may therefore 
be appropriate approach for synthesising MCoTI-I and MCoTI-II due to their 
characteristics (macrocyclic together with cysteine knot motifs). The synthetic 
strategy is show as follows.  
 
2.3.1 Synthetic strategy for the naturally occurring cyclotides MCoTI-I and II 
A synthetic strategy for MCoTI cyclotides was considered to involve three major 
challenges (Thongyoo et al., 2008; Thongyoo et al., 2006): 
 
1. The assembly of the backbone through Fmoc SPPS strategy  
2. Head-to-tail backbone cyclisation with the assistance of a thiol (-SH) 
3. Oxidative folding to form the three disulfide bonds, arranged into the correct 
cystine-knot geometry  
 
Prior to backbone assembly, the disconnection point between C-terminal thioester 
and Nα-cysteine was determined. 
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2.3.2 Determining the disconnection point for the syntheses of MCoTIs  
Comparison of the sequences of Kalata B1, Circulin A, Circulin B and CPT with 
our targeted cyclotides MCoTI-I and MCoTI-II (as shown in Table 2.1) provided 
information about the disconnection point for thia zip assisted NCL of the cyclotide 
syntheses.  
 
The C-terminal thioester and Nα-cysteine are the functional groups required to 
mediate thia zip cyclisation. Importantly, it was reported that the efficiency of 
macrocyclic cyclisation  depends greatly on the length of the C-terminal peptidyl 
thioester chain and it appears that the cylisation of large peptidyl thioesters is much 
more favourable compared to that of small peptidyl thioesters mainly due to an 
increase in the entropic stability of the cyclisation intermediate involved during 
cyclisation (Tam et al., 1999b). 
 
Additionally, steric hindrance between the disconnection points is one of the major 
factors affecting cyclisation efficiency (Shao et al., 1998). Of all peptide bonds 
within cyclotides, the peptide bond between Gly-Cys has been preferentially 
selected as the site of disconnection in the case of Kalata B1, Circulin A, Circulin B 
and CPT syntheses, mainly due to the minimised steric interaction experienced 
during the cascade cyclisation process (Tam & Lu, 1998).  
 
No Gly-Cys peptide bond is found in MCoTIs (Table 2.1). The cysteine peptide 
bonds (Tyr-Cys, Ile-Cys, Asp-Cys, Lys-Cys, Val-Cys and Ala-Cys) found in 
MCoTI cyclotides are potential disconnection points for thia-zip NCL mediated 
MCoTI syntheses as shown in Figure 2.3. It was decided that the Ala-Cys peptidic 
bond is the preferred disconnection point for C-terminal peptidyl thioester 
synthesis. This was mainly due to the comparatively minimised steric hindrance 
towards macrolactamisation between alanine and cysteine and the absence of a 
nuclophilic heteroatom (S, O, N) within side chain as the presence of a nucleophilic 
heteroatom (S, O, N) such as amino or hydroxyl groups within side chain may 
result in the side reaction.  
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The Ala terminus was synthesised as a C-terminal alanine thioester, bearing an N-
terminal cysteine on the linear peptidyl thioester chain. 
 
In the case of Lys, the nucleophilic nitrogen (–NH2) of the side chain might 
possibly react with the C-terminal peptidyl thioester to generate a lactam through 
macrolactamisation. This would terminate the thia-zip cyclisation efficiency 
between the Nα-cysteine and C-terminal peptidyl thioester completely. In addition, 
backbone cyclisation might also be carried out by exposing a (suitably side chain 
protected) backbone, bearing an amino N-terminus and a carboxy C-terminus, to 
standard peptide coupling conditions. However, this approach may suffer from 
multiple drawbacks: (i) poor peptide solubility, (ii) the need of high dilution and 
(iii) inability of purification and characterisation of protected peptides (Kent, 2009). 
First, poor peptide solubility may cause problems in synthesising proteins as many 
fully protected peptides have limited solubility in organic solvent, which in turn 
result in slow and incomplete coupling reactions. Second, intermolecular coupling 
reaction may be predominant if high concentration is used. To overcome this 
problem, low concentration is required. Finally, fully protected peptides are 
considerably difficult to purify due to the limited solubility. Therefore, multiple re-
crystallisations are applied for purification and all peptides are required to be 
deprotected prior to characterisation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.3 Possible disconnection points in the MCoTI
selected amino acids represented by the colours indicated
 
Six possible disconnection points to be selected are shown; valine (
alanine (A), isoleucine (I) and tyrosine (
preferred as the disconnection point for MCoTI
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V), lysine (K), aspartic acid (
Y), and the peptide bond between alanine
-II synthesis.  
VCPKILKKCRRDSDCPGACICRGNGYCG 
 
 
-IIs syntheses  
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Table 2.2 Possible disconnection points for the MCoTI-II synthesis strategy 
 
Six possible peptide bonds as disconnection points are shown; the alanine residue appears to 
minimise steric hindrance due to small side chain (-CH3) relative to others and no heteroatoms is 
observed; while lysine contains an amine side chain that could possibly react with the thioester. 
 
 
 
 
 
 
 
 
 
 
disconnection 
point side chain steric hindrance 
neighboring 
group 
participation 
 √    Ala24-Cys25        CH3
 
× × 
 
Ile26-Cys27 
 
CH3
CH3
 
√ × 
 
Tyr32-Cys33 
CH2
OH
 
√ × 
Asp20-Cys21 
 
CO2H
 
√ × 
Lys14-Cys15 
 
NH2
 
√ √ 
Val7-Cys8 
 
CH3
CH3
 
√ × 
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2.4 Synthetic route for synthesis of the cyclotide MCoTI-II 
The proposed strategy for backbone assembly in the synthesis of MCoTI-II depends 
markedly on the correct cyclisation and folding (Daly et al., 1999; Tam et al., 
1999b). Boc/tBu strategy, microwave enhanced and Fmoc based solid phase peptide 
synthesis (SPPS) have all been applied to cyclotide backbone construction (Tam et 
al., 1999b; Thongyoo et al., 2006). However, a recent report has shown that 
bacterial expression can also be an effective approach for smaller scale production 
of cyclotides as mentioned in Chapter 1 (Camarero et al., 2007). In this thesis, we 
selected Fmoc-based SPPS syntheses for C-terminal thioester backbone assembly, 
followed by thia-zip NCL for the total syntheses of MCoTI-II and its analogues. 
 
2.4.1 Synthetic route for linear MCoTI-II thioester synthesis 
The strategy for the synthesis of the MCoTI-II thioesters is shown in Figure 2.4 
(Thongyoo et al., 2008; Thongyoo et al., 2006). Fmoc SPPS was applied to MCoTI-
II thioester backbone assembly, carried out by the use of a polystyrene resin bearing 
a sulfamylbutyryl “safety catch linker”, mainly due to its stability against basic 
condition. The target compound can then be released from linker upon treating with 
a specific condition (Backes & Ellman, 1999; Ingenito et al., 1999).  
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Figure 2.4 Synthetic route for SPPS synthesis of MCoTI-II backbone thioester 
Conditions: (a) Fmoc-Ala-OH, DIPEA, PyBop, -20°C, 8 hrs; (b) Fmoc SPPS; (c) NMP, DIPEA, 
iodoacetonitrile (excess), 24 hrs, r.t.; (d) sodium thiophenolate (cat.), ethyl 3-mercaptopropionate, 
DMF, 16 hrs, r.t.; (e) TFA, H2O, EDT, TIPS (94:2.5:2.5:1). Picture is adapted from (Thongyoo et 
al., 2006). 
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The C-terminal alanine was loaded onto the sulfamylbutyryl “safety catch” linker 
resin under conditions (PyBOP/DIPEA/-20οC) to yield an excellent loading  
(> 70%). The MCoTI-II backbone was then assembled according to an Fmoc SPPS 
protocol (Atherton & Sheppard, 1989), and several optimisations were required to 
achieve efficient amino acid assembly via SPPS, such as the double coupling of 
some residues (also shown in the experimental section; the double coupling of 
Val8, Lys15 and Ile14 were required for MCoTI-II syntheses) as double coupling of 
these residues were found to increase the resulting yield.  The prediction of the 
coupling difficulty of some residues was achieved via the Peptide Companion 
program (CSPS Pharmaceuticals Inc, USA) to improve the sequence assembly 
efficiency. 
 
Cys34 of the MCoTI-II sequence was introduced as Boc-Cys(Trt)-OH to prevent  
N-terminal amine alkylation with iodoacetonitrile during the activation step 
(Ingenito et al., 1999; Thongyoo et al., 2006). The residues Asp21 and Gly20 were 
further introduced as a dipeptide building block, bearing a hydroxyl-4-
methoxybenzyl (Hmb) protecting group on a glycine backbone nitrogen to suppress 
aspartimide formation at this position (Mergler, 2003). The omission of this Hmb 
group might result in only trace quantities of linear product from SPPS. The 
structure of the dipeptide building block Fmoc-Asp(OtBu)-(Hmb)Gly-OH is shown 
in Figure 2.5. 
Figure 2.5 The structure of dipeptide building block Fmoc-Asp(OtBu)-(Hmb)Gly-OH 
O
O
N
H
N
O
CO2H
OCH3
O
HO
O
  
  Chapter 2 Thia-zip assisted NCL for MCoTI-IIs syntheses  
78 
 
 
The activation and displacement of the resultant C-terminal sulphonamide was then 
carried out with iodoacetonitrile and ethyl 3-mercaptopropionate (in the presence of 
a catalytic amount of sodium thiophenolate) to give excellent overall yield of the 
fully protected linear peptidyl thioester with respect to a sequence of more than 60 
synthetic steps. Subsequent acidolysis using a deprotection mixture 
(TFA:H2O:TIPS:EDT: 94:2.5:2.5:1) was followed by precipitation (with tert-butyl 
methyl ether) and purification to give the free N-terminal cysteine thioester in 
excellent yield (approximately 6% for over 65 synthetic steps), based on the initial 
resin loading. 
 
2.4.2 Thia-zip NCL for the cyclotide MCoTI-II synthesis 
For the cyclotide MCoTI-II syntheses, ring-closing NCL was achieved smoothly in 
100 mM phosphate buffer in the presence of excess tricarboxyethylphosphine 
(TCEP) to afford the head-to-tail cyclic backbone, with >95% conversion by RP-
HPLC (Thongyoo et al., 2006). The presence of TCEP in reaction mixture is to 
prevent the formation of difulfide bond. This reaction is expected to proceed via the 
so-called thia-zip (or cysteine zipper) mechanism, whereby a dynamic equilibrium 
of intermediate cyclic thioester is trapped by an irreversible S-to-N rearrangement 
at the N-terminal cysteine, and it is important to note that thia-zip approach 
overcomes the otherwise unfavourable formation of the 103-atom macrolactam, and 
also the reaction can be conducted in the absence of protecting groups at relatively 
high concentration (≥ 0.5mg/mL). Notably, it was found that the macrolactam thus 
formed is prone to rapid and spontaneous disulfide formation to yield the correctly 
folded MCoTI-II cyclotides. However, mild air oxidation and refolding in the 
presence of glutathione allowed the microprotein to adopt the native cysteine knot 
topology (Thongyoo et al., 2006) as shown in Figure 2.6. 
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Figure 2.6 One-pot thia-zip NCL and refolding of linear precursor MCoTI-II thioester  
 
Solid bond: backbone cyclisation; dashed bonds: disulfide bridges. Conditions: (a) glutathione (1 
mM, reduced form), aqueous ammonium carbonate (100 mM, pH 7.4), r.t., 24 hrs. The intermediate 
head-to-tail cyclic peptide undergoes spontaneous refolding under these conditions to yield the 
target MCoTI-II in a one-pot reaction. Adapted from (Thongyoo et al., 2008). 
 
 
The ring closing NCL conditions of the MCoTI-II cyclotide syntheses were 
optimised successfully to achieve both ring closure and refolding steps via a one pot 
reaction that was mediated by dissolving the N-terminal cysteine thioester (oc-
MCoTI-II thioester) and glutathione (reduced form) with 50% acetonitrile in 
carbonate buffer at pH 7.5 (without TCEP), resulting in excellent conversion to the 
cyclotide MCoTI-IIs, as shown in Figure 2.6. Acetonitrile is believed to have a 
major role in stabilising the solvent exposed elements within the MCoTI-II 
scaffold, which in turn lead to the formation of the correctly folded MCoTI-II 
scaffold (Daly, 1999).  
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Figure 2.7 Thia-zip NCL mechanism of MCoTI-II synthesis   
Ring expansion occurs via an inter-converting series of macrothiolactones, the largest of which can 
be trapped by an N-to-C rearrangement (NCL) to yield the target macrolactam. 
 
The thia-zip assisted cyclisation mechanism is as follows: initiation by trans-
thioesterification through an internal thiol within the C-terminal thioester, results in 
a thiolactone intermediate which then undergoes S- to N- acyl rearrangement to 
yield the amide-linked cyclic peptides. As shown in Figure 2.7, unprotected 
peptides containing one or more internal thiols form thiolactones under ring-chain 
tautomeric equilibrium which then proceed by successive ring expansion via a 
series of small thiolactone intermediates. These reversible thiolactone exchanges 
are sequence dependent, and are assisted by appropriate placement of internal thiols 
(Tam et al., 1999b).  
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Thia-zip assisted macrolactam formation is usually carried out under mildly basic 
buffered aqueous conditions, and has been applied to the synthesis of several 
naturally and non-naturally occurring cyclotides. The presence of thiols within 
sequences is believed to play a great role in the successive ring enlargement 
pathway (thiol-thiolactone exchange). However, it is not proved that whether all 
thiols or only a few thiols contributes to thia-zip assisted macrocyclic cyclisation 
(Tam et al., 1999b).  
 
The advantages and disadvantages of ring closing NCL reactions previously 
reported by Tam with Boc/tBu SPPS strategy (Tam et al., 1999b) and recently 
developed by our group with Fmoc SPPS strategy via a one pot reaction (Thongyoo 
et al., 2006) are as follows: 
 
Ring closing NCL strategy optimised by Tam (Tam et al., 1999b) 
 
(i) Boc/tBu SPPS chemistry strategy: highly toxic HF was required for the 
cleavage of peptide from resin 
(ii) Harsh reaction conditions: 8M urea for the peptide extraction step prior 
to the macrocyclisation and highly reductive condition (a 5-10 fold 
excess TCEP) to prevent the formation of disulfide bond 
(iii) Multiple steps are required: macrolactamisation and refolding steps are 
carried out separately.  
 
Ring closing NCL strategy recently reported by our research group (Thongyoo et 
al., 2006) 
 
(i) Fmoc SPPS chemistry strategy: only TFA was required for the cleavage 
step  
(ii) Mild reaction conditions: 0.3 mM glutathione/50% acetonitrile in 
carbonate buffer at pH7.5  
(iii) One pot reaction: macrolactamisation and refolding steps 
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The great advantage of the Fmoc SPPS strategy is the milder conditions compared 
to that of the Boc/tBu strategy, also the cascade macrocyclisation of a  
C-terminal thioester was achieved with the formation of disulfide bonds arranged 
into the correctly folded topology. Interestingly, the cyclic MCoTI-II (without the 
disulfide bond) could be observed under reducing conditions (100 µM 
TCEP/carbonate buffer at pH7.5) and isolated by HPLC despite being readily 
oxidised by air. Furthermore, it was found that thia-zip NCL was completed in 20 
min; the resulting cyclic MCoTI-II (without disulfide bond) was obtained and 
readily oxidised to render disulfide bonds. More than ten possible isomers were 
observed by analytical HPLC (with six cysteinyl thiols). However, after 24 hrs, 
ONLY the desired product (correctly folded MCoTI-II) was detected by HPLC with 
excellent yield, and it is believed that the formation of correctly folded MCoTI-II 
was achieved by the conversion of the misfolded MCoTI-II product to the correctly 
folded MCoTI-II with the assistance of glutathione.  
 
It is interesting to note that MCoTI-II synthetic strategy reported in this thesis is 
simpler than the synthetic strategy in CPT and KalataB1 syntheses reported by 
Tam. The main reason is that MCoTI-II can fold more readily relative to those of 
CPT/KalataB1 (Trabi & Craik, 2002).  
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Figure 2.8 Overlay of RP-HPLC traces of the synthetic MCoTI-II 
Picture is adapted from (Thongyoo et al., 2006) 
 
 
Synthetic C-terminal peptidyl thioester (oc-MCoTI-II), cyclic-MCoTI-II (without 
disulfide bonds) and MCoTI-II were characterised by RP-HPLC and MALDI-MS 
as presented in Figure 2.8 and Figure 2.9. Retention time, MALDI-MS, 1D and 
TOCSY proton NMR spectral data of the cyclotide MCoTI-II demonstrate 
unequivocally that synthetic MCoTI-II cyclotide adopts the native cystine knot 
configuration. The MCoTI-II NMR spectra will be presented and analysed in more 
details in Chapter 5.  
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Figure 2.9 Selected characterisation data for synthetic MCoTI-II 
This figure shows the characterisation data of MCoTI-II: (A) oc-MCoTI-II thioester positive ion 
MALDI-TOF; (B) cyclic-MCoTI-II positive ion MALDI-TOF; (C) MCoTI-II positive ion MALDI-
TOF. Picture is adapted from (Thongyoo et al., 2006).  
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2.5 Syntheses of MCoTI-II analogues 
 
The compact topology of the cystine knot scaffold of MCoTI-II, together with its 
high potency, specificity and exceptional stability (Colgrave & Craik, 2004) has led 
MCoTI to become a promising peptidic drug scaffold (Werle et al., 2006). All of 
the cyclotides studied in this thesis share a common fold, according to the presence 
of the conserved cyclic cystine knot (CCK) motif, embedded within a cyclic 
backbone. The MCoTI-II scaffold itself might also potentially be applied as a drug 
lead compound due to the properties mentioned previously (Colgrave & Craik, 
2004). It is especially amenable to re-engineering to broaden biological activity 
against serine “trypsin-like” proteases, including cysteine protease (FMDV 3Cpro).  
 
For this thesis, a large number of variant MCoTI-II based scaffold cyclotides have 
been made to target a broad spectrum of serine “trypsin-like” proteases, including 
trypsin, chymotrypsin, thrombin, subtilisin, β-tryptase, hepatitis C virus (HCV 
NS3/4A) and matriptase (a transmembrane serine protease), which differ 
significantly in terms of substrate specificity and therapeutic applications as 
discussed in Chapter 1. In addition, Foot and Mouth Disease Virus (FMDV) is also 
one of our targeted proteases (Birtley et al., 2005), classified as cysteine 
“chymotrypsin-like” protease.  
 
To this end, a set of chemically synthesised MCoTI-II variants were synthesised by 
modifying the MCoTI-II inhibitory loop to alter inhibitory specificity. Furthermore, 
MCoTI-I, a naturally occurring cyclotide closely related to MCoTI-II in both its 
structural and biological activities (exceptionally potent against trypsin with Ki ~ 
pM), was also one of the target cyclotide. As a result, the MCoTI-II scaffold was 
re-engineered by replacing amino acid residues at the expected cleavage site P1 
with a large number of alternative amino acids. It is important to note that the 
inhibitory specificity of individual proteases relies on the S1 pocket at the catalytic 
site (described in Chapter 1). All of the targeted serine trypsin-like proteases share 
a common catalytic triad, composed of Ser, His and Asp in the active site, but differ 
greatly in the characteristics of the S1 pocket, especially in terms of size. 
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One group of these proteases (trypsin, thrombin, tryptase and matriptase) share the 
great similarity in terms of their catalytic sites, and the S1 pocket in which the 
bottom of the S1 pocket is significantly deep that is composed of a negatively 
charged Asp as discussed in Chapter 1. Notably, it was reported that the positively 
charged amino acids, such as Lys and Arg at the P1 position are preferred due to the 
favourable interaction between the negatively charged aspartate side chain (CO2-) 
at the bottom of the S1 pocket and the positive charge of the amino group (-NH2) of 
the lysine side chain, or guanidino group (-NH-CNH2-NH2+) of the arginine side 
chain. 
 
In the case of the chymotrypsin and subtilisin S1 pocket, hydrophobic residues at 
the P1 position such as Phe, Tyr and Trp are required to fill the deep hydrophobic 
pocket that is generated by Ser189, Gly216 and Gly226 residues on the 
chymotrypsin catalytic site (Hedstrom, 2002), while smaller residues such as Ala 
and Val are necessary to fit into the smaller S1 pocket of elastase. The details 
protease inhibition results against target serine “trypsin-like” proteases will be 
discussed in Chapter 4. 
 
2.5.1 Syntheses of MCoTI-II analogues 
The syntheses of variant MCoTI-IIs (oc-MCoTI-II analogues) were achieved 
through an Fmoc SPPS strategy similar to that of the MCoTI-II synthesis: (i) amino 
acid assembly, (ii) activation and displacement strategies, (iii) acidolysis of side 
chain deprotection and (iv) thia-zip assisted NCL. Step (i) – (iii) involved the order 
of synthetic strategy of the C-terminal peptidyl thioester. Moreover, double 
coupling of some residues was achieved for the amino acid assembly step (i). The 
details are shown in the experimental section (Chapter 7). After the acidolysis step 
(iii), C-terminal peptidyl thioesters (oc-MCoTI-II thioesters) were obtained and 
further applied to the macrocyclic cyclisation step (iv) via a series of thiol-
thiolactone exchanges, followed by the refolding step to yield the correctly folded 
MCoTI-II analogues.  
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The contribution of increasing ring size to macrocyclisation efficiency was also 
studied where the Lys at the P1 position of the cyclotide MCoTI-II was replaced by 
a number of different amino acids including the tripeptides Ala-Lys-Gln as 
displayed in Table 2.3. 
 
Table 2.3 Synthesised MCoTI-II analogues 
 
 
 
 
 
 
 
 
Examples of MCoTI-I and MCoTI-II analogues in which the amino acids at P1, P2 and/or P1’ are 
replaced with a variety of amino acids are shown. MCoTI-II[AKQ] is the largest cyclotide 
synthesised with 36 amino acids long. Retention time and yield of individual cyclotide are also 
included. 
  
Cyclotides 
P2 P1 P1’ P3’ P4’ 
Yield 
(%) 
Retention Time (Rt): 
Method B,C* 
     
MCoTI-I P K I Q R 68 12.3 
MCoTI-II [R] P R I K K 72 11.8 
MCoTI-II [F] P F I K K 64 15.2 
MCoTI-II [Q] P Q I K K 64 12.5 
MCoTI-II [A] P A I K K 63 10.15* 
MCoTI-II [V] P V I K K 64 10.25* 
MCoTI-II [AKQ] P AKQ I K K 71 11.7* 
MCoTI-II [AVP] A V P K K 65 10* 
MCoTI-II [PVP] P V P K K 76 10* 
SGSDGGVC L CRRDSDCPGACICRGNGYCG 
P2P1P1’ P3’P4’ 
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MCoTI-I, II and all variant MCoTI-IIs were synthesised successfully in excellent 
yield, with the assistance of thia-zip NCL strategy. The corresponding re-
engineered MCoTI-II sequences were varied according to the characteristics of the 
targeted proteases, as follows: 
 
(i) Re-engineering of Lys or Arg at the P1 position was hypothesised to 
target all serine “trypsin-like” proteases; such as trypsin, tryptase and 
matriptase, etc (Beckmann et al., 1988; Li et al., 2007). 
 
(ii) Hydrophobic residues, such as Phe at the P1 position were proposed to 
fill the S1 pocket, which increases the binding affinity with chymotrypsin 
and subtilisin (Longstaff et al., 1990). 
 
(iii) Small hydrophobic residues such as Ala, or Val at the P1 residues were 
reported to fit well into the small hydrophobic cavity of the S1 site of 
both porcine pancreatic and human leukocyte elastases. Substituting 
Ile11 with Pro was also investigated (McBride et al., 1999; Ohmoto et 
al., 2000).  
 
(iv) The tripeptide Ala-Lys-Gln at the P1 position was introduced to mimic 
the recently reported FMDV 3Cpro inhibitors, which bear Ala-Lys-Gln in 
their inhibitory loop sequences (Roque-Rosell, 2008). 
 
 
Thia-zip assisted macrocyclisation is entropically more favourable compared to the 
conventional cyclisation strategy, mainly due to the formation of discrete 
intermediates followed by successive ring enlargement, assisted by a thiol (-SH). 
The resulting macrocyclic peptides were subsequently refolded in the presence of 
glutathione to yield the correctly folded re-engineered MCoTI-II analogues.  
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It should be noted that the increase of inhibitory loop size upon introduction of the 
tripeptide Ala-Lys-Gln did not affect the cyclisation efficacy. The reaction was 
carried out smoothly under the similar condition to that of MCoTI-II.  
 
To the best of our knowledge, chemically synthesised MCoTI-II [AKQ] at 36 
amino acids long appears to be among the largest cyclotides reported to date, and 
was prepared in excellent yield. The activities of a variety of re-engineered MCoTI-
IIs were determined against a panel of proteases, discussed in Chapter 4.  
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Summary 
The cyclisation of macrocyclic peptides is disfavoured, mainly according to the 
distance between the two ends. The head-to-tail cyclisation of a macrocyclic 
peptide with only one step of N- to C- thiolactone formation and subsequently 
spontaneous ring contraction with an S, N acyl migration was very slow (Tam et al., 
1999b). 
 
In contrast, the macrocyclic cyclisation of peptides with internal thiols (thia-zip 
NCL) was achieved, assisted by the small discrete intermediate rings of 13-110 
atoms with extraordinary speed (>100 times faster) compared to that of head-to-tail 
cyclisation alone. This clearly suggests that the ring enlargement through thiol-
thiolactone exchange was facilitated by the presence of the internal thiol. The 
macrocyclisation efficiency was largely influenced by the reversible S-acylation 
and irreversible S, N acyl migration. Intramolecular S-acylation was chemoselective 
due to the greater nucleophilicity of the thiol compared to the amine at nearly 
neutral pH, leading to only thiol-thiolactone exchange being observed. The side 
chain participation reaction of Lysine (-NH2) and Arginine (guanidine) was not 
observed. The final S-acyl intermediate at the Nα-Cys residue was driven by the 
close proximity between C-terminal thiolactone and Nα-Cys, allowing the 
spontaneous irreversible S to N acyl transfer to generate the stable peptide bond. 
 
The disulfide bond connectivity of the resulting product (correctly folded MCoTI-
II) was confirmed by NMR spectra compared to that of natural MCoTI-II isolated 
from plants, previously reported by Craik, both of which shared great similarities in 
both NMR spectra and inhibition results against trypsin (with Ki ~ 30 pM, see 
Chapter 4). The methodology reported here was further applied to non-naturally 
occuring macrocyclic cyclotides through re-engineering its inhibitory loop as well 
as truncating the mobile loop, further discussed in Chapter 5.  
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Chapter 3 Immobilized Protease Assisted 
Synthesis of MCoTI-II and Analogues 
 
This chapter presents the syntheses of naturally 
occurring MCoTI-I and II by chemoenzymatic 
means. This is also applied to the syntheses of non-
naturally occurring cyclotides based on the MCoTI-
II scaffold. 
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3.1 An Overview of Protease-Assisted Peptide Synthesis 
The proteolytic role of proteases has long been recognised (Barrett et al., 1998; 
Hedstrom, 2002). However, the ability of proteases to form peptidic bonds has also 
been among of great interest, and how been increasingly studied in organic 
syntheses (Beck-Piotraschke & Jakubke, 1998; Bordusa, 2001; Bordusa, 2002; 
Malak, 1999; Yadav et al., 2001).  
 
Protease-assisted bioactive peptide synthesis has become of considerable interest 
due to advantages over conventional chemical methods, including high specificity 
(both regio- and stereo-specific) (Bordusa, 2002; Shen, Tian & Ye, 2005; Yan, Tian 
& Ye, 2001) and the reduction of side reactions and racemisation (Bordusa, 2002). 
Typically, protease-catalysed peptide synthesis is carried out in aqueous solution, 
however, it has been reported that protease-mediated cyclisation could also be 
implemented in the presence of organic media. This shifts the thermodynamic 
equilibrium of the favorable ligation over that of the hydrolysis (Shen et al., 2005). 
The synthetic efficiency is dependent on many factors, including temperature, 
reaction time and substrate structure. 
 
Currently, a large number of proteases have been applied in the syntheses of 
organic molecules (Beck-Piotraschke & Jakubke, 1998; Bordusa, 2001; Bordusa, 
2002; Jackson et al., 1995; Liu & Tam, 2001; Malak, 1999; Wu et al., 2003; Yadav 
et al., 2001), and protease-mediated peptide synthesis has become one of the most 
useful tools for the synthetic organic chemist, mainly focusing on the formation of 
peptide bond. The mechanism of protease-mediated peptide bond formation appears 
to be that the protease can accelerate the formation of the peptide bond under 
conditions where hydrolysis is less favourable than ligation (Bordusa, 2002; Shen et 
al., 2005). However, the uses of proteases in organic synthesis are largely restricted 
by their low reaction rates and the high enzyme concentration required (Bordusa, 
2002; Jackson et al., 1995). The synthesis efficacy is particularly affected by 
enzyme specificity, in which the specificity of the acyl donor and acceptor binding 
domains varies greatly between enzymes (Bordusa, 2002; Jackson et al., 1995). 
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To date, there are a small number of publications, which report protease-catalysed 
peptide syntheses, especially protease-mediated peptide cyclisation.  
 
Chymotrypsin, trypsin and subtilisin are examples of serine proteases that have 
been used widely in peptide synthesis (Beck-Piotraschke & Jakubke, 1998; Jackson 
et al., 1995; Liu & Tam, 2001; Shen et al., 2005). 
 
Subtilisin and subtiligase (a mutated version of subtilisin) are examples of serine 
proteases that have been utilised extensively for peptide ligation, including head-to-
tail cyclisation in which the efficiency of cyclisation is remarkably related to the 
peptide sequences and the peptide length (Jackson et al., 1995; Liu & Tam, 2001). 
In the case of subtilisin, large hydrophobic residues at P1 position (the donor site) 
are preferentially required to fit perfectly into the S1 binding pocket, while the S1’ 
binding pocket (the acceptor site) favors non-polar type residues (Jackson et al., 
1995; Liu & Tam, 2001). Furthermore, it was found that only peptides longer than 
10 residues are capable of cyclisation, mainly due to their flexibility that allow 
them to adopt a productive binding conformation. In contrast, shorter peptides were 
found to be readily hydrolysed and dimerised rather than cyclised (Jackson et al., 
1995; Liu & Tam, 2001). 
 
Currently, serine proteases used as catalysts in peptide synthesis have progressed 
significantly, and one of the latest reports of trypsin mediated peptide cyclisation 
has been published on the synthesis of naturally occurring cyclic peptide, named 
sunflower trypsin inhibitor-1 (SFTI-1) (Marx et al., 2003). Linear SFTI-1[6, 5] was 
incubated with trypsin, conferring a corresponding ratio of cyclic SFTI-1 and open 
chain SFTI-1[6, 5] of 9:1 as displayed in Figure 3.1. Indeed, SFTI-1 has been 
recognised as one of the most potent trypsin inhibitors, comprising 14 amino acid 
peptides as discussed previously in Chapter 1.   
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The novel cyclisation mechanism for trypsin-mediated SFTI-I synthesis gives an 
effective means of synthesing cyclic protease inhibitors, and so it seemed possible 
that this synthetic strategy might potentially be applied in the synthesis of 
macrocyclic cysteine knot microproteins. MCoTI-I and MCoTI-II sequences, in the 
form of unprotected linear peptides (assembled via SPPS), might be cyclised by 
using trypsin to achieve the MCoTI cyclotides syntheses (both MCoTI-I and II). 
 
 
Figure 3.1 Trypsin assisted SFTI-I [6, 5] cyclisation (Marx et al., 2003) 
The cyclisation of SFTI-I [6, 5] is mediated by trypsin. SFTI-I [6, 5] is composed of an opended 
peptide chain bearing the P1 = Lys, and the P1’ = Ser. This reversible reaction results in the 
corresponding products (SFTI-I [6, 5]: SFTI-I = 1:9). 
 
3.2 The synthetic strategy of protease-assisted MCoTI syntheses 
The discovery of trypsin-mediated cyclisation in SFTI-I synthesis has revealed the 
possibility of using serine proteases, especially trypsin and chymotrypsin, in the 
syntheses of macrocyclic cysteine knot microproteins, MCoTI-I and MCoTI-II. All 
previously reported syntheses of macrocyclic cysteine knot microproteins were 
achieved successfully by the thia-zip assisted NCL strategy (Tam, 1997; Tam, Lu & 
Yu, 1999; Tam et al., 1999b; Thongyoo et al., 2006), and there have been no 
protease-mediated macrocyclic cysteine knot microprotein syntheses reported so 
far. The well-defined trypsin binding site of the MCoTI backbone, coupled with the 
inherent reversibility displayed in protease cleavage of head-to-tail cyclic peptides 
might permit protease mediated ligation of the cyclotide backbone between 
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positions P1 and P1’ in the active loop (i.e. Lys10-Ile11 in the case of MCoTI-I and 
II), leading to a novel synthetic strategy of chemoenzymatic cyclisation in the total 
synthesis of the MCoTI cyclotides. 
 
The synthetic strategy of protease-assisted MCoTI syntheses involved three distinct 
stages that are significantly similar to that of thia zip assisted MCoTI synthesis 
strategy as previously discussed in Chapter 2 in some stages: 
 
1. Linear peptide backbone assembly through SPPS strategy 
2. Oxidative folding to the native cysteine knot topology 
3. Protease-mediated macrocyclic cyclisation of linear peptides 
 
First of all, prior to the backbone assembly, an appropriate backbone disconnection 
point of MCoTI cyclotides needed to be selected, greatly depending on the enzyme 
binding site used in cyclisation (Bordusa, 2002). Therefore, the requisite Ile11-
Lys10 (P1 and P1’ residues) were chosed as the disconnection point (in the case of 
MCoTI-I and II syntheses) due to the trypsin specificity requirement of cyclisation 
that primarily depends on the amino acid at the P1 position, which prefers a positive 
amino acid such as lysine or arginine. However, the hydrophobic P1 residue, such 
as phenylalanine was preferentially required for chymotrypsin-mediated 
cyclisation, mainly according to its complementary to the binding pocket (the S1 
binding pocket). 
 
Additionally, the influence of the amino acid replacement at the P1 position against 
protease-assisted cyclisation strategy was investigated. Therefore, a range of 
unnatural MCoTI-II analogues were designed in which the amino acid residue at 
the P1 position was switched to a number of different types of amino acids, ranging 
from a non-charged amino acid (Gln), a hydrophobic amino acid (Phe) and a 
positively charged amino acid (Arg). In this thesis, two different serine proteases, 
trypsin and chymotrypsin were applied to this chemoenzymatic strategy.  
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Our protease-mediated the MCoTI synthesis strategy was initiated by assembling 
the C-terminal acid backbone via Fmoc SPPS (Atherton & Sheppard, 1989); the 
resins used for the syntheses are shown in Table 3.1.  
 
Table 3.1 Preloaded Wang resins used in the assembly of MCoTIs backbone 
 
Examples of preloaded Wang resin used in amino acid assembly of MCoTI-I, II and analogues are 
shown. 
 
3.2.1 The synthetic route for refolded MCoTI (rf-MCoTI) synthesis 
The synthetic strategy of rf-MCoTI synthesis is shown in Figure 3.2 where Lys10 
(the P1 residue) of MCoTI-II sequence was successfully re-engineered to a number 
of other amino acids as shown in Table 3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
Compounds P1 residue [X1] P1-Wang resin (X1) 
Loading 
(mmol/g) 
oc-MCoTI-I acid K Fmoc-Lys(Boc)-Wang 0.69 
oc-MCoTI-II acid K Fmoc-Lys(Boc)-Wang 0.69 
oc-MCoTI-II[R] acid R Fmoc-Arg(Pbf)-Wang 0.51 
oc-MCoTI-II[F] acid F Fmoc-Phe-Wang 0.74 
oc-MCoTI-II[Q] acid Q Fmoc-Gln(Trt)-Wang 0.62 
oc-MCoTI-II[AKQ] acid Q Fmoc-Gln(Trt)-Wang 0.62 
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Figure 3.2 The synthetic route for rf-MCoTI synthesis 
  
The synthetic strategy for rf-MCoTI-II synthesis is initiated by amino acid assembly via Fmoc/tBu 
SPPS (a), followed by acidolysis (b) and refolding in the presence of glutathione (c), respectively to 
yield the correctly folded rf-MCoTI-II: a) Fmoc/tBu SPPS, b) TFA, H2O, EDT, TIPS (94:2.5:2.5:1), 
c) 0.1 M ammonium carbonate (pH 7.8/acetonitrile 1:1, 1 mM glutathione (reduced form). X1 = X3 = 
X4 = K (rf-MCoTI-II), X1 = K, X3 = Q, X4 = R (rf-MCoTI-I). 
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In this thesis, standard Fmoc SPPS protocol was applied to the backbone assembly 
(Atherton & Sheppard, 1989; Carpino & Han, 1972), with several optimisations. 
Asp4-Gly5 was introduced as a dipeptide building block incorporating a 2-hydroxy-
4-methoxy benzyl (Hmb) protecting group on the glycine backbone to suppress 
aspartimide formation (Mergler, 2003), and double coupling of certain residues was 
needed (shown in experiental section 7.3.1). The resulting fully protected peptide 
bound to Wang resin was then cleaved using deprotection mixture 
(TFA/EDT/H2O/TIPS; 9.4:2.5:2.5:1) which was followed by precipitation with 
TBME to afford the oc-MCoTI acids in excellent yield as shown in Figure 3.2. 
Interestingly, no oxidation of cysteine was observed during the deprotection and 
purification steps, and purity and molecular mass were confirmed by analytical-
HPLC and MALDI-MS, respectively.  
 
oc-MCoTI sequences were subsequently refolded to the cysteine-knot peptide  
rf-MCoTIs by exposure to a mild oxidant (glutathione in 50% acetonitrile/0.1 M 
ammonium bicarbonate) to provide correctly folded rf-MCoTI in excellent yield as 
shown in Table 3.2. The oxidative folding of oc-MCoTI acids in the presence of 
acetonitrile yielded a high proportion of correctly folded forms as it has been 
reported that organic solvent (acetonitrile) used in the oxidative folding step could 
stabilise hydrophobic moieties which in turn increases the exposure of hydrophobic 
moieties to solvent, resulting in the formation of correctly folded rf-MCoTI (Daly, 
1999). Under this optimised condition, no misfolded peptide was observed by 
HPLC and yield is shown in Table 3.2. 
 
3.2.2 Immobilised protease-assisted cyclisation 
In our initial attempts to achieve backbone ligation of MCoTI cyclotides, trypsin-
mediated backbone cyclisation of rf-MCoTI-II was firstly conducted using solution 
phase proteases, bovine-β-trypsin (Aldrich) and chymotrypsin (Aldrich). Not only 
was the fully folded cyclotide detected, autodigested products (from the proteases 
themselves) were also observed together with the fully folded cyclotides.  
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As a consequence, on-bead cyclisation has been developed using solid supported 
proteases. Both solid supported trypsin and chymotrypsin were thus introduced for 
protease-assisted MCoTI syntheses in order to prevent the autodigestion problem 
from the proteases themselves that directly affected the purity of the products after 
cyclisation. Typically, trypsin immobilised on Sepharose beads (polymer-supported 
trypsin, PST) is used extensively for sequencing applications, since contaminations 
through autocleavage is greatly suppressed. The challenge of using PST as a 
polymer-supported ligase for clean MCoTI macrolactamisation greatly depends on 
the cyclisation efficacy and specificity, and has also been one of our great interests.  
 
In this experiment, MCoTI-II was synthesised via immobilised trypsin, following 
by the further synthesis of MCoTI-II analogues where the amino acid residue at P1 
position (from MCoTI-II sequence) was switched to a wide range of amino acids: 
the positively charged residues (Arg/Lys), hydrophobic residue (Phe) and 
uncharged residue (Gln). The synthetic strategy is shown in Figure 3.2 and Figure 
3.3, and the yields are given in Table 3.2. 
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Figure 3.3 Chemoenzymatic synthesis of MCoTI-II with polymer-supported trypsin (PST)  
 
Chemoenzymatic cyclisation of rf-MCoTI-II is initiated by incubating rf-MCoTI-II with PST, which 
is subsequently cyclised to yield MCoTI-II. Finally, MCoTI-II is released from enzyme complex 
after adding 0.1 % TFA. (Buffer B: 100 mM sodium phosphate pH 7.0). A picture is adapted from 
(Thongyoo et al., 2007; Thongyoo et al., 2008). 
 
A typical binding procedure is described in detail as follows; an immobilised 
trypsin was initially washed with 0.1 M phosphate buffer prior to continuing 
protease-assisted macrocyclisation processes. Subsequently, a two-fold excess of rf-
MCoTI-II was incubated with sequencing-grade PST suspended in phosphate buffer 
(100 mM, pH 7.4), after which the beads were washed several times with buffer to 
minimise contamination by uncyclised products. The newly formed cyclotide was 
believed to bind tightly to the trypsin catalytic site, enabling facile in situ affinity 
purification. Additionally, it was known that increased protonation at the trypsin 
active site might enable the cyclotide to be  released from the putative cyclotide-
enzyme complex in a non-denaturing and pH-dependent manner, and thus allow the 
PST to be recycled. Finally, 0.1% TFA was added to the washed immobilised 
protease to yield the cyclised products (MCoTI-II) in good yields  
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(> 90 %). Interestingly, it was found that ratio between an expected product 
(MCoTI-II) and rf-MCoTI-II (starting material) was approximately 9:1 for all 
MCoTI-I, II and MCoTI-II[R]. The comparison between enzymatically synthesised 
MCoTI-I, II and MCoTI-II[R] with authentic material from thia-zip NCL assisted 
MCoTI-II syntheses has shown that MCoTI-IIs synthesised by this 
chemoenzymatic method was identical in all respects with that of naturally 
occurring MCoTI-II from thia-zip strategy; identical retention time and trypsin 
inhibition result (further discussed in Chapter 4). Protease-assisted cyclisation 
HPLC traces of MCoTI-II synthesis are shown in Figure 3.4. 
 
 
 
 
Figure 3.4 HPLC trace representation of synthetic intermediates  
HPLC traces showing synthetic intermediates: A) oc-MCoTI-II; B) rf-MCoTI-II; C) elution of 
MCoTI-II from PST with 0.1 % TFA. Gradient: 0 to 85 % MeCN in H2O (+ 0.1 % TFA) over 40 
min (see the experimental section). A picture is adapted from (Thongyoo et al., 2007). 
 
 
Interestingly, it should be noted that the oxidative folding step, immobilised 
protease-mediated cyclisation, and also the the affinity purification could be 
accomplished within a single pot by simple incubation of crude oc-MCoTI-II in 
buffer containing 1 mM glutathione with polymer-supported trypsin (PST), giving 
MCoTI-II and ~ 10% residual rf-MCoTI-II with relatively high purity upon elution 
with 0.1% TFA. This facile approach was further applied to re-engineered MCoTI 
syntheses, such as MCoTI-I, MCoTI-II[R] and MCoTI-II[F] as shown in Table 3.2.  
5 7 9 11 13 15 17 Time (s)
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The open chain forms (oc-MCoTI) of the naturally occurring cyclotides MCoTI-I 
(P1 = Lys) and three MCoTI-II analogues in which the P1 residue was subtituted by 
Arg, Gln and Phe were synthesised via SPPS, and the subsequent refolding 
strategy, and including PST, or PSC-mediated cyclisation as appropriate.  
 
Table 3.2 Yield of cyclotides and intermediates synthesised by SPPS, refolding and proteases 
mediated backbone ligation  
 
Cyclotides  
Lys10 = [X] 
Yield (%) 
SPPS  
oc-Cyclotides 
Refolding  
rf-Cyclotides 
PST 
Cyclotides 
PSC 
Cyclotides 
MCoTI-I 7 72 93a 0b 
MCoTI-II 8 65 92a 0b 
MCoTI-II[R] 13 59 94a 0b 
MCoTI-II[F] 10 64 0b 90a 
MCoTI-II[Q] 5 60 0b 0b 
MCoTI-II[AKQ] 5 36 0b 0b 
a
 In each case, residual rf-cyclotide was returned in 7-10% yield after in situ affinity purification. 
b Starting material partially digested 
 
 
As seen from Table 3.2, it is clearly found that polymer-supported trypsin (PST) 
displayed high ligation specificity, with only positively charged amino acid residues 
at the P1 position in the inhibitory loop (Arg or Lys) giving the cyclic product. Both 
naturally and non-natually occurring macrocyclic MCoTI-I (93%) and MCoTI-
II[R] (94%) were synthesised successfully via PST with high purity compared to 
that of MCoTI-I and MCoTI-II[R] synthesised via thia-zip NCL based strategy. 
However, in the case of PST mediated cyclisation open chain fully folded  
rf-MCoTI-II[F] and rf-MCoTI-II[Q] were found to be cleaved by PST at one or 
more positions on the backbone, with multiple peaks detected in the RP-HPLC 
traces.  
 
Furthermore, re-engineering the inhibitory loop of rf-MCoTI-II scaffold at the P1 
residue with Phe was expected to be cyclised by chymotrypsin. As a consequence, 
oc-MCoTI-II[F] was refolded, and incubated with commercially available 
sequencing-grade polymer-supported chymotrypsin (PSC) to yield MCoTI-II[F] 
(90%), with 10% residual rf-MCoTI-II [F]. It is interesting to note that protease-
assisted cyclisation reaction appeared to be highly specific since only open chain  
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rf-MCoTI-II in which amino acid residues at the P1 position was Lys and Arg can 
be cyclised by trypsin, and only Phe is cyclised by chymotrypsin as shown in  
Table 3.2. It is important to note that rf-MCoTI-II[F] has been the only MCoTI-II 
analogue in the series that is susceptible to be cyclised by PSC whereas others were 
either inreactive or partially digested under the same condition. It is important to 
note that selectivity of protease-mediated macrocyclisation appears to be closely 
related to inhibition potency since the only most potent inhibitory cyclotides are 
susceptible to ligation with given solid-supported proteases. A wide range of mutant 
rf-MCoTI-IIs were treated with PSC, but only rf-MCoTI-II in which the amino acid 
residue at the P1 residue was Phe was cyclised by chymotrypsin. There is therefore 
a clear mechanistic implication: to be cyclised by the protease it is necessary to 
have a sequence that will ultimately act as a potent inhibitor of that protease. 
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3.2.3 The proposed mechanism of immobilised proteases assisted cyclisation 
This work has shown that proteases have the potential to be applied as catalysts for 
macrocyclic peptide syntheses, including MCoTI-I and MCoTI-II. To the best of 
our knowledge, the protease-mediated macrocyclic peptide syntheses reported here 
represent the first examples of using proteases in the syntheses of cyclotides.  
 
Although resyntheses of the peptide bond between the P1-P1’ residues have been 
reported extensively for various protease inhibitors, the MCoTI syntheses reported 
here are different in that they involve formation a cyclic cysteine knot (Jackson et 
al., 1995; Liu & Tam, 2001; Shen et al., 2005). Also, macrocyclisation was found 
to be achieved under very mild conditions. 
 
As observed from the trypsin-assisted cyclisation HPLC traces (Figure 3.4), open 
chain starting material (rf-MCoTI-I) was detected together with the targeted 
products (MCoTI-I) with a ratio of approximately 9:1. It is hypothesised that two 
possibilities might explain this. First, rf-MCoTI-I (starting material) might be 
remaining. Second, it is possible that the remaining rf-MCoTI-I might be an 
intermediate that resulted from ligation and cleavage equilibrium. Therefore, the 
incubation of MCoTI-I with immobilised trypsin experiment was needed to confirm 
this mechanism. It was found that after incubation of intact MCoTI-I cyclotide, rf-
MCoTI-I (starting material) was still detected by HPLC with a ratio between 
MCoTI and rf-MCoTI-I of approximately 9:1. HPLC traces were shown in Figure 
3.5. This suggests that the 9:1 ratio represents the equilibrium position between 
open chain and closed chain forms and that the enzyme catalyses the formation of 
this equilibrium, irrespective of whether the starting point is either of these species. 
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Figure 3.5 HPLC traces of MCoTI-I after being incubated with trypsin  
 
This figure displays the reversibility in trypsin mediated MCoTI-I synthesis as MCoTI-I was 
incubated with trypsin to yield the corresponding products (rf-MCoTI-I: MCoTI-I = 1:9). Std. 
MCoTI-I (A); MCoTI-I after incubated with trypsin (B) 
 
 
Currently, protease-mediated cyclisation mechanism is not certain, but it is likely 
that the mechanism of chemoenzymatic cyclisation involves the nucleophilic attack 
of the hydroxyl group of Ser195 to the carbonyl carbon of amino acid residue at the 
P1 residue as depicted in Figure 3.6; the positively charged residues such as Lys10 
15 
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B 
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or Arg10 (in the case of trypsin mediated macrocyclisation), or the large 
hydrophobic residue such as Phe10 (in the case of chymotrypsin mediated 
macrocyclisation), resulting in the formation of the tetrahedral intermediate (B) that 
subsequently decomposes to yield an acyl-enzyme intermediate (C). This acyl-
enzyme intermediate (C) is an important intermediate in protease-mediated 
macrocyclisation. This intermediate can readily be hydrolysed by water, which 
gives rf-MCoTI-, or attacked by the amino group of the P1’ residue, which results 
in the formation of a peptide bond between Lys10 and Ile11 (D). Finally, the 
cyclised MCoTI-II bound tightly with the protease active site after cyclisation that 
can be cleaved from active site by adding 0.1 % TFA as represented in Figure 3.6.  
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Figure 3.6 The proposed mechanism of protease-assisted cyclisation 
 
 
 
 
 
The proposed mechanism of protease-mediated cyclisation is initiated by the nuclophilic attack of 
oxygen nucleophile of Ser195 at the carbonyl oxygen of the P1 residue (A) to give an acyl-enzyme 
intermediate (C). 
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Figure 3.6 (continued) The proposed mechanism of protease-assisted cyclisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This acyl-enzyme intermediate (C) is reacted with hydroxyl oxygen from water to yield a recovered 
product (rf-MCoTI), or reacted with an amino nitrogen from the P1’ residue to generate cyclic 
peptide (D).  
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3.2.4 The synthesis of MCoTI-II (via selective disulfide bond formation) 
I had also developed the synthetic strategy for the synthesis of  
MCoTI-II via orthogonal deprotection of cysteine. This synthetic strategy was 
designed to generate disulfide bonds selectively, leading to the reduced number of 
product possibilities (rf-MCoTI-II). The proposed synthetic strategy is displayed in 
Figure 3.7. This synthetic strategy is focussed on the selective formation of 
disulfide bonds. As can be observed from the MCoTI-II sequences, there are six 
cysteine residues in MCoTI-II. As a result, more than ten product possibilities 
might theoretically be observed after the oxidative folding process. To reduce the 
number of possible disulfide forms, a synthetic strategy of rf-MCoTI-II involving 
selective disulfide bond formation was carried out as similar as discussed 
previously in Section 3.2.1: (1) amino acid assembly through SPPS strategy, (2) 
oxidative folding to form the correct cysteine knot topology and (3) trypsin-
mediated macrocyclisation. However, the great difference was two different types 
of protected cysteine used in the amino acid assembly step, acetamidomethyl (Acm) 
and triphenylmethyl (Trt). These were applied for amino acid assembly that can be 
deprotected orthogonally, leading to the selective formation of disulfide bonds 
under different conditions. 
  
The disulfide bond between Cys8-Cys25 was proposed as the first appropriate 
disulfide bond formed, mainly due to its flexibility (located closed to the mobile 
loop). In addition, the requisite Ile11-Lys10 was selected as the disconnection point 
as similar to previous strategy. 
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Figure 3.7 The representation of proposed synthetic methodology for selective disulfide bond 
formation of rf-MCoTI-II 
 
This synthetic methodology is as follows: first, amino acid assembly (A) with Fmoc/tBu SPPS 
strategy; then orthogonal disulfide bond formation (B-C) using two different protected cysteine, 
Fmoc-Cys(Acm)-OH and Fmoc-Cys(Trt)-OH and finally protease-mediated MCoTI-II cyclisation 
(D). 
 
 
 
The synthetic strategy of MCoTI-II cyclotide using a selective disulfide bond 
formation protocol is shown in Figure 3.8. 
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Figure 3.8 The synthetic strategy of rf-MCoTI-II synthesis via selective disulfide bond formation  
a) Fmoc/tBu SPPS, b) (1). TFA, H2O, EDT, TIPS (94:2.5:2.5:1), (2). 20% DMSO in AcOH, c) 10 
eq. I2 in AcOH-H2O (4:1) 
 
This synthetic strategy is initiated by amino acid assembly via Fmoc/tBu SPPS (a), followed by 
acidolysis and DMSO oxidation (b). Acm protected oc-MCoTI-II is cleaved by I2/AcOH to yield the 
misfolded rf-MCoTI-II [B]. 
 
The requisite Lys10 C-terminal acid open chain backbone (oc-MCoTI-II), where 
four cysteine residues were protected with acetamidomethyl (Acm) and two 
remaining cysteine residues protected by triphenylmethyl (Trt), were assembled 
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according to the Fmoc-tBu SPPS strategy. Aspartimide formation of the Asp-Gly 
(DG) motif was effectively suppressed by Hmb protection at the glycine backbone 
nitrogen. After acidolysis, the material that was partially protected with Acm was 
subsequently oxidised via DMSO oxidation to yield the first disulfide bond 
between Cys8 and Cys25 called oc-MCoTI-II (A). It was reported that this disulfide 
bond (Cys8-Cys25) was crucial for the oxidative folding mechanism of MCoTI-II 
due to its flexibility (Cemazar et al., 2006; Daly, Clark & Craik, 2003). Acm-
protected oc-MCoTI-II (A) was thus cleaved by iodine in acetic acid (Cline, Thorpe 
& Schneider, 2004) to yield the fully folded MCoTI-II (B) with moderate yield 
(60%), which was subsequently analyzed by analytical HPLC and MALDI-MS 
means to confirm its molecular mass. Interestingly, only one product was observed 
despite six cysteine residues in the molecules. However, a great difference between 
the resulting rf-MCoTI-II (B) from this strategy and the correctly folded rf-MCoTI-
II was observed. The resulting rf-MCoTI-II (B) appeared with retention time 
around 11.5 min, as compared to the correctly folded rf-MCoTI-II (Rt = 11.4 min). 
The difference of hydrophobicity between rf-MCoTI-II via selective disulfide bond 
strategy and rf-MCoTI-II as previously reported in Section 3.1.1 is attributed to the 
different folding between both rf-MCoTI-IIs.  
 
After confirming purity by analytical HPLC, the resulting rf-MCoTI-II (B) was 
subsequently incubated with trypsin in phosphate buffer (100 mM, pH 7.4) at 37 °C 
for 15 min after which the reaction mixture was quenched by adding 0.1 % TFA 
and analysed with analytical HPLC and MALDI-MS. Unfortunately, no expected 
MCoTI-II was detected from the reaction mixture and only digested fragments were 
detected.  
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As a result, it became clear that the great difference of the folding between two  
rf-MCoTI-IIs was one of the most significant factors to ascribe to its unsuccessful 
cyclisation by trypsin. Therefore, re-folding of incorrectly folded of rf-MCoTI-II 
into correctly folded scaffold was required, and achieved in the presence of 
glutathione as shown in Figure 3.9.  
 
 Figure 3.9 The representation of re-folding strategy of rf-MCoTI-II and trypsin mediated 
cyclisation 
 
This synthetic strategy is initiated by the conversion of a misfolded rf-MCoTI-II (B) into a correctly 
folded rf-MCoTI-II in the presence of glutathione. The correctly folded rf-MCoTI-II is subsequently 
cyclised by PST and released from enzyme complex after adding 0.1 % TFA.  
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As shown in Figure 3.9, incorrectly folded rf-MCoTI-II (B) from the selective 
disulfide bond strategy can be converted to the correctly folded rf-MCoTI-II in the 
presence of glutathione with an excellent yield (75%) as confirmed by comparison 
of the retention time between standard correctly folded rf-MCoTI-II, displaying the 
identical retention time (Rt = 1.4). Then, rf-MCoTI-II was subsequently incubated 
with trypsin with similar conditions as previously displayed in Figure 3.3. It was 
found that MCoTI-II was detected by analytical HPLC and confirmed by MALDI-
MS. Interestingly, it should be noted that the cyclisation efficiency via protease 
mediated macrocyclisation appeared to primarily depend not only on its sequence 
specificity (amino acid residues at the P1 position), but it also relied significantly 
on its folding. The misfolded rf-MCoTI-II (B) did not cyclise by trypsin, despite  
rf-MCoTI-II (B) possessing a necessary Lys10 (at the P1 residues) that is crucial for 
trypsin assisted macrocyclisation. Nevertheless, the misfolded rf-MCoTI-II (B) was 
further refolded in the presence of glutathione to provide the correctly folded  
rf-MCoTI-II scaffold, which was subsequently cyclised by trypsin with excellent 
yield. 
 
3.2.5 The comparison of MCoTI-II synthesis strategy between thia zip assisted 
cyclisation and protease-assisted macrocyclisation 
 
Thia-zip assisted macrocyclisation and protease-mediated macrocyclisation have 
been developed successfully for MCoTI-IIs syntheses, both of which were 
markedly different in terms of synthetic specificity and synthetic efficiency.  
 
The advantages and drawbacks of both synthetic strategies are addressed as 
follows: 
 
Thia zip assisted macrocyclisation strategy  
 
(i) The great advantage of this strategy lies largely in its synthetic 
efficiency, allowing a large number of re-engineered MCoTI-II 
scaffolds to be synthesised via substituting the amino acid at the P1 
position. This enables targeting a panel of serine proteases, ranging 
    Chapter 3 Immobilized protease-assisted synthesis of MCoTI-IIs  
115 
 
from trypsin, tryptase to matriptase in which Lys/Arg residues were 
required at the P1 position and including chymotrypsin and subtilisin 
where Phe was required at the P1 residues. 
 
(ii) The large scale syntheses could be accomplished via this strategy 
with excellent yield although optimisations were necessary in some 
stages. 
 
(iii) The limitation of this strategy was that several synthetic steps were 
involved, such as backbone assembly, activation and displacement as 
well as thia-zip NCL, which directly affected to the resulting yield.  
 
Protease-mediated macrocyclisation strategy  
 
(i) This synthetic strategy was conducted by using protease attached to 
solid supports in order to achieve on-bead cyclisation, and the fact 
was that after cyclisation with trypsin, resulting MCoTI-I and II 
bound tightly to the trypsin catalytic site. All unreacted starting 
materials, including side products, could then be simultaneously 
removed from the reaction media, resulting in no purification 
needed after cyclisation. Therefore, this strategy effectively 
combined the macrocyclisation with on-bead affinity purification. 
 
(ii) The limitation of the protease-mediated cyclisation strategy is that 
protease attached solid support used in this strategy is very costly 
although it can be recycled for at least five cycles after being used. 
Recycled proteases attached to solid support (both trypsin and 
chymotrypsin) were examined for residual activity, and no 
detectable loss of activity was observed. 
 
(iii) Protease-assisted cyclisation is highly regio- and stereo-specific and 
particularly restricted to only amino acids that are preferentially 
required to individual proteases; such as Lys/Arg at P1 position for 
trypsin or Phe at the P1 position for chymotrypsin. 
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Summary 
We have achieved the total synthesis of the MCoTI cyclotides via a novel 
biomimetic strategy. Commercially available polymer-supported proteases, 
showing a role of ligating the refolded cyclotide backbone, have been utilised for 
this chemoenzymatic strategy. This chemoenzymatic approach reported here has 
shown greater efficacy than the non-enzymatic approach, previously reported in 
Chapter 2 (thia zip assisted cyclisation strategy) with in situ affinity purification of 
the target cyclotide. 
 
The correctly folded rf-MCoTI analogues were subsequently ligated in the presence 
of appropriate proteases, raising the possibility that biosynthesis of MCoTI 
cyclotides might follow a protease/ligase pathway in vivo, in a similar manner to 
the structurally related Kalata cyclotide family. It is important to note that their 
structures can be re-engineered without loss of activity and we have reported the 
first instance of redesigning the active loop of a cyclotide to redirect its specificity 
towards an alternative target whilst retaining high affinity.  
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Chapter 4 Protease Inhibition Results for 
MCoTI-II and Analogues 
 
This chapter mainly focuses on the ability of the 
MCoTI cyclotide to inhibit the well-studied serine 
proteases trypsin and chymotrypsin, along with 
some medically important serine proteases: β-
tryptase, matriptase, hepatitis C vitus, elastase and 
FMDV 3Cpro 
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4.1 Overview of Biological Activities of Cyclotides 
Currently, cyclotides have become one of the most actively studied microproteins 
mainly due to their conformational rigidity, which imparts great thermal and 
proteolytic stability (Colgrave & Craik, 2004), and might potentially be utilised as 
peptidic inhibitors in drug discovery and pharmaceutical applications. A diverse 
range of therapeutically useful biological activities have been found in cyclotides, 
ranging across anti-insecticidal activity, uterotonic action, haemolytic activity, anti-
HIV activity, anti-bacterial activity and neurotensin binding inhibition (Daly, 1999; 
Gustafson et al., 1994; Lindholm et al., 2002; Tam et al., 1999a; Witherup et al., 
1994). More than 50 cyclotide sequences have been discovered so far as illustrated 
in Table 1.1 (Chapter 1) (Craik et al., 1999; Simonsen et al., 2005; Trabi & Craik, 
2002). Kalata B1, Circulins and Cyclopsychotride are important examples of 
naturally occurring cyclotides, bearing a broad spectrum of anti-microbial activities 
(Daly, 1999; Gustafson et al., 1994; Lindholm et al., 2002; Tam et al., 1999a; 
Witherup et al., 1994).  
 
The plant-derived cyclotides MCoTI-I and MCoTI-II from Momordica 
cochinchinensis have been investigated extensively as some of the most potent 
trypsin inhibitors to date (Avrutina et al., 2005; Felizmenio-Quimio et al., 2001; 
Heitz et al., 2001). These trypsin inhibiting cyclotides have been categorised as a 
novel class of cyclotide proteins as determined by its cysteine knot scaffold, the 
cyclic backbone motif and its well-defined structure, known as a “knot cysteine 
core”, which makes MCoTI-I and MCoTI-II stable to both thermal and enzymatic 
degradation (Colgrave & Craik, 2004).  
 
In this chapter, the inhibitory activity of both wide-type and mutant MCoTI-IIs 
against a broad spectrum of serine proteases, ranging from trypsin, chymotrypsin, 
elastase, β-tryptase, Hepatitis C virus NS3/4A to matriptase have been evaluated, 
including in addition the chymotrypsin-like cysteine protease (FMDV 3Cpro). 
Importantly, the initial trypsin inhibition results for MCoTI-I and MCoTI-II were 
determined and utilised to further design re-engineered MCoTI-II cyclotides, which 
contained a range of substitutions at the P1 position to redirect specificity towards 
alternative protease targets whilst retaining excellent to moderate affinity.  
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4.2 Protease Inhibition Assay 
The enzyme kinetics applicable to this study are briefly introduced as follows:  
 
Enzyme kinetics 
Inhibitors have the ability to reduce the rate of an enzyme-catalysed reaction when 
present in the reaction mixture. Typically, inhibitors can be classified in two main 
groups: reversible inhibitors and irreversible inhibitors (Bowden, 1995). 
 
Irreversible inhibitors are molecules that can bind to an enzyme and result in 
permanent loss of its activity. 
 
Reversible inhibitors are molecules that form complexes with an enzyme, resulting 
in the temporary loss of enzyme activity, which can be reactivated after removal of 
the inhibitor. Enzymes with bound inhibitor show different catalytic properties 
compared to those of free enzyme; therefore, the inhibition potency of inhibitor can 
be determined.    
 
All MCoTI cyclotide inhibitors studied in this thesis are treated as competitive, 
reversible tight binding inhibitors. The mechanism of the kinetics of competitive, 
reversible inhibitors and competitive reversible tight binding inhibitors are outlined 
as follows: 
  
Types of reversible inhibitors:  
The reversible inhibitors can be grouped into four major types (Fersht, 1985): 
 
• non-competitive 
• uncompetitive 
• mixed 
• competitive
    
  Chapter 4 Protease inhibition results  
120 
 
 
Non-competitive, uncompetitive and mixed inhibition occurs when an inhibitor and 
a substrate bind simultaneously to an enzyme and the substrate and inhibitor are not 
competing for the same binding site. 
 
Competitive inhibition can be observed when an inhibitor binds to the active site of 
an enzyme reversibly, and prevents the binding of the substrate to the enzyme. The 
inhibitor structure may appear to be significantly complementary to the structure of 
the substrate-binding site as shown in Figure 4.1.  
 
    
 
 
 
 
Figure 4.1 Representation of Competitive Inhibition  
This figure represents competitive binding inhibition where substrate and inhibitor compete at the 
same binding site. Enzyme binds inhibitor to form enzyme-inhibitor complex, preventing substrate 
binding to the enzyme (Fersht, 1985). 
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Kinetics of Reversible, Competitive Inhibition 
The mechanism of reversible, competitive inhibition is represented as follows 
(Fersht, 1985) 
 
  
 
I is the free inhibitor, and EI is the enzyme-inhibitor complex, which is assumed to 
render the enzyme inactive. In this scheme the enzyme is unable to bind both S and 
I simultaneously.  
 
Solving the rate equation leads to: 
 
 
  E S
1  I ⁄   S   
S1  I ⁄   S                            2.1 
 
 
Kinetic treatment of tight-binding reversible inhibitors 
Many methods of describing the kinetics of inhibitors are available – see (Bieth, 
1995). The Ki measurements used in this thesis were largely based on determination 
of the free enzyme concentrations present at equilibrium after the enzyme is 
incubated with a series of inhibitor concentrations. The residual activity of the free 
enzyme was determined using a known concentration of a fluorogenic substrate.  
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As a result, the initial velocities v0 and vi were measured in the absence and 
presence of inhibitor, respectively and subsequently plotted against inhibitor 
concentration [I] at constant enzyme concentration [E0] and substrate concentration 
[S0] with the using the GraFit software package (Leatherbarrow, 2001). 
 
The equilibrium constant (Ki) for the enzyme-inhibitor complex is given by: 
 
                 ##   $
E % EI& % $I % EI&EI                            2.2 
 
Whereas “a” is the fraction of total enzyme that is not bound to the inhibitor (Bieth, 
1995) 
   
                 $E % EI&E  1 %
EIE                                                      2.3 
 
And also, the fractional rate (vi/vo) is equal to  as following: 
 
                 v )1 % EIE*                                                                2.4 
 
Classical versus tight-binding reversible inhibitors 
Typically, in the case of classical reversible inhibitors, the inhibition is observed 
only when a large excess of inhibitor is reacted with enzyme to generate enzyme-
inhibitor complexes. In this case, the concentration of bound inhibitor [EI] is 
negligible compared to the concentration of total inhibitor I (Bieth, 1995). 
 
Thus, the concentration of free inhibitor can be assumed to be equivalent to I  
          
I ≈ [I] 
By arranging equations 2.3 and 2.4, 
 
                                          ,1 % --./01                                             2.5 
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In the case of tight binding reversible inhibitors, the inhibition takes place when 
equimolar (or close to equimolar) concentrations of enzyme and inhibitor are 
reacted. Thus, the concentration of bound inhibitor [EI] is required to be taken into 
account with respect to that of total inhibitor I. 
 
As a result, the total concentration can be written as follows: 
 
                                              I  I  EI                                           2.6 
By arranging equation 2.6 whereas, EI  E1 %  
 
                    I    456 7  E1 %                   2.7 
 
As seen in equation 2.7, both Ki and [E0] are important factors in tight-binding 
inhibition and a tight binding graph can be plotted by using equation 2.8 which has 
been derived from equation 2.7. 
 
   91 % E  I   % :E  I  ; % 4EI2E <   2.8 
 
Since the binding behavior of the enzyme-inhibitor complex in a tight-binding 
complex depends largely on E >⁄ , (especially if E >⁄  ? 100), the binding 
curve is almost linear and intercepts the abscissa at I E⁄  1. In this case all 
enzymes are bound to inhibitor. As a result, Equation 2.3 can be written as I A
 EB 1 %  and under these conditions, it can be written as 
 
                                           1 % -CDC                                                      E 2.9 
 
In this thesis, the tight binding inhibition constant (Ki) is evaluated by using non-
linear least square fit of the reaction velocities to Equation 2.8, where v is the initial 
reaction velocity, v0 is the initial reaction velocity obtained in the absence of 
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inhibitor and E is the active enzyme concentration which is treated as a constant 
parameter.  
 
In this thesis, the inhibitory activities of all MCoTI-II cyclotides were assessed 
against trypsin and other proteases using competitive binding assays at 25°C. All of 
these MCoTI-II inhibitors were subsequently treated as competitive reversible 
inhibitors. The most selective and potent of the naturally extracted MCoTI-II 
cyclotides against trypsin had been previously reported with Ki values in the sub-
nanomolar region (Avrutina et al., 2005). As a result, an accurate method of 
measuring Ki approach was required, as a small difference in Ki may be hidden 
within an experimental error. In order to achieve the accurate dissociation constant 
(Ki) together with consistent results, three assays for each inhibitor were performed 
using freshly prepared solutions of buffers and reagents each time.  
 
All MCoTI cyclotides studied in this thesis were synthesised, either via a thia-zip 
assisted NCL strategy (Chapter 2) or chemoenzymatic strategy (Chapter 3). The 
comparison of Ki values against trypsin and chymotrypsin using both synthetic 
strategies was carried out to confirm that the scaffold of MCoTI-II cyclotides was 
correctly folded.  
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4.2.1 Inhibition against Serine Proteases: Trypsin, Chymotrypsin, Thrombin 
and Subtilisin 
 
The inhibitory activities of wild-type and mutant MCoTI-II cyclotides were 
examined against a panel of serine proteases including trypsin, chymotrypsin, 
thrombin and subtilisin – see Table 4.1. These proteases have different functions in 
nature as previously discussed in Chapter 1. The major differences between the 
individual serine proteases studied in this thesis lie not only in their potential 
therapeutic applications, but in the specificity of their recognition pockets (the S1 
pocket). The re-engineering of the MCoTI-II scaffold has been carried out in order 
to broaden its inhibitory activity against a panel of serine proteases. The active loop 
was re-designed to re-direct its inhibitory activity towards an alternative target 
protease. As a consequence, the amino acid residues at the P1 position were 
switched to a series of amino acids ranging from the positively charged Arg and 
Lys to the aromatic residue Phe, the hydrophobic residues Ala and Val, and the 
neutral polar residue Gln. 
 
Determination of the Equilibrium Dissociation Constant (Ki) against Trypsin 
Prior to determining the Ki values of the MCoTI inhibitors against trypsin, an 
accurate MCoTI concentration determination was required. As the potency of the 
inhibitors is in the low pM region, a slight error in MCoTI concentration 
determination would lead to a large error in the Ki determination. However in the 
case of the inhibitory activity of MCoTI cyclotides was not as potent as MCoTI-I 
and II, the MCoTI cyclotide concentration could not be determined using titration 
with trypsin. Therefore, a standard addition method was developed using analytical 
HPLC and the standard addition graph from all trypsin active MCoTI cyclotides 
was subsequently plotted with varying active cyclotide concentrations versus peak 
area, which was measured at 223 nm (the intensity of the peak corresponds to the 
the number of peptide bonds, which obeys the Beer-Lambert Law). The procedure 
was described in detail in Section 7.7.0, and also applied to determine all other 
cyclotide concentrations, such as MCoTI-II[A], MCoTI-II[V], MCoTI-II[F], and 
MCoTI-II[Q]. 
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Nevertheless, the drawback of this standard addition approach is that the MCoTI 
cyclotides that require this form of concentration determination must contain 34-
amino acids, to be of comparable absorbance value to that of standard MCoTI 
cyclotides in a standard curve. Therefore, MCoTI-II[AKQ] and truncated MCoTI-II 
cyclotides (further discussed in Chapter 5), which have more or less than 34 amino 
acids, were not appropriate for use with the standard graph to determine 
concentration. As a result, absorbance at 280 nm was measured (all analogues have 
a single tyrosine residue) to overcome this difficulty and used the molar extinction 
coefficient of tyrosine at 280 nm, which is approximately 1,280 M-1.cm-1(Pace et 
al., 1995).  
 
Nevertheless, the disadvantage of measuring the tyrosine absorbance at 280 nm was 
that at least 50 µM of the MCoTI-II samples was required, whereas using the 
standard addition strategy required only concentrations of cyclotide in the low-nM 
region for the concentration determination.   
 
Ki value determinations of the MCoTI-II variants against trypsin and chymotrypsin 
were carried out using a competitive binding assay at 25°C (see Chapter 7). The 
residual trypsin (or chymotrypsin) activity was measured in a 96-well microplate 
following the cleavage of N-p-tosyl-Gly-Pro-Arg-7-AMC (trypsin substrate) 
(Avrutina et al., 2005) and Suc-Ala-Ala-Pro-Phe-7-AMC (chymotrypsin substrate) 
(Jaulent, 2004), which were subsequently plotted against serial dilutions of the 
MCoTI-IIs cyclotide inhibitors (Figure 4.2).  
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Figure 4.2 An example of trypsin inhibition curve of cyclotide  
 
This figure represents trypsin inhibition by increasing concentrations of MCoTI-I cyclotide and the 
Ki was found to be 29±2 pM as determined with GraFit computer package (Leatherbarrow, 2001). 
The error bars represent the standard deviation from the mean value of triplicates. 
 
 
 
Subsequently, the curve was fitted to the equation 2.8. For the experimental 
conditions used, addition of substrate does not result in significant dissociation of 
the enzyme-inhibitor complexes, therefore K = Ki. The residual trypsin (or 
chymotrypsin) activity was also measured in triplicate and the average Ki values 
(Avrutina et al., 2005) are reported in Table 4.1.  
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Table 4.1 Inhibition constants (Ki) of MCoTI cyclotides against trypsin, chymotrypsin, subtilisin and thrombin 
  
Cyclotides 
Residues within the inhibitory loop Trypsin (pM) Chymotrypsin (nM) Subtilisin (µM) Thrombin (µM) 
P2 P1 P1’ P3’ P4’ PST
a
 NCLb PSTa NCLb NCLb NCLb 
MCoTI-I P K I Q R 16 ±0.8 29 ± 2 ND >104 >100 >100 
MCoTI-II P K I K K 45 ± 3 75 ± 5 ND >104 >100 >100 
MCoTI-II [R] P R I K K 70 ± 0.2 85 ± 7 ND >104 >100 >100 
MCoTI-II [F] P F I K K ND 3 × 106 12 ± 0.5 9.8 ± 0.7 49.4±4 >100 
MCoTI-II [Q] P Q I K K ND 5 × 106 ND 2 × 103 >100 >100 
MCoTI-II [A] P A I K K ND 109 ND >104 >100 >100 
MCoTI-II [V] P V I K K ND 109 ND >104 >100 >100 
              
SGSDGGVC L CRRDSDCPGACICRGNGYCG 
P2P1P1’ P3’P4’ 
aProtease-mediated cyclisation strategy,  bThia zip native chemical ligation strategy, ND = not determine 
 
This table shows inhibition constants (Ki) of MCoTI-I, MCoTI-II and re-engineered MCoTI-II variants against trypsin, chymotrypsin, subtilisin and thrombin. MCoTI-I, 
MCoTI-II and MCoTI-II[R] were found to be potent inhibitors of trypsin with approximate Ki values of 29, 75 and 85 pM respectively (via NCL strategy). MCoTI-II[F] 
was found to inhibit trypsin, chymotrypsin and subtilisin with Ki values of 3µM, 10 nM  and 50 µM (respectively)  
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As seen in Table 4.1, the two naturally occurring cyclotides, MCoTI-I and MCoTI-
II, were found to be the most potent trypsin inhibitors in the series, with Ki values in 
the low-pM region (29 and 75 pM respectively). The naturally extracted MCoTI-I 
and MCoTI-II from M.cochinchinensis as reported by Craik, have trypsin inhibitory 
activities of Ki = 20 and 30 pM, respectively (Avrutina et al., 2005; Felizmenio-
Quimio et al., 2001). Therefore, it is clear that MCoTI-I and MCoTI-II, which have 
been chemically synthesised via thia-zip assisted NCL and enzymatically 
synthesised MCoTI-I and MCoTI-II, have adopted the correctly folded MCoTI 
scaffold and have identical Ki values (within error) to those which have been 
naturally extracted. 
 
In addition, the presence of an Arg residue at the P1 residue in MCoTI-II[R] was 
also found to exhibit significant trypsin inhibition, with a Ki value of approximately 
85 pM. This further indicated that MCoTI-II[R], containing a substitution at a 
conserved residue, is tolerated in trypsin substrates, as the potency of the parent 
natural product has been maintained. To the best of our knowledge, MCoTI-II[R] 
reported here has been the first example of a re-engineered MCoTI-II which 
displays an inhibitory activity against trypsin which is close to that of naturally 
occurring MCoTI cyclotides. It was also found that both wild-type MCoTI 
(MCoTI-I and II) and mutant (MCoTI-II[R]) were the only cyclotides to have a 
high selective inhibition against trypsin.  
 
However, all other MCoTI-II analogues have shown 103-104 fold lower activities as 
seen in Table 4.1, emphasising the importance of the positively charged residue at 
the P1 residue. It is important to state that the trypsin inhibition activity of MCoTI-
II was effectively switched to chymotrypsin inhibition when the Lys10 residue is 
changed to match the preferred P1 residue of this enzyme (Phe), and MCoTI-II[F] 
was found the only cyclotide in the series tested that showed potent inhibitory 
activity against chymotrypsin, with Ki = 9.8 nM. However, other uncharged 
residues (Q, V, A) at the P1 position were also tolerated to some degree; such as 
MCoTI-II[Q], showing Ki = 2 µM against chymotrypsin as shown in Table 4.1. 
  
    
  Chapter 4 Protease inhibition results  
130 
 
 
Despite displaying high sequence similarity, trypsin and chymotrypsin are 
structurally different in terms of the substrate binding pocket preference (the S1 
pocket) as previously mentioned in Chapter 1. The positively charged amino and 
guanidino groups of Lys and Arg residues, respectively, could fit perfectly into the 
deep S1 pocket of trypsin by way of electrostatic interactions to Asp189, located at 
the bottom of the pocket. These interactions are the main contributors to the very 
high potency of the MCoTI-I, MCoTI-I and MCoTI-II[R] cyclotides.   
 
Currently, there is no crystal structure of trypsin complexed with MCoTI-II 
reported. A model of trypsin complexed with MCoTI-II was built as shown in  
Figure 4.3. The crystal structure of trypsin complexed with EETI-II (pink) was 
selected (PDB ID 1H91) as shown in Figure 4.3A. EETI-II molecule was 
superimposed by MCoTI-II (blue) within trypsin active site as seen in Figure 4.3B. 
EETI-II molecule was subsequently removed from the complex to give only 
MCoTI-II complexed with trypsin (Figure 4.3C). As seen in Figure 4.3C, it clearly 
revealed that Lys (at the P1 residue) of MCoTI-II located in the catalytic triad of 
trypsin in which its side chain was deeply buried in the S1 pocket.   
 
In the case of MCoTI-II[F], this variant was found to be a quite potent inhibitor of 
chymotrypsin activity with Ki of 9.8 nM. This inhibition is believed to be a result of 
favorable hydrophobic interactions involving the aromatic moity of Phe at P1 and 
the hydrophobic S1 pocket located at chymotrypsin’s active site (Hedstrom, 2002). 
 
None of the MCoTI cyclotides in the series were found to exhibit an inhibitory 
activity against thrombin, despite this enzyme possessing a similar specificity to 
trypsin at P1 (favouring Arg and Lys at P1). MCoTI-II[F] was also found to have a 
slight inhibitory activity against subtilisin in the low micromolar region (Ki = 49 
µM) corresponding to a subtilisin specificity with the preferred residues being 
aromatic such as Phe, Tyr, Trp at the P1 residue (Gron & Breddam, 1992; Gron et 
al., 1992). Therefore, it should be concluded that all MCoTI cyclotides studied in 
this thesis are highly selective inhibitors for trypsin family proteases, since they 
only show potent inhibition against trypsin-like proteases, such as trypsin and 
chymotrypsin. 
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Figure 4.3 The superimposition experiment of trypsin catalytic site with MCoTI-II  
(A) The crystal structure of trypsin complexed with EETI-II (pink, PDB ID 1H9I) is displayed. (B) 
The superimposition between EETI-II (pink) and MCoTI-II (blue) with R = 0.39 is represented. (C) 
The active site of trypsin complexed with MCoTI-II (blue) in which the surface of MCoTI-II 
showing the Lys (at P1 residue) side chain of the inhibitor being deeply buried in the pocket of 
trypsin is shown. 
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The preliminary inhibition results of the MCoTI cyclotides against a wide range of 
trypsin-like serine proteases (trypsin, chymotrypsin and subtilisin) have allowed us 
to further examine the applicability of using the MCoTI cyclotides to develop novel 
inhibitors, and that may even have implications in drug discovery. Currently, the 
peptidic inhibitor has now become of enormous interest, mainly due to its 
therapeutic property (Greenwood et al., 2007; Werle et al., 2006). As a 
consequence, the inhibitory activity of the MCoTI cyclotides against the medically 
important trypsin-like serine proteases human β-tryptase, matriptase, human 
leukocyte elastase (HLE) and hepatitis C virus NS3/4A was evaluated as described 
below. 
 
4.2.2 Inhibition against Medically Important Serine Proteases 
Human β-tryptase, human leukocyte elastase (HLE) and matriptase are medically 
important trypsin-like serine proteases, all of which play key roles in pathological 
conditions, thus representing promising protease targets for drug discovery.  
 
Human β-tryptase is found extensively in human mast cells and is secreted during 
mast cell activation. This rising level of tryptase is directly related to various 
allergic and certain inflammatory disorders such as asthma (Pereira et al., 1998). 
Much effort has been made to identify effective and selective human β-tryptase 
inhibitors. To date, a large number of human β-tryptase inhibitors including small 
molecules shown in Figure 4.4 and peptidic inhibitors have been published 
(Costanzo et al., 2008; Di Marco & Priestle, 1997; Scarpi, McBride & 
Leatherbarrow, 2004), both types of which have generally contained at least one or 
more amino (-NH3+), or guanidino (-NH-CNH2-NH2+) group. These form salt 
bridges (the electrostatic interaction) with the aspartic acid residue at 189 in human 
β-tryptase at the bottom of the recognition pocket (the S1 pocket) (Scarpi, McBride 
& Leatherbarrow, 2002). 
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Figure 4.4 Examples of non-peptidic Human β-tryptase inhibitors 
This figure shows examples of potent nonpeptidic inhibitor against human β-tryptase (with Ki values 
in low nM region). Both contain guanidino (1), or amino (2) groups (Costanzo et al., 2008). 
 
Human leukocyte elastase (HLE) is one of the medically important serine 
proteases due to its function in the tissue destruction seen in pulmonary 
emphysema, rheumatoid arthritis, cystic fibrosis, adult respiratory distress 
syndrome, chronic bronchitis and pancreatitis (McBride et al., 1999). A large 
number of both small molecule and peptidic inhibitors of HLE have been reported 
so far. Depsipeptide isolated from Flexibacter sp. Q 1789 (Fujita et al., 1994) and 
Curcubita maxima trypsin inhibitor-III (CMTI-III) are known to act as potent HLE 
inhibitors (McBride et al., 1999). The potency and specificity of peptidic HLE 
inhibitors depend on the nature of their P1 residue with amino acids with small 
alkyl chains, such as Ala, or Val being greatly preferred. The P1 sidechain can 
interact favourably with the S1 cavity, which in turn increases its inhibitory activity 
against HLE (McBride et al., 1999). 
 
Matriptase, one of the emerging classes of type II transmembrane serine proteases, 
can be isolated in large quantities in its transmembrane form from human breast 
cancer cell lines. It has been reported that by blocking the level of matriptase, the 
balance of matriptase was restored in the cell and would eventually modulate 
tumorigenensis and metastasis (Friedrich et al., 2002). Sunflower trypsin inhibitor-1 
(SFTI-1), isolated from sunflower seeds, was found to be an example of a peptidic 
matriptase inhibitor, which shows a very potent matriptase inhibitory activity, with 
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a Ki value in the low-nM range (Li et al., 2007). The SFTI structure is shown in 
Figure 4.5.     
 
 
 
 
 
Figure 4.5 The structure of the bicyclic peptide sunflower trypsin inhibitor-1 (SFTI-1)  
This figure represents the structure of SFTI-1, consisting of 14 amino acids with a disulfide bond 
(red). The Lys residue (the P1 residue) has an important role in protein binding (Li et al., 2007).  
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At the moment, the study of using peptidic inhibitors in targeting proteinase 
enzymes has become of enormous interest in the pharmaceutical industry, mainly 
due to its apparent advantage of painless oral administration, which improves 
patient compliance and is less toxic compared to others (Greenwood et al., 2007; 
Werle et al., 2006). 
 
However, the development of these therapeutic peptides has encountered several 
barriers, such as low oral drug bioavailability, low diffusion across the mucus layer 
covering the gastrointestinal (GI) epithelia, enzyme barrier due to luminally 
secreted and membrane-bound proteases, which result in comparatively poor drug 
permeation (Greenwood et al., 2007; Werle et al., 2006). As a consequence, the 
cyclic cysteine knot scaffold (CCK) has been applied in an attempt to overcome the 
problems generally observed with peptidic inhibitors. CCK proteins are typically 
composed of a cyclic moiety and a well-defined structure, which makes a CCK 
protein closely packed and results successful permeation through the intestinal 
mucosa (Werle et al., 2006). This unique cyclic cysteine knot scaffold of the 
MCoTI cyclotide has been known to have a great impact on its inhibitory potency 
and its stability (Werle et al., 2006). 
 
Within this study the inhibitory activity of both wild-type and re-engineered MCoTI 
cyclotides has been evaluated against a panel of medically important serine 
proteases, including tryptase, HLE, matriptase, FMDV 3Cpro and hepatitis C virus 
NS3/4A. For routine Ki examination, an assay was performed as previously 
discussed in the “Ki determination of the MCoTI cyclotides against trypsin” section 
and the average Ki was quoted unless otherwise specified (also explained in 
experimental section). The average Ki values are shown in  
Table 4.2. 
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Figure 4.6 Tryptase inhibition curve of MCoTI-II cyclotide  
 
This figure represents tryptase inhibition curve by MCoTI-II and the Ki value was found to be 
0.6±0.03 µM as determined with the GraFit computer package (Leatherbarrow, 2001). The error 
bars show the standard deviation from the mean value of triplicates  
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Table 4.2 Inhibition constants (Ki) of MCoTI cyclotides against human β-tryptase, human leukocyte elastase and matriptase 
 
  
Cyclotides 
Residues at inhibitory loop Human β- 
Tryptase (µM) 
Human Leukocyte 
Elastase (nM) Matriptase (nM) P2 P1 P1’ P3’ P4’ 
MCoTI-I P K I Q R 1.6 ± 0.14 N.I. 155 ± 31 
MCoTI-II P K I K K 0.6 ± 0.03 N.I. 9 ± 1 
MCoTI-II [R] P R I K K 0.12 ± 0.05 N.I. 158 ± 46 
MCoTI-II [F] P F I K K >50 >7500 >50 
MCoTI-II [Q] P Q I K K >50 N.I. >50 
MCoTI-II [A] P A I K K >50 32 ± 13 >50 
MCoTI-II [V] P V I K K >50 21 ± 7 >50 
         
SGSDGGVC L CRRDSDCPGACICRGNGYCG 
P2P1P1’ P3’P4’ 
 
This table shows inhibition results of MCoTI-I, II and re-engineered MCoTI-IIs against human β-tryptase, HLE and matriptase. MCoTI-I, II and MCoTI-II[R] were 
found to inhibit tryptase with Ki values of 1.6, 0.6 and 0.12 µM respectively and also found to inhibit matriptase with a Ki value of 155 nM (for MCoTI-I), 9 nM (for 
MCoTI-II) and 158 nM (for MCoTI-II[R]). MCoTI-II[F] was found to inhibit both HLE with a Ki value of > 7.5µM. MCoTI-II[A] and MCoTI-II[V] were found to 
inhibit HLE with Ki values of 32 and 21 nM respectively. 
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Inhibition of Tryptase 
As shown in Table 4.2, both naturally occurring cyclotides (MCoTI-I and II) were 
found to exhibit significant inhibitory activity against tryptase, with Ki values of 1.6 
and 0.6 µM for MCoTI-I and MCoTI-II, respectively. Also, MCoTI-II[R] was 
found to show an inhibitory activity against tryptase with a Ki of 0.12 µM which 
was approximately 5-fold higher than the inhibition of MCoTI-II. However, the 
other MCoTI cyclotides tested did not show significant inhibitory activity against 
tryptase, with Ki values >50 µM.   
 
The potency and specificity of these MCoTI cyclotides against tryptase is mainly 
due to the positively charged amino, or guanidino groups at the P1 residue, in a 
similar manner to that found with trypsin. When the P1 residue was switched to 
other amino acids, a less potent inhibitory activity was observed (Ki > 50 µM). 
Tryptase is a homotetrameric protein, consisting of four trypsin-like monomers, 
each with an active site structurally similar to typsin, as well as analogous 
specificity (Pereira et al., 1998; Scarpi et al., 2004).  
 
A model of tryptase complexed with MCoTI-II is built as follows; the crystal 
structure of tryptase (PDB ID 2BM2) can be retrieved the Protein Data Bank. The 
monomer of tryptase was superimposed by trypsin complexed with MCoTI-II as 
shown in Figure 4.7A. Subsequently, trypsin was removed from complex to give 
the active site of tryptase complexed with MCoTI-II (Figure 4.7B). As seen in 
Figure 4.7B and Figure 4.7C, it clearly reveals that Lys (at the P1 residue) of 
MCoTI-II is close proximity to the catalytic triad of tryptase in which its side chain 
is best fitted into the S1 pocket. 
 
As shown in Figure 4.7C, Lys at the P1 residue plays a vital role in the binding 
efficacy with the basic side chain of Lys deeply buried in the S1 pocket and 
forming a key hydrogen bond with negatively charged Asp located in the tryptase 
catalytic site. Comparing the inhibitory activity of MCoTI-II against trypsin (low-
pM range) and tryptase (low-µM range) suggest that further factors must be 
important and has led us to further examine the structure-inhibitor relationship in 
order to improve the tryptase inhibitory activity of MCoTI-II cyclotides.  
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It is likely that steric interaction caused by MCoTI molecule and the human β-
tryptase surface might be the remarkable factor that affected its tryptase inhibitory 
activity as seen in Figure 4.7. As a result, contracting the MCoTI-II scaffold may 
potentially be the solution to improve the tryptase inhibitory activity against human 
β-tryptase, which will be further discussed in Chapter 5.  
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Figure 4.7 Superimposition of the catalytic site of human β-tryptase and MCoTI-II 
(A) Trypsin complexed with MCoTI-II (yellow) is superimposed at an active site of the tryptase 
tetramer. (B) MCoTI-II (yellow) docked at an active site of the tryptase tetramer. (C) Magnification 
shows Lys10 of MCoTI-II in proximity to the tryptase catalytic site. 
 
A 
B 
C 
    
  Chapter 4 Protease inhibition results  
141 
 
 
Inhibition of Matriptase 
According to the matriptase inhibitory activity screening, MCoTI-I, MCoTI-II and 
MCoTI-II[R] were found to inhibit matriptase with Ki values of 155 and 9 nM (for 
MCoTI-I and MCoTI-II, respectively). Re-engineered MCoTI-II[R] was also found 
to significantly inhibit matriptase, with a Ki of 158 nM.  
 
The inhibition specificity of MCoTI cyclotides against matriptase can be accounted 
for mainly due to the specificity of the basic side chain of Lys at the P1 residue for 
the matriptase S1 pocket accepted. This results in the highly potent inhibitory 
activity against matriptase of MCoTI-I and II and also MCoTI-II[R], for similar  
reason to those previously discussed for tryptase and trypsin.  
 
Inhibition of HLE 
An orally active inhibitor of HLE was reported in 1994 (Ohmoto et al., 2000), 
which used a valine-proline dipeptide of the trifluoromethyl ketone (TFMK). 
Examples of these inhibitors are shown in Figure 4.8 (Ohmoto et al., 2000). A 
series of novel chemically modified Val-Pro dipeptides have been made to improve 
the inhibitory activity against HLE and its crystal structure has revealed that the 
isopropyl group of valine at the P1 residue is the moiety chiefly responsible for its 
inhibitory activity, mainly due to the favourable binding of isopropyl (Val) or 
methyl (Ala), within the S1 pocket. The specificity S2 subsite in HLE is a 
hydrophobic pocket in which small lipophilic Pro residues at P2 bind favourably. 
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Figure 4.8 Examples of HLE active peptides  
This figure represents examples of valine-proline dipeptides reported by Zeneca (Ohmoto et al., 
2000) that are potent inhibitors of HLE. The valine residue located next to ketone appears to have an 
important role in protein binding. 
 
The inhibitory activity of a series of P1- modified and P1’- modified MCoTI-II 
cyclotides were evaluated against human leukocyte elastase (HLE). It was found 
that small alkyl residues, Ala or Val, resulted in inhibitory activity.  
Table 4.2-Table 4.3 summarise the inhibition data against HLE and PPE. The 
constrained MCoTI-II analogues, where P1 was either Ala or Val, were found, as 
expected, to be potent inhibitors of HLE, with Ki values of 32 and 21 nM, 
respectively. Only two MCoTI cyclotides in the series show potent inhibition of 
HLE, with Ki values in the low-nanomolar range.  
 
Of the other analogues, MCoTI-II[F] also shows inhibitory activity against HLE, 
with a Ki of 7500 nM. The constrained P1’ modified MCoTI-II analogues, in which 
P1’ was replaced with Pro (named MCoTI-II[PVP]) according to the S1’ pocket 
requirement preferring the hydrophobic residue at P1’ position (Bode et al., 1989b), 
revealed a loss in binding affinity (Ki = 520 nM) compared to MCoTI-II[A] and 
[V]. Also the constrained P2 and P1’ modified cyclotides, named MCoTI-II[AVP] 
has exhibited a loss of inhibitory affinity (Ki = 500 nM) and none of inhibitors was 
active against PPE, as shown in Table 4.3. Noticeably, from the synthetic point of 
view, re-engineered MCoTI-II [PVP] encountered the difficulty which might affect 
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to corresponding yield, presumably due to the close proximity of two proline 
residues in the sequence, resulting in unfavourable steric interactions and the 
formation of a strained intermediate.  
 
Table 4.3 Inhibition activity (Ki) of naturally occurring and re-engineered MCoTI cyclotides against 
HLE and PPE 
 
 
 
 
 
This table represents inhibition results of MCoTI-II[A], MCoTI-II[V], MCoTI-II[AVP] and  
MCoTI-II[PVP] against HLE and PPE. All variants exhibited inhibition against HLE with Ki values 
of 32, 21, 500 and 520 nM respectively, but none were found to inhibit (PPE). 
 
 
The findings represented here show the promising discovery that slight 
modifications of the MCoTI scaffold can improve its HLE inhibitory activity. 
  
Cyclotides 
Residues at inhibitory loop HLE (nM) PPE (nM) 
P2 P1 P1’ 
 
 
MCoTI-II[A] P A I 32±13 N.I. 
MCoTI-II [V] P V I 21±13 N.I 
MCoTI-II [AVP] A V P 500±13 N.I. 
MCoTI-II [PVP] P V P 520±13 N.I. 
      
 
P2P1P1’ 
 
SGSDGGVC LKKCRRDSDCPGACICRGNGYCG 
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4.2.3 Inhibition against Hepatitis C NS3/4A and Foot-and-Mouth Disease 
Virus 3Cpro 
 
Hepatitis C virus NS3/4A (HCV NS3/4A) and foot-and-mouth disease virus 3Cpro 
(FMDV 3Cpro) are of great medical or agrochemical importance, and each are 
proteases involved in viral maturation. Both proteases are in different class of 
enzyme, however, they show significant similarity in their mechanistic inhibition. 
HCV NS3/4A is classified as a trypsin-like serine protease, whilst FMDV 3Cpro is 
regarded as a cysteine protease with a chymotrypsin-like fold (Birtley et al., 2005). 
As a result, both HCV NS3/4A and FMDV 3Cpro are potential protease targets 
where MCoTI cyclotides might provide potent inhibitors. 
 
To date, several promising antiviral targets for HCV have emerged in recent years, 
including NS3/4A protease inhibitors. Typically, the design of protease inhibitors 
has focused on the optimisation of substrate-based peptides, mainly according to 
the sequence homology of the substrate cleavage site (Tsantrizos, 2008). The 
discovery of more effective anti-HCV compounds has been a great challenge for 
pharmaceutical companies, mainly due to its shallow and solvent-exposed active 
site of HCV protease. Also the substrate binding site of HCV is rather flat and has 
minor surface depression (Venkatraman et al., 2005).  
 
The favourable interaction of the P1 residue to the S1 subsite was found to be vital 
for its inhibitory activity. The hepatitis C virus NS3/4A catalytic site was found to 
be featureless, solvent-exposed and shallow (Venkatraman et al., 2005). As a result, 
the development of hepatitis C virus inhibitors is extremely difficult. Noticeably, 
cysteine and norvaline were found to be particularly suitable P1 residues, in which 
the sulfhydryl group (SH) in cysteine, or the propyl chain of the norvaline were 
deeply buried in the S1 pocket, which improved the binding efficiency of the 
resulting inhibitor (Liverton et al., 2008; Llinas-Brunet et al., 2004; Njoroge et al., 
2008; Poupart et al., 2001; Prongay et al., 2007; Slater et al., 2002; Venkatraman et 
al., 2005). Examples of hepatitis C inhibitors are illustrated in Figure 4.9. 
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Figure 4.9 Examples of Hepatitis C inhibitors  
 
This figure shows an example of hepatitis C inhibitor (Tsantrizos, 2008). A norvaline residue (the P1 
residue) was found to have an important role in protein binding. 
 
 
In this study, the MCoTI cyclotides were assessed for their inhibitory activity and it 
was found that MCoTI-II[AVP] was the only cyclotide (represented in Table 4.4) 
that exhibited slight inhibitory activity against hepatitis C virus protease, with a Ki 
of more than 50 µM. However, MCoTI-II[V] did not exhibit measurable inhibition 
despite possessing valine at the P1 residue as the size of alkyl group between valine 
and norvaline is fairly similar. We have therefore reasoned that the particulary 
unusual catalytic site of HCV NS3/4A might be one of the important factors 
contributing to its inhibitory activity. Also, it was observed that MCoTI-II[AVP] 
was not just a specific inhibitor against HCV. As shown in Table 4.3, it was also 
found to exhibit inhibitory effects against human leukocyte elastase (HLE), with a 
Ki value of 500 nM. HLE is a serine protease, which is structurally related the 
NS3/4A protease of HCV (Njoroge et al., 2008).  
 
While the inhibitory activity of the MCoTI cyclotide against HCV NS3/4A protease 
shown in this thesis is a potentially promising result, the potency would need to be 
futher optimised in order to generate useful inhibitors. This would require more 
extensive modification of the MCoTI scaffold to improve the inhibition efficacy.  
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Table 4.4 Inhibition constant (Ki) of MCoTI cyclotides against FMDV 3Cpro and Hepatitis C NS3/4A 
Cyclotides 
Residues at inhibitory loop Hepatitis C NS3/4A 
(µM) FMDV 3Cpro (µM) P2 P1 P1’ P3’ P4’ 
MCoTI-I P K I Q R N.I >100 
MCoTI-II P K I K K N.I >100 
MCoTI-II [R] P R I K K N.I. >100 
MCoTI-II [F] P F I K K N.I. >100 
MCoTI-II [A] P A I K K N.I. >100 
MCoTI-II [V] P V I K K N.I. >100 
MCoTI-II [AVP] A V P K K >50 >100 
MCoTI-II [PVP] P V P K K N.I. >100 
MCoTI-II [Q] P Q I K K N.I. 41 ± 25 
MCoTI-II [AKQ] P AKQ I K K N.I. 56  ± 35 
        
SGSDGGVC L CRRDSDCPGACICRGNGYCG 
P2P1P1’ P3’P4’ 
 
This table presents inhibition results of MCoTI-I, II and re-engineered MCoTI-IIs against hepatitis C NS3/4A and FMDV 3Cpro. MCoTI-II [AVP] was found to have a 
slight inhibition against the hepatitis C protease with a Ki value of >50 µM. MCoTI-II[Q] and MCoTI-II[AKQ] were found to have an inhibition against FMDV 3Cpro 
with Ki values of 41 µM and 56 µM respectively.  
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Inhibitory activity against Foot-and-mouth Disease Virus 3Cpro  
The 3C protease from foot-and-mouth disease virus (FMDV 3Cpro) is known as a 
chymotrypsin-like cysteine protease, possessing an overall fold similar to that of 
chymotrypsin with a Cys-His-Asp catalytic triad similar to the Ser-His-Asp triad 
typically conserved in most serine proteases (Birtley & Curry, 2005; Birtley et al., 
2005). FMDV 3Cpro has a critical role in both processing of the polyprotein 
precursor and RNA replication in FMDV (discussed in Chapter 1). The crystal 
structure of the FMDV 3Cpro has shown its substrate preference and the cleavage 
site specificity which has resulted in the design of the FMDV 3Cpro inhibitor 
(Birtley & Curry, 2005; Birtley et al., 2005). 
 
Figure 4.10 An example of an FMDV 3Cpro inhibitor  
 
This figure illustrates the structure of FMDV 3Cpro inhibitor (irreversible inhibitor), consisting of 
Pro-Ala-Lys-Gln motif and a warhead (Michael acceptor) (Roque-Rosell, 2008). 
 
The synthesis of the FMDV 3Cpro inhibitor was recently achieved within our 
research group by using its recognition sequence, spanning from residues P4-to-P1, 
together with a warhead as illustrated in Figure 4.10 (Roque-Rosell, 2008).  
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In the present study, we have replaced the amino acid at the P1 residue of the 
MCoTI-II scaffold with the Ala-Lys-Gln chain in an aim to target FMDV 3Cpro. 
Along with a set of re-engineered MCoTI-II cyclotides we have assessed its 
inhibitory activity against FMDV 3Cpro (Table 4.4). It is observed that MCoTI-
II[AKQ], as expected, was found to exhibit inhibitory activity against FMDV 3Cpro, 
with a Ki of 56 µM, whilst MCoTI-II[Q] showed inhibitory activity with a Ki of 41 
µM. However, other MCoTI-II analogues showed no detectable activity against 
FMDV 3Cpro. 
 
To the best of our knowledge, the preliminary inhibition result against FMDV 3Cpro 
represented in this thesis has been the first finding of a re-engineered MCoTI-II 
scaffold to re-direct inhibitory activity towards FMDV 3Cpro. 
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Summary 
 
It can be concluded that naturally occurring MCoTI-I and II, which have been 
synthesised both chemically and chemoenzymatically in this thesis, show 
comparable inhibitory activity against trypsin, with Ki values in the picomolar range 
similar to that of naturally extracted MCoTI-I and II. Furthermore, the re-
engineered MCoTI-II with substituent amino acids at P1 and other positions has 
broadened the inhibitory activity not only against a panel of trypsin-like serine 
proteases, such as tryptase, chymotrypsin, matriptase, but also against other types of 
proteases, such as FMDV 3Cpro (cysteine protease). 
 
The results provide clear evidence to support the use of a MCoTI-II based structure 
as a promising inhibitor against trypsin-like serine proteases and give the potential 
for this cysteine knot scaffold to be used as drug scaffold. 
 
     
  Chapter 5 Synthesis and activities of truncated MCoTI-IIs  
150 
 
 
  
Chapter 5 The synthesis of truncated 
MCoTI-II analogues and their inhibitory 
activities 
 
This chapter mainly focuses on design and synthesis 
of truncated MCoTI-II cyclotides, and their 
inhibitory activities against a range of proteases, 
particularly β-tryptase. NMR analysis of both 
MCoTI-II and truncated MCoTI-II is also discussed. 
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5.1 The overview of the MCoTI cyclotides against human β-tryptase inhibitory 
activity 
 
To date, a number of therapeutic peptidic inhibitors against human β-tryptase have 
been published (Di Marco & Priestle, 1997; Erba et al., 2000; Scarpi et al., 2002; 
Scarpi et al., 2004; Sturzebecher et al., 1992). Leech-derived β-tryptase inhibitor 
(LDTI) comprising of 46 amino acid residues is an example of known peptidic 
inhibitor against human β-tryptase which exhibited potent tryptase inhibitory 
activity, with a Ki value in the low-nanomolar region (Di Marco & Priestle, 1997; 
Erba et al., 2000). More recently, re-engineered Bowman-Birk inhibitors (BBIs) 
have been found to exhibit β-tryptase inhibitory activity (Scarpi et al., 2002; Scarpi 
et al., 2004), while wild-type BBIs did not show a measurable β-tryptase inhibitory 
activity (Scarpi et al., 2002; Ware et al., 1997). The difference in size between wild-
type and re-engineered BBIs was one of the most important factors contributing to 
the difference in inhibitory activity (Di Marco & Priestle, 1997; Scarpi et al., 2002; 
Scarpi et al., 2004; Stubbs et al., 1997). The re-engineered BBIs are small peptidic 
inhibitors composed of 9-11 amino acid residues (Scarpi et al., 2002; Scarpi et al., 
2004) compared to wild-type BBIs containing 60-90 amino acid residues (Ware et 
al., 1997).  
 
According to their inhibitory activities as described in Chapter 4, MCoTI-I, II and 
MCoTI-II[R] were classified as among the most potent trypsin inhibitors, and also 
found to display a measurable β-tryptase inhibitory activity, with Ki values of 1.6, 
0.6 and 0.12 µM respectively. It is interesting to note that the β-tryptase inhibitory 
activity presented as shown in Chapter 4 displays the evidence of using the 
MCoTI-II scaffold to target β-tryptase. The different potency against β-tryptase and 
trypsin of MCoTI cyclotides was ascribed mainly as a result of the significant 
difference between trypsin and β-tryptase structures. Steric hindrance observed 
between β-tryptase and inhibitor molecules is believed to be an extremely important 
factor, directly affecting their β-tryptase inhibitory activity (Di Marco & Priestle, 
1997; Scarpi et al., 2002; Scarpi et al., 2004; Stubbs et al., 1997). 
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As a result, minimisation of the MCoTI scaffold was hypothesised to be a possible 
approach to improve its β-tryptase inhibitory activity. As shown in Figure 5.1, the 
superimposition between MCoTI-II and β-tryptase molecules (described previously 
in Chapter 4) suggests that an unfavourable electrostatic interaction between the 
MCoTI-II Asp4 sidechain and β-tryptase surface may also negatively impact on β-
tryptase inhibition. Therefore, to abolish this interaction by removing Asp4 from 
sequences is also of potential interest.  
 
Typically, of all six loops observed within the MCoTI scaffold (Avrutina et al., 
2005; Felizmenio-Quimio et al., 2001), the mobile loop (loop 6) containing 10 
amino acid residues was found to be the most flexible by NMR analysis. 
Minimising this flexible loop size without changing the overall MCoTI fold was 
felt to be an interesting approach to improve β-tryptase inhibitory activity (Di 
Marco & Priestle, 1997; Scarpi et al., 2002; Stubbs et al., 1997); however, it may 
also be supposed that if this caused a significant change in the MCoTI scaffold 
structure then the result might be to reduce or eliminate β-tryptase inhibitory 
activity.  
 
 
5.2 The size variation study of the MCoTI scaffold  
 
The initial objective of the work described in this chapter was to simplify the 
methodology of truncated MCoTI-II cyclotide synthesis, with concurrent 
minimisation of the MCoTI-II flexible loop size. This synthetic strategy was 
achieved by varying the flexible loop size between four residues (MCoTI-II[A24G] 
∆[GSDGGV]) and ten residues (wild-type MCoTI-II). Re-engineering of the 
MCoTI-II scaffold within the inhibitory loop via substitution of the P1 amino acid 
was also explored with the aim of increasing β-tryptase inhibition activity. 
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Figure 5.1 Superimposition of the catalytic site of human β-tryptase and MCoTI-II 
A) MCoTI-II (ribbon, the disulfide is shown in yellow) docked at an active site of the tryptase 
tetramer (electrostatic potential surface; blue: positive charge; red: negative charge), B) 
Magnification showing Asp4 of MCoTI-II in proximity to two negatively charged patches on the 
tryptase surface. The active site residues of the docked tryptase monomer are shown in Green. 
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The strategy for truncated MCoTI-II synthesis and evaluation was as follows: 
 
(i) Firstly, the size of MCoTI-II scaffold was minimised by removing the 
Asp4-Gly5 segment from the sequence, since the presence of Asp-Gly may 
lead to the formation of aspartimide (as mentioned previously in Chapter 
2), which can in turn cause racemisation. Furthermore, to improve 
efficiency in the NCL reaction, the mutation A24G was made in most 
analogues, as discussed below.  
 
(ii) The variation of the flexible loop size was studied and the inhibitory activity 
of resulting truncated MCoTI-IIs were subsequently evaluated against a 
panel of serine proteases (trypsin, chymotrypsin, β-tryptase and matriptase).    
 
(iii) It was proposed that re-engineering of truncated MCoTIs by the 
replacement of amino acids at the P1 residue with the positively charged 
Arg residues could broaden its inhibitory activity towards a panel of trypsin-
like serine proteases (trypsin, β-tryptase and matriptase). 
 
(iv) A novel cysteine knot MCoTI-II/EeTI hybrid linear protein, named 
MCoEeTI, was recently reported (Avrutina et al., 2008; Niemann et al., 
2006; Werle et al., 2007). This linear protein displays potent β-tryptase 
inhibitory activity, with a Ki value in the nanomolar region. In this thesis, a 
synthetic strategy for MCoEeTI was proposed that further included 
backbone cyclisation via thia-zip NCL strategy, and its protease inhibitory 
activity was subsequently evaluated.     
 
(v) The structure elucidation of truncated MCoTIs was achieved with the use of 
1D and 2D NMR spectra and the structural integrity of the truncated 
MCoTI-IIs was verified by comparison with that of MCoTI-II NMR spectra. 
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Table 5.1 Solution phase NMR structure of MCoTI-II and truncated MCoTI-IIs sequences  
 
This figure presents (A) solution phase NMR structure of MCoTI-II; α-helix (deep pink), mobile 
loop (red) and disulfide bonds (yellow) are shown, and (B) sequence alignment of naturally-
occurring MCoTI-I and -II, and analogues (truncated MCoTI-II cyclotides) described in this chapter. 
The P1 residue of the trypsin-binding loop is marked in bold; significant sequence variations are 
underlined. Note that ck-MCoEETI retains the cystine knot motif, with Val7 and Gly2 becoming 
free N- and C-termini, respectively.  
 
 I Loop I II Loop II III Loop III IV  V Loop V VI Loop VI 
MCoTI-II V C PKILKK C RRDSD C ····PGA C I C ··RGNGY C GSGSDGG 
MCoTI-I V C PKILQR C RRDSD C ····PGA C I C ··RGNGY C GSGSDGG 
 MCoTI-II[A24G] 
∆[SDGG] V C PKILKK C RRDSD C ····PGA C I C ··RGNGY C GSG···· 
 MCoTI-II[A24G]  
∆[SDGG][K10R] V C PRILKK C RRDSD C ····PGA C I C ··RGNGY C GSG···· 
 MCoTI-II[A24G]  
∆[SDGGV] · C PKILKK C RRDSD C ····PGA C I C ··RGNGY C GSG···· 
 MCoTI-II[A24G]  
∆[GSDGGV] · C PKILKK C RRDSD C ····PGA C I C ··RGNGY C GS····· 
MCoEeTI V C PKILKK C RRDSD C ····LAG C V C ··GPNGY C GSG···· 
MCoEeTI[K10R] V C PRILKK C RRDSD C ····LAG C V C ··GPNGY C GSG···· 
ck-MCoEeTI H-V C PKILKK C RRDSD C ····LAG C V C ··GPNGY C GSG-OH 
A 
B 
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5.3 The synthesis of truncated MCoTIs and MCoEeTI  
According to MCoTI-II syntheses discussed in Chapter 2, Ala24-Cys25 was 
chosen as the C-terminal thioester and N-terminal cysteine mainly due to its 
comparatively minimised steric hindrance towards cyclisation. However, in this 
case the synthetic strategy of the truncated MCoTI-II syntheses was simplified by 
replacing Ala24 from the MCoTI-II sequence with Gly24. This was expected to 
enhance the cyclisation efficiency, mainly due to the decreased steric hindrance 
between the two ends which may in turn contribute to an improvement in yield.  
 
The linear cysteine knot protein MCoEeTI is composed of Gly20-Cys21 within the 
sequence as shown in Table 5.1. As a result, Gly20 was subsequently chosen as the 
C-terminal thioester, and Cys21 was selected as the N-terminal cysteine, 
respectively. The synthetic strategy of both truncated MCoTI-IIs and MCoEeTI was 
achieved according to the Fmoc SPPS strategy similar to that of the MCoTI-IIs 
syntheses discussed previously in Section 2.3. Backbone assembly was carried out 
by the use of polystyrene resin bearing a sulfamyl butyryl “safety-catch linker” 
followed by activation and displacement, with iodoacetonitrile and 3-ethyl 
mercaptoproprionate respectively, to render the protected N-terminal cysteine 
thioester which was further deprotected with the mixture of TFA/EDT/H2O/TIPS. 
Subsequently, the resulting MCoEeTI and MCoTI truncate thioesters were 
subjected to cyclisation under mild conditions in the presence of glutathione. The 
fully folded MCoTIs and MCoEeTI were recovered in excellent yield after 
purification by RP-HPLC as illustrated in Table 5.2. The detail of these syntheses 
was described in Chapter 2.  
 
The absence of an Asp-Gly moiety in the truncated MCoTI-II and MCoEeTI 
sequences would be expected to result in minimal racemisation during the 
syntheses. The shorter backbone length (approximately 30 amino acids long) of 
truncated MCoTI-IIs and MCoEeTI may also contribute to the increase in yield 
compared to that of wildtype MCoTI-II. 
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Table 5.2 Yields of truncated MCoTI-II cyclotides and characterisation data of peptidyl thioester and cyclotides (yields and Retention time)  
Cyclotides 
The peptidyl thioesters 
 
Cyclotides 
Yield (%) Retention Time Yield (%) Retention Time 
MCoTI-II 5.4 14.35 
 
72 11.5 
MCoTI-II[A24G]∆[DG] 3 15  58 11.28 
MCoTI-II [A24G]∆[SDGG] 4 10.2  60 9.5 
 
MCoTI-II [A24G]∆[SDGG] 
[K10R] 
 
4 10.2 
 
67 9.5 
MCoTI-II [A24G]∆[SDGGV] 5 13.6 
 
70 10.7 
MCoTI-II 
[A24G]∆[GSDGGV] 1 12.85 
 
69 11 
MCoEeTI 7 10.9 
 
53 10.2 
MCoEeTI[K10R] 3 11  60 10.3 
 The peptidyl acid  Cysteine knot linear protein (ck-MCoEeTI) 
ck-MCoEeTI acid 8 10.45 
 
52 9.7 
This table presents characterization data (yield and retention time) of peptidyl thioesters, cyclotides and MCoEeTI (both linear cysteine knot (ck-MCoEeTI) and cyclic 
cysteine knot (MCoEeTI, MCoEeTI[R]). ck-MCoEeTI acid is a linear peptide without disulfide bonds, but ck-MCoEeTI is a linear cysteine knot peptide (fully folded) 
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As shown in Table 5.2, the comparison of corresponding yield between truncated 
MCoTI-II syntheses (ranging from 60 % to 70 %) with Gly used as the C-terminal 
thioester and MCoTI-II synthesis (72%) where Ala was used as the C-terminal 
thioester has clearly revealed that the overall yield did not significantly change 
despite the minimised steric interaction between both ends, probably due to the 
fairly similar size of glycine and alanine. 
 
All truncated MCoTIs cyclotides, including the MCoEeTI cyclotides shown in 
Table 5.2 were subsequently evaluated for inhibitory activity against both trypsin 
and chymotrypsin. The relationship between the Gibbs free energy and inhibition 
constant (Ki) is shown as following. 
 
Protein-Ligand interaction 
In reversible binding between ligand [I] and protease [E], the inhibition constant 
(Ki) can be written as follows (Lesk, 2004). 
 
 
                 ##                                               2.2 
 
 
Ki represents the concentration of free ligand [I] whereas half of proteins are 
binded, and half are free, and is also related to the Gibbs free energy change of 
dissociation as following: 
 
 
∆GI  ∆HK %  T∆SK  % RTIn>                         2.10 
 
 
Whereas G = Gibbs free energy, H = enthalpy, T = absolute temperature,  
S = entropy, R = gas constant and θ represents standard state 
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5.4 The Inhibition Activity against Trypsin and Chymotrypsin  
All truncated MCoTI-IIs and MCoEeTIs were screened for inhibitory activity 
against trypsin and chymotrypsin, using competitive binding assays at 25°C. The 
details can be found in the experimental section (Chapter 7). The significant 
sequence similarity between truncated MCoTI-II and MCoEeTI has allowed the 
relationship between sequence similarity and its inhibitory activity to be studied. 
The cysteine knot scaffold observed in ck-MCoEeTI is similar to that of MCoTI-II.  
 
In this study, the length of the flexible loop was varied, ranging from four residues 
(MCoTI-II[A24G, ∆GSDGGV]) to ten residues (wild-type MCoTI-II). MCoTI-
II[A24G, ∆GSDGGV] is the smallest MCoTI cyclotide in the series, consisting of 
only twenty eight amino acid residues.  
 
All trypsin and chymotrypsin inhibition results are summarised in Table 5.3. The 
cyclotides were found to show significant differences in trypsin inhibition potency 
across the series. MCoTI-II[A24G, ∆DG] and MCoTI-II[A24G, ∆SDGG] were 
found to be the most potent trypsin inhibitors in the series, with Ki values of 4.3 and 
2.6 nM respectively, compared to that of natural occurring MCoTI-II showing a Ki 
value of 75 pM. Whilst the other truncated MCoTIs showed trypsin inhibitory 
activity, they had Ki > 100 nM. 
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Table 5.3 Ki values for the truncated MCoTI-II analogues, and MCoEeTI analogues against trypsin and chymotrypsin; N.I. = no inhibition (up to 50 µM) 
 
 
 
Cyclotides a.a. 
Residues at inhibitory loop 
Trypsin  
(nM) 
Chymotrypsin 
(nM) P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 
MCoTI-II 34 C V G G D S G S G C 0.075 N.I. 
MCoTI-II[A24G, ∆DG] 32 C V G - - S G S G C 4.3±1 N.I. 
MCoTI-II [A24G, ∆SDGG] 30 C V - - - - G S G C 2.6±0.5 N.I. 
MCoTI-II [A24G, ∆SDGGV] 29 C - - - - - G S G C 130±10 N.I. 
MCoTI-II [A24G, ∆GSDGGV] 28 C - - - - - - S G C 155±15 N.I. 
ck-MCoEeTI 30 C V - - - - G S G C 99±9 N.I. 
MCoEeTI 30 C V - - - - G S G C 48±5 N.I. 
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Table 5.3 shows the results of individual inhibition constant (Ki) against trypsin 
and chymotrypsin. According to trypsin inhibitory activity, all truncated MCoTIs 
may be categorised into two major groups as a result of their trypsin inhibitory 
potency. It appears that trypsin inhibitory activity is greatly governed by the length 
of mobile loop (loop 6). As can be easily seen from Table 5.3, MCoTI-II, 
consisting of 34 amino acids is the most potent trypsin inhibitor in the series, while 
MCoTI-II[A24G, ∆GSDGGV] and MCoTI-II[A24G, ∆SDGGV] comprising of 28-
29 amino acid residues showed comparably weak trypsin inhibition, with Ki values 
of 130 nM and 155 nM, respectively. 
 
Two reasons explaining these inhibition results can be envisaged. First, mobile loop 
length: the shorter MCoTI-II analogues that showed modest trypsin inhibition may 
result directly from reduced inhibitor size which could not perfectly occlude into 
trypsin active site pore, leading to unfavorable binding between ligand and trypsin. 
As the size of truncated MCoTIs was increased, increasing trypsin inhibitory 
activity was observed, with MCoTI-II[A24G, ∆DG] and MCoTI-II[A24G, ∆SDGG] 
showing promising Ki values of 4.3 and 2.6 nM. There is some other evidence that 
implicates the mobile loop in contributing to protease inhibition activity: amino 
acid replacements within mobile loop can result in increasing protease inhibition 
activity (Avrutina et al., 2008). 
 
It is important to note that protease inhibitory activity is not governed just by the 
requisite P1 residue together with cysteine knot scaffold, but also by the cyclic 
motif itself. As can be seen from protease inhibition results of ck-MCoEeTI and 
MCoEeTI, MCoEeTI which comprises of cysteine knot scaffold together with 
cyclic motif showed greater inhibition than that of ck-MCoEeTI. 
 
5.5 Inhibition activity against medically important serine proteases  
All truncated MCoTIs and MCoEeTI were subsequently examined for inhibitory 
activity against two medically important trypsin-like serine proteases, β-tryptase 
and matriptase. The inhibition results are listed in Table 5.4. 
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Table 5.4 Ki values for the truncated MCoTI-II analogues, and MCoEeTI analogues against tryptase and matriptase (N.I. = no inhibition at 50 µM)  
 
 
 
 
 
 
 
Cyclotides a.a. 
Residues at inhibitory loop Tryptase 
(nM) 
Matriptase 
(nM) P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 
MCoTI-II 34 C V G G D S G S G C 600±30 9±1 
MCoTI-II[A24G, ∆DG] 32 C V G - - S G S G C 600±20 N.I. 
MCoTI-II [A24G, ∆SDGG] 30 C V - - - - G S G C 9±0.5 N.I. 
MCoTI-II [A24G, ∆SDGGV] 29 C - - - - - G S G C 3000 N.I. 
MCoTI-II [A24G, ∆GSDGGV] 28 C - - - - - - S G C 2000 N.I. 
ck-MCoEeTI 30 C V - - - - G S G C 110±9 >2500 
MCoEeTI 30 C V - - - - G S G C 33±7 380±30 
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β-Tryptase inhibition activity 
As shown in Table 5.4, all truncated MCoTI-IIs in the series were found to exhibit 
tryptase inhibitory potencies that varied considerably as a result of the altered size 
of the mobile loop. MCoTI-II[A24G, ∆SDGG] was found to be the most potent 
tryptase inhibitor in the series with a Ki value of 9 nM. MCoTI-II[A24G, ∆DG] was 
found to have tryptase inhibition activity in a similar range to that of MCoTI-II (Ki 
= 600 nM), 67-fold greater than MCoTI-II[A24G, ∆SDDG]. MCoTI-II[A24G, 
∆SDGGV] and MCoTI-II[A24G, ∆GSDGGV] exhibited still poorer tryptase 
inhibitory activity with Ki values of 3 and 2 µM, respectively.  
 
The chemically synthesised linear cysteine knot MCoEeTI (ck-MCoEeTI) was 
found to have tryptase inhibitory activity with a Ki value of 110 nM and it is widely 
known as one of the most potent tryptase peptidic inhibitors to date (Avrutina et al., 
2008; Niemann et al., 2006; Werle et al., 2007). MCoEeTI cyclotide, which 
includes a cyclic backbone, showed 3-fold greater inhibition (Ki = 33 nM) relative 
to the linear cysteine knot MCoEeTI (ck-MCoEeTI).  
 
Matriptase inhibition activity 
ck-MCoEeTI and MCoEeTI showed matriptase inhibitory activity with Ki values of 
>2500 nM and 380 nM, respectively. It is noteworthy that all truncated MCoTI-IIs 
show no measurable matriptase inhibitory activity. 
 
According to the inhibition results shown in Table 5.4, both truncated MCoTI-IIs 
and MCoEeTI displayed a promising tryptase inhibition activity. Therefore, further 
re-engineering of truncated MCoTI-II[A24G, ∆SDGG] and MCoEeTI scaffold was 
investigated, with the replacement of the P1 residue with the positively charged 
Arg. MCoTI-II[A24G, ∆SDGG, K10R], and MCoEeTI [K10R] were synthesised 
and their inhibitory activities against trypsin, tryptase and matriptase were 
evaluated as shown in Table 5.5. 
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Table 5.5 Ki values for MCoTI-II[A24G, ∆SDGG, K10R], and MCoEeTI[K10R] against trypsin, 
tryptase and matriptase  
 
 
 
 
 
As seen in Table 5.5, both MCoTI-II[A24G, ∆SDGG, K10R] and MCoEeTI[K10R] 
retained inhibitory potency against trypsin and tryptase. MCoTI-II[A24G, ∆SDGG, 
K10R] exhibited both trypsin and tryptase inhibition activities, with Ki values of 18 
and 10 nM respectively. Unfortunately, no measurable matriptase inhibition was 
detected. Similarly, MCoEeTI[K10R] retained inhibitory potency against trypsin, 
tryptase and matriptase with Ki values of 8.8, 28 and 158 nM, respectively. 
 
Interpretation of Ki values for truncated MCoTI cyclotides against tryptase 
and matriptase 
 
According to tryptase inhibition activity shown in Table 5.4 and Table 5.5, the 
reason for the observed tryptase inhibition can be envisaged as follows. As 
previously mentioned, human β-tryptase is a tetramer composed of four almost 
identical monomers, each of which contains its own active site and displays trypsin-
like structure (Pereira et al., 1998). The four active sites face a central elliptical 
pore, restricting the accessibility of inhibitor to fit within tryptase active site. 
Therefore, to prevent steric interaction (between negatively charged Asp within the 
mobile loop of MCoTI-II molecule and the protease surface), the MCoTI-II 
molecule was minimised by removing negatively charged Asp4 from mobile loop 
and also truncating some residues within the mobile loop.  
Cyclotides a.a. 
Inhibitory Activity 
Trypsin 
(nM) 
Tryptase 
(nM) 
Matriptase 
(nM) 
MCoTI-II[A24G, ∆SDDG, K10R] 30 18±4 10±0.6 N.I. 
MCoEeTI[R] 30 8.8±3 28±2 158±30 
     
This table shows inhibition results of truncated MCoTI-II cyclotides (MCoTI-II[A24G, ∆SDDG, K10R] 
and MCoEeTI[R], both of which were synthesized by replacing amino acid residue at P1 position from 
Lys to Arg to target against serine trypsin-like protease (trypsin, β-tryptase and matriptase) and assays 
were performed at 25°C similar to the method previously described in Chapter 4. 
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As a result of these changes, all truncated MCoTI-IIs exhibited tryptase inhibitory 
activity (Table 5.4) and it appears that the magnitude of inhibitory activity is 
significantly related to MCoTI-II size, as MCoTI-II[A24G, ∆SDGG] consisting of 
30 amino acid residues is found to be the most potent tryptase inhibitor in the series 
with a Ki  value of 9 nM, while wild-type MCoTI-II showed a mediocre tryptase 
inhibitory activity with a Ki value of 600 nM. It has already been demonstrated that 
tryptase inhibitory activity is governed by the characteristic of the mobile loop 
(Avrutina et al., 2008), as the presence of tripeptide (KKV) in place of SDG within 
the MCoEeTI mobile loop was found to result in 4×103 fold greater inhibition. This 
clearly shows that the characteristics of the mobile loop make a contribution to 
tryptase inhibitory activity.  
 
It is widely known that size and shape of an inhibitor can play a vital role in activity 
and is extremely important in designing tryptase inhibitors. The results reported in 
this thesis clearly indicate that inhibitor size is important; however, small size 
together with the requisite P1 residue is not the only factor required. As can be seen 
in Table 5.4 that MCoTI-II[A24G, ∆GSDGGV], which is the smallest truncated 
MCoTI in the series, shows relatively poor tryptase inhibition (Ki = 2000 nM), 
while the native MCoTI-II sequence, which is the largest tested, exhibits better 
potency (Ki = 600 nM). 
 
Optimal inhibition comes at an intermediate size that presumably represents the 
best compromise of reducing steric clashes while avoiding excessive distortion of 
the inhibitory loop (MCoTI-II[A24G, ∆SDGG]). 
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5.6 NMR Spectroscopy: The structure of the MCoTI-II cyclotides (wild-type 
and mutant MCoTI-II)  
 
Typically, proteins adopt a highly ordered structure in the cellular environment 
according to the nature of the substituents and the stereochemistry of the amino 
acids on the polypeptide chain (Cavanagh, 2007; Dobson, 2001). Indeed, the overall 
structure is strongly influenced by the order of each amino acid making up the 
polypeptide chain (Dobson, 2001). The α-carbons of each amino acid (except 
glycine) have the L-configuration and are separated by three covalent bonds 
arranged as Cα-C-N-Cα, and two bonds can rotate freely (N-Cα and Cα-C) as shown 
in Figure 5.2. 
 
 
Figure 5.2 The representation of the Phi (φ) and Psi (ψ) angles 
This illustration shows the Phi (φ) and Psi (ψ) angles of a peptide backbone; the grey area represents 
the peptide bond plane (Dobson, 2001). 
 
There are two important dihedral angles contributing to the formation of three 
dimensional structure of protein, namely φ (Phi) and ψ (Psi), both of which are 
greatly restricted by steric interference associated with the rotation. Generally, L-
amino acids prefer conformations in which φ is between -60° and -180°, while ψ 
favors either in the region of -60°, or in the region of +120° to +180°, depending on 
α 
ψ 
φ 
α 
α 
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the nature of the individual amino acids concerned. Generally, the common 
secondary structures observed in protein can be categorized into two major 
elements, α-helix and β-sheet; these each have a distinct and repeating set of 
dihedral angles. 
 
The α-helix has φ = -60°, ψ = -50° and is generated by linear hydrogen bonds 
formed between carbonyl oxygen (i) and the hydrogen atom of an amide group 
(i+4). All amino acids can adopt to be α-helix, except proline. β-Sheets have 
φ = -120°, ψ = +120° and are formed by hydrogen bonding between the carbonyl 
group and N-H of the amide group from two adjacent polypeptide chains. There are 
two arrangements: parallel (the strands run in the same direction) and or anti-
parallel (the strands run in opposite directions). Moreover, a β-turn is also one of 
the most important structures found in proteins, comprising of two anti-parallel 
strands connected by a short loop of two to five amino acids. Both β-sheet and β-
hairpin are the predominant structural elements observed in naturally occurring 
MCoTI-II (Felizmenio-Quimio et al., 2001).  
 
The structure elucidations of both naturally occurring MCoTI-II and MCoTI-
II[A24G, ∆SDGG] are of great interest mainly due to the unique cysteine knot 
scaffold observed in MCoTI-II cyclotides (discussed in Chapter 1). A prepared 
concentration of MCoTI proteins for NMR experiments required approximately 
1 mM sample in 90% D2O, and 10% H2O (v/v) at pH 3.5. The spectra were 
recorded at 298 K on a Bruker Avance 500 MHz spectrometer. The 2D-NMR 
experiments applied for this study were similar for both MCoTI-II and 
MCoT-II[A24G, ∆SDGG].  
 
In this thesis the structure of two cyclotides, MCoTI-II and MCoTI-II[A24G,  
∆SDGG] were elucidated by NMR spectrometry (1H-NMR, TOCSY and NOESY). 
Prior to NMR experiments, all MCoTIs cyclotides were generally purified by RP-
HPLC to confirm the purity, with detection at 220 nm, which corresponds to the 
maximum absorbance for the peptidic bond. Molecular weights [MCoTI-II (3453) 
and MCoTI-II[A24G, ∆SDGG] (3126)] were analysed by MALDI-MS 
spectrometry.    
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5.6.1 1H-NMR Spectroscopy: The Initial Analyses 
1H-NMR spectra of MCoTI-II and MCoTI-II[A24G, ∆SDGG] were analysed as 
shown in Figure 5.5 and Figure 5.6 (magnification), showing the amide region 
between 6-10 ppm. The extremely potent trypsin inhibitor MCoTI-II is 34 amino 
acids long, however two proline residues are included which do not give amide 
proton peaks. Therefore, thirty-two protons were expected to show in the amide 
proton region. However, it has also been suggested that a peptidic bond between 
Asp4 and Gly5 in the MCoTI-II sequence was likely to form succinimide and β-
aspartyl (Mergler, 2003) which might contaminate the MCoTI-II sample, resulting 
in complication of the MCoTI-II spectra, particularly in the sequential connectivity 
of TOCSY and NOESY spectra.  
 
Interestingly, both 1H and TOCSY and NOESY spectra of the synthetic MCoTI-II 
were found to be greatly similar to that previously published for natural MCoTI-II 
(Felizmenio-Quimio et al., 2001). It was therefore possible to use this information 
to assign the spectra. The fingerprint region of the 1H-NMR spectra of MCoTI-II 
was well-dispersed as illustrated in Figure 5.5 and Figure 5.6 which strongly 
facilitated the assignment of the TOCSY and NOESY spectra (the sequential 
correlation). The excellent dispersion of the amide region together with the well-
resolved cross-peaks of both TOCSY and NOESY spectra provided significant 
information for the sequential assignment. This in turn could then be applied to the 
structure elucidation of MCoTI-II and MCoTI-II[A24G, ∆SDGG].  
 
Further analyses were performed in which the 1H-NMR spectra were compared 
between MCoTI-II and MCoTI-II[A24G, ∆SDGG]. The wide dispersion of 
chemical shifts ranging from 6.3-9.3 ppm for the amide protons allowed the 
secondary structure of MCoTI-II and MCoTI-II[A24G, ∆SDGG] to be elucidated. 
Generally, the 3JHNHα coupling constants were found to be > 8Hz. All 3JHαHβ 
coupling constants were > 4Hz, or > 10Hz except for those involving the proline 
residues. It is interesting to note that the αH chemical shift comparison between 
MCoTI-II and MCoTI-II[A24G, ∆SDGG] strongly supports the conclusion that 
these proteins have significant similarity of their scaffolds (Table 5.6 and  
Table 5.7).  
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Table 5.6 The chemical shift comparison (αH) between naturally occurring MCoTI-II and MCoTI-
II[A24G, ∆SDGG] 
 
 
 
 
  
Residues 
No. 
Chemical shift (αH) 
Residues 
No. 
Chemical shift (αH) 
MCoTI-II Truncated MCoTI-II MCoTI-II 
Truncated 
MCoTI-II 
Ser (1) 4.40 4.15 Asp (18) 4.06 4.02 
Gly (2) 4.40 not observed Ser (19) 4.21 3.97 
Ser (3) 4.41 - Asp (20) 4.56 4.53 
Asp (4) 4.76 - Cys (21) 5.01 4.59 
Gly (5) 4.03 - Pro (22) - - 
Gly (6) 3.83 - Gly (23) 3.71 not observed 
Val (7) 3.95 4.23 Ala (24) 4.44 4.29 
Cys (8) 5.12 4.20 Cys (25) 4.53 not observed 
Pro (9) - - Ile (26) 4.33 4.23 
Lys (10) not observed not observed Cys (27) 4.51 4.77 
Ile (11) 4.31 4.23 Arg (28) 4.28 4.96 
Leu (12) 4.26 4.33 Gly (29) 3.87 3.80 
Lys (13) 4.51 4.48 Asn (30) 4.61 4.66 
Lys (14) 4.88 4.23 Gly (31) 3.60 3.88 
Cys (15) 4.81 4.76 Tyr (32) 5.20 5.18 
Arg (16) 4.38 4.30 Cys (33) 5.33 5.18 
Arg (17) 4.66 4.62 Gly (34) 4.50 4.29 
   
 
  
This table shows the chemical shift comparison between MCoTI-II and MCoTI-II[A24G, ∆SDGG]. 
Some residues in mobile loop (from residue 33 to 8) in MCoTI-II[A24G, ∆SDGG] shift upfield 
relative to MCoTI-II, and some residues did not show a cross peak such as Pro, etc.  
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Table 5.7 The chemical shift comparison (NH) between naturally occurring MCoTI-II and MCoTI-
II[A24G, ∆SDGG] 
 
 
  
Residues 
Residue 
No. 
Chemical shift (NH) 
Residues 
Residue No. 
Chemical shift (NH) 
MCoTI-II Truncated MCoTI-II MCoTI-II 
Truncated 
MCoTI-II 
Ser (1) 8.73 8.6 Asp (18) 9.37 9.21 
Gly (2) 9.03 not observed Ser (19) 8.12 8.19 
Ser (3) 8.59 - Asp (20) 7.62 7.64 
Asp (4) 8.51 - Cys (21) 8.03 8.08 
Gly (5) 8.14 - Pro (22) - - 
Gly (6) 8.02 - Gly (23) 8.41 not observed 
Val (7) 8.39 8.55 Ala (24) 8.35 8.24 
Cys (8) 8.61 8.43 Cys (25) 8.23 not observed 
Pro (9) - - Ile (26) 8.98 8.54 
Lys (10) not observed not observed Cys (27) not observed 8.86 
Ile (11) 7.65 7.49 Arg (28) 8.02 7.94 
Leu (12) 8.55 8.45 Gly (29) 8.82 8.8 
Lys (13) 8.82 8.71 Asn (30) 7.73 7.82 
Lys (14) 8.49 8.52 Gly (31) 8.33 8.28 
Cys (15) 8.35 8.31 Tyr (32) 7.21 7.21 
Arg (16) 9.22 9.32 Cys (33) 8.74 8.79 
Arg (17) 7.98 7.95 Gly (34) 9.69 9.62 
   
 
  
This table shows the chemical shift (NH) comparison between MCoTI-II and MCoTI-II[A24G, 
∆SDGG]. A slight chemical shift difference (0.05-0.15) is observed in many residues, and some 
residues did not show a cross peak such as Pro, etc.  
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Figure 5.3 Comparison of the chemical shifts (αH and HN) of the two cyclotides: MCoTI-II and 
MCoTI-II[A24G, ∆SDGG] 
 
A 
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Figure 5.3A shows αH chemical shift difference between MCoTI-II and MCoTI-II[A24G, 
∆SDGG]. A considerable chemical shift difference is observed in residues within mobile loop 
(loop6) from residue Cys33 to Cys8, including some residues; Lys14, Ser19, Cys21, Cys27 and 
Arg28. Figure 5.3B displays HN chemical shift difference between MCoTI-II and MCoTI-
II[A24G, ∆SDGG], showing a slight chemical shift difference (approximately 0.05 to 0.15) 
observed in many residues.  Truncated region = no Ser3-Gly6 sequence in MCoTI-II[A24G, 
∆SDGG],  =  missing signal. 
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The comparison of αH and HN chemical shifts of both MCoTI-II and  
MCoTI-II[A24G, ∆SDGG] are shown in Figure 5.3A and Figure 5.3B. Only minor 
chemical shift differences (αH) are observed throughout the molecule (less than 
±0.2) except for residues within or adjacent to loop 6 which show considerably 
greater chemical shift difference.  
 
The residues within mobile loop; Gly34, Ser1, Val7 and Cys8 displayed a markedly 
greater chemical shift difference (> ±0.2), probably due to changes in the overall 
conformation of the mobile loop resulting from the truncation of residues Ser3- 
Gly6. Interestingly, only slight αH chemical shift differences (less than ±0.1) are 
observed in residues within the inhibitory loop itself. This strongly suggests that the 
conformation of the inhibitory active site is unaffected by the truncation of the 
mobile loop. 
 
 
 
 
 
Figure 5.4 The presentation of perturbed residues in MCoTI-II molecule  
This picture shows the structure of MCoTI-II, and in the case of MCoTI-II[A24G, ∆SDGG] 
structure residue Ser3-Gly6 is truncated (labelled in red). The perturbations in chemical shift for 
residues within the mobile loop and some residues within loop 4; Cys27 and Arg28 in MCoTI-
II[A24G, ∆SDGG] are indicated        = the most perturbed residues [loop 6 (mobile loop) and loop 
4].  
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The large chemical shift differences observed for Cys27 and Arg28. As seen in 
Figure 5.4, the position of these residues is next to Cys25 that is linked to Cys8 
(via disulfide bond). Also, Cys27 is located in the smallest loop (loop 4), which 
might be greatly affected by the truncating four residues in mobile loop. 
 
Finally, it can be concluded that the inhibitory loop structure is conserved despite 
the four residues truncation in the mobile loop. As seen in Figure 5.3A and Figure 
5.3B, only slight chemical shift differences (both αH and HN) are observed within 
inhibitory loop. 1H-NMR spectra of MCoTI-II and MCoTI-II[A24G, ∆SDGG] are 
shown in Figure 5.5 and Figure 5.6. 
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Figure 5.5 1H-NMR spectrum for the synthetic MCoTI-II, which has the naturally occurring 
sequence 
 
A) 
 
 
 
 
 
B) 
 
 
 
 
The full 1D-1H NMR spectra is shown (A) and the expansion of the amide protons region of 
synthetic MCoTI-II is shown (B).  
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Figure 5.6 1H-NMR spectrum for the truncated MCoTI-II  
 
A) 
 
 
 
 
 
B) 
 
 
 
 
The full 1D-1H NMR spectra is shown (A) and the expansion of the amide protons region of the 
truncated MCoTI-II is shown (B).   
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5.6.2 Sequence-Specific Assignment 
The chemical shifts of all NH protons of the two proteins studied were identified, 
with the assistance of TOCSY and NOESY spectra. 
 
5.6.2.1 TOCSY Analyses 
Typically, the cross-peaks of TOCSY spectra are manifest only via through-bond 
interaction (scalar coupling), since protons cannot couple through the peptide bond 
(through space coupling) (Cavanagh, 2007). The characteristic pattern of each 
amino acid is greatly different largely depending on its specific environment, and 
especially on the number of carbons and protons within that residue. The 
connectivity diagrams of common amino acid residues are described in many 
sources (Cavanagh, 2007). Not all amino acid residues give unique patterns and 
several amino acids with the same patterns and in a similar environment were 
observed in MCoTI-II and MCoTI-II[A24G, ∆SDGG]. In particular, sequences 
such as serine and cysteine in which only the Hα and Hβ were connected are 
observed. In addition, leucine and isoleucine display very similar patterns, making 
discrimination between these two residues impossible by simple inspection. The 
three dimensional structure of MCoTI-II had been determined previously 
(Felizmenio-Quimio et al., 2001) and this provided the starting point for the 
structure assignment, using the known MCoTI-II scaffold. For example, the β-
hairpin observed between Ile26 and Gly34 residues has an interaction with the β-
sheet formed within the Lys13-Cys15 segment (shown in Figure 5.8B). This 
important feature has allowed us to further determine whether this arrangement is 
also found in the structure of MCoTI-II[A24G, ∆SDGG], as discussed in the next 
section. TOCSY spectra of both MCoTI-II and MCoTI-II[A24G, ∆SDGG] are 
displayed in Figure 5.7A and B, providing structural information regarding 
MCoTI-II. It was found that most cross-peaks shown in the TOCSY spectra of 
MCoTI-II were also found in that of MCoTI-II[A24G, ∆SDGG] despite a slight 
chemical shift difference observed in some residues as displayed in Figure 5.7A 
and B. 
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A) 
Figure 5.7 The representation of TOCSY spectra of MCoTI-II and MCoTI-II[A24G, ∆SDGG] 
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TOCSY spectrum of MCoTI-II in the amide proton region is shown (picture A) and TOCSY spectrum of MCoTI-II[A24G, ∆SDGG] in the amide protons region is 
shown (picture B). The signals corresponding to residues are shown along with the dotted red lines. The chemical shift of Arg17 and Arg28 in MCoTI-II[A24G, 
∆SDGG] is nearly identical and the position between Arg16 (      ) and Asp18 (       ) in MCoTI-II is inverse to that of MCoTI-II[A24G, ∆SDGG]. 
B) 
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Figure 5.7A and B show the fingerprint region of MCoTI-II and MCoTI-II[A24G, 
∆SDGG]. Both proteins show great similarity in terms of chemical shifts and cross 
peaks, even though four residues (Ser-Asp-Gly-Gly) of MCoTI-II within the mobile 
loop have been truncated. Nevertheless, some residues do not give discernable cross 
peaks and some residues have different chemical shifts to those of MCoTI-II. 
 
In addition, distinguishing between Arg17 and Arg28 was not possible due to them 
having identical NH proton chemical shifts. Proline residues were difficult to assign 
due to the inherent lack of NH protons. The identified residues of both MCoTI-II 
and truncated MCoTI-II are shown in Figure 5.7A and B. 
 
It was not possible to identify all residues from these two proteins on the basis of 
TOCSY specta alone, mainly due to the lack of the correlation information between 
two adjacent residues (Cavanagh, 2007; Dobson, 2001). Therefore, NOESY 
experiments have been applied to determine additional correlations between 
residues (Cavanagh, 2007). 
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5.6.2.2 NOESY Analyses 
NOESY spectra provide spatial information that is critical for sequential 
determination of structures, where two protons displaying NOESY cross-peaks are 
required to be separated by a distance of less than 5Å (Cavanagh, 2007; Dobson, 
2001). Importantly, the size of the NOE cross-peak is inversely correlated to the 
sixth power of the inter-nuclear separation. NOESY spectra can be used in 
conjunction with TOCSY spectra, but usually show a superset of peaks which 
include through-space coupling between protons of adjacent residues. This enables 
identification of the sequential correlation between Hα of one residue (i) and the 
HN of the residue nearby (i+1) as well as sequential HN-NH correlations. 
 
A schematically sequential identification of all assigned residues (MCoTI-II) is 
depicted in Figure 5.8.  
 
NMR structure of MCoTI-II 
NOESY spectra analyses of MCoTIs have allowed the three dimensional structure 
of MCoTI cyclotides to be elucidated and the sequential correlation was assigned as 
illustrated in Figure 5.8A. Along a vertical line, the cross-peaks corresponded to all 
residues that correlate with the NH proton (i), whether through-bond or through-
space coupling. Horizontal lines reveal the sequential correlation between the HN 
(i+1) and Hα (i) in which the sequential correlation was initially numbered from the 
Gly34 residue. It is important to note that the total correlation between the NH-Hα 
region, Hα-Hα region and NH-NH region allowed not only the sequential backbone 
correlation of MCoTI-II sequences assigned, but could also be applied to determine 
the three dimensional structure of MCoTI-II and MCoTI-II[A24G, ∆SDGG] in 
which the additional cross-peaks compared to those from the TOCSY spectrum 
corresponded to through space correlation.  
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A) 
Figure 5.8 The sequential connectivity of MCoTI-II NOESY spectra 
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In picture A, the sequential connectivity in the αH-NH region of MCoTI-II is shown. The schematic 
representation of the β-sheet and β-turn region of MCoTI-II and NH-NH correlation of NOESY 
spectra of MCoTI-II is shown in picture B (pink). 
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The sequential connectivity of MCoTI-II as assigned from the NOESY spectra is 
depicted in Figure 5.8A and B and it was also found that the β-hairpin observed 
between Ile26 and Gly34 residues associates with the β-sheet element (residue 
Lys13-Cys15) via a hydrogen bond interaction. This unique feature has been 
regarded as a predominant characteristic of MCoTI-II’s three dimensional structure 
(as shown in Figure 5.8B). 
 
Indeed, it is known that the cyclic structure of MCoTI-II is linked by three disulfide 
bonds to generate the corresponding six loops, each of which has significantly 
different characteristics in terms of size and amino acid composition, described as 
follows (Felizmenio-Quimio et al., 2001). Firstly, the inhibitory loop (loop 1) which 
is known as one of the most important loops in the MCoTI-II scaffold, is formed 
between Cys I and Cys II, comprising the putative active site, with residues Lys and 
Ile at the P1 and P1’ residues, respectively. The high content of positively charged 
residues observed within this loop 1 is believed to have a significant role in the 
inhibition activity (Avrutina et al., 2008). Loop 4, which is the smallest loop, is 
formed between Cys IV and Cys V, and only one amino acid in this loop is 
associated with the β-strand element (within loop 5). Loop 5 has been regarded as 
the major characteristic in the MCoTI-II scaffold in which a type I β-turn is located 
(Felizmenio-Quimio et al., 2001). This major characteristic would possibly be 
observed in MCoTI-II[A24G, ∆SDGG]. Lastly, loop 6 is known to be the most 
flexible loop and contains a high Gly content. A small number of corresponding 
NOEs cross-peaks was observed in loop 6 relative to the other loops. Therefore, the 
use of NOE’s cross-peak correlation within loop 6 to verify an accuracy of three 
dimensional structure of MCoTI-II[A24G, ∆SDGG] was limited. 
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NMR structure of MCoTI-II[A24G, ∆SDGG] 
The NMR structure of MCoTI-II[A24G, ∆SDGG] was determined by using the 
sequential assignment process assisted by NOESY spectra as shown in Figure 5.9. 
The identified NOESY spectrum of MCoTI-II compared to that of MCoTI-
II[A24G, ∆SDGG] has allowed the corresponding connectivity of MCoTI-II[A24G, 
∆SDGG] to be identified.  
 
As illustrated in Figure 5.9A, the sequential correlation of MCoTI-II[A24G, 
∆SDGG] was started at Gly34 residue which continued to Cys33 and so on. It was 
also found that some residues that did not reveal the cross-peaks which correlated to 
the adjacent residue, which could prevent the identification of the MCoTI-II[A24G, 
∆SDGG] sequence. The sequential correlation of MCoTI-II[A24G, ∆SDGG] is 
shown in Figure 5.9A and B. 
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A) 
Figure 5.9 The sequential connectivity of MCoTI-II[A24G, ∆SDGG] NOESY spectra 
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The sequential connectivity in the αH-NH region of MCoTI-II[A24G, ∆SDGG] NOESY spectra is 
shown (picture A). The schematic representation of the β-sheet and β-turn region of MCoTI-
II[A24G, ∆SDGG] and NH-NH correlation of NOESY spectra of MCoTI-II[A24G, ∆SDGG] is 
shown in picture B (pink). 
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As seen in Figure 5.9B, the unique β-hairpin element has also been observed in 
MCoTI-II[A24G, ∆SDGG]. The details of given correlations are described as 
follows: the corresponding hydrogen bond formed between NH protons of Arg28 
and Tyr32 forms the β-hairpin and the β-sheet is generated by hydrogen bonding 
formed between NH protons of Ile26 and Gly34, including Arg28 and Tyr32. 
Furthermore, this β-hairpin was also associated with other segments (Lys14-
Arg16).  
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Summary  
In this chapter, truncated MCoTI-IIs have been synthesised successfully with the 
use of thia-zip assisted native chemical ligation. In this synthesis the length of the 
mobile loop in the MCoTI-II scaffold was also varied in order to target β-tryptase. 
All truncated MCoTI-IIs were assessed for inhibitory activity and it was found that 
truncated MCoTI-II in which four amino acids from the mobile loop were removed, 
MCoTI-II[A24G, -SDGG], had the greatest tryptase inhibition activity with a Ki of 
9 nM, and was the most potent tryptase inhibitor in the series. This implied that 
only appropriately sized truncated MCoTI-II together with abolished interaction 
between Asp4 and tryptase surface can give a strong tryptase inhibitor, as compared 
to those with a larger or smaller mobile loop which show only a slight inhibitory 
activity in the low micromolar region. 
 
In addition, the synthesis of a novel cysteine knot hybrid MCoTI-II/EETI, named as 
MCoEeTI has been successfully achieved. Previously, this moderately potent 
tryptase inhibitor was reported as a linear cysteine knot protein, and in the present 
case the macrocyclisation of linear MCoEeTI was carried out with the use of a thia-
zip assisted native chemical ligation. Cyclised MCoEeTI was found to have 
improved tryptase inhibition activity, with a Ki value of 33 nM. Additionally, both 
MCoTI-II[A24G, -SDGG] and MCoEeTI scaffolds have been re-engineered via 
substitution of the amino acid at the P1 residue to the positively charged Arg, and 
the resulting MCoTI-II[A24G, -SDGG, K10R] and MCoEeTI[R] retained tryptase 
inhibitory activity, with Ki values of 10, and 28 nM respectively. 
 
Lastly, the structure of MCoTI-II[A24G, -SDGG] has been studied with the use of 
1D and 2D NMR techniques and it was found that the characteristic β-turn 
observed in MCoTI-II is also present in the MCoTI-II[A24G, -SDGG] structure. It 
is interesting to note that MCoTI-II[A24G, -SDGG] has retained a similar fold to 
that of wild-type MCoTI-II although four residues were truncated. 
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6.1 Conclusions and Perspectives 
  
The major objective of this thesis was to explore the first total synthesis of 
macrocyclic cysteine knot microproteins (MCoTI-I and MCoTI-II) isolated from 
the seeds of the plant Momordica cochenchinensis, both of which exhibited an 
exceptionally potent trypsin inhibition with Ki values in the subnanomolar range 
(Avrutina et al., 2005; Felizmenio-Quimio et al., 2001). The cysteine knot scaffold 
formed by the arrangement of three disulfide bonds in which two disulfides form a 
ring that is penetrated by the third disulfide bond is a unique characteristic observed 
in cyclotides, and is of significant importance to their stabilities; both thermal and 
proteolytic (Colgrave & Craik, 2004; Heitz et al., 2008). 
 
In this thesis, syntheses and evaluation of inhibitory activity of MCoTI cyclotides 
against a panel of serine proteases have been investigated. This includes 
measurement of inhibitory activities against medically important serine proteases; 
such as β-tryptase, matriptase, hepatitis C virus and human leukocyte elastase, etc. 
 
6.1.1 Synthetic Methodology for MCoTI Cyclotides  
 
Two complementary approaches have been developed successfully for the first total 
synthesis of MCoTI-I and MCoTI-II cyclotides via thia-zip NCL (Chapter 2) and 
biomimetic strategies (Chapter 3). The former strategy relies on a series of 
intramolecular rearrangements in which N-terminal cysteine, C-terminal thioester 
and at least one free internal thiol are required. This synthetic strategy involves 
three major stages: the amino acid backbone assembly, ring closing macrolactam 
via native chemical ligation (NCL) and refolding to the native cysteine knot. First, 
the amino acid assembly for the peptidyl thioester synthesis was achieved by using 
Fmoc strategy. Ring closing native chemical ligation proceeded smoothly in the 
presence of excess tricarboxyethylphosphine (TCEP) to confer head-to-tail cyclic 
backbone followed by the formation of disulfide bond in the presence of 
glutathione (Thongyoo et al., 2008; Thongyoo et al., 2006).  
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Conditions applied to thia-zip assisted cyclisation strategy have been optimised via 
combining cyclisation and refolding steps in a one-pot reaction in the presence of 
glutathione, affording a correctly folded MCoTI-I and II (Thongyoo et al., 2008). It 
is important to note that the conditions used in this strategy are significantly milder 
than that of the Boc strategy reported previously by Tam (Tam et al., 1999b). This 
synthetic strategy was subsequently applied to the synthesis of MCoTI-II 
analogues.  
 
The biomimetic strategy (protease-mediated cyclisation) required synthesis of the 
requisite Ile11(P1’)-Lys10(P1) C-terminal acid peptide backbone which was 
subsequently refolded, and cyclised by protease. This biomimetic strategy involves 
three important stages; the assembly of C-terminal acid peptide backbone, the 
oxidative folding and protease-mediated cyclisation. First, an unprotected backbone 
peptide bearing a C-terminal lysine (the P1 residue) acid was assembled (for 
MCoTI-I and II syntheses) according to Fmoc SPPS protocol to yield oc-MCoTIs 
acids. Then, oc-MCoTI acids were refolded in the presence of glutathione, 
affording cysteine-knot peptide followed by protease-mediated cyclisation. 
Importantly, we have discovered that only correctly folded material is cyclised by 
proteases. 
 
This result clearly indicated that the protease-mediated strategy relies not only on 
the requisite P1 residues, Arg or Lys (for trypsin mediated cyclisation), or Phe (for 
chymotrypsin mediated cyclisation), but also on the folding of the cysteine knot 
peptide. Moreover, on-bead cyclisation for cyclotide syntheses by using trypsin 
immobilised on Sepharose beads (polymer-supported trypsin, PST) and polymer 
supported chymotrypsin (PSC) has been developed. This has the great advantage 
that contamination through autocleavage from the protease itself is greatly 
suppressed. These immobilised proteases were further applied as an efficient 
polymer-suppported ligase for clean MCoTI macrocyclisation, which combined 
macrocyclisation and purification in one pot. They were also applied to the 
syntheses of MCoTI-II analogues in which the P1 residue was switched into a 
positively charged residue Arg (MCoTI-II[R]) or hydrophobic residue Phe 
(MCoTI-II[F]).  
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6.1.2 Inhibition results of MCoTI cyclotides  
 
An inhibitory activity against a panel of trypsin-like serine proteases of MCoTI 
cyclotides has been evaluated, including trypsin, chymotrypsin and medically 
important serine proteases such as β-tryptase, matriptase, FMDV 3Cpro and human 
leukocyte elastase. MCoTI-I and II are among the most potent trypsin inhibitors in 
the series, with Ki values of 29±2 pM and 75±5 pM respectively. MCoTI-II[R] was 
the only re-engineered MCoTI-II in the series to show potent trypsin inhibiton, with 
a Ki value of 85±7 pM, while MCoTI-II[F] exhibited chymotrypsin inhibitory 
activity, with a Ki value of 9.8±0.7 nM and it was the only cyclotide in the series to 
display potent chymotrypsin inhibition.  
 
In addition, MCoTI-I and II and some of re-engineered MCoTI-IIs were also active 
against medically important serine proteases. MCoTI-I, MCoTI-II and MCoTI-
II[R] were active against β-tryptase, with Ki values of 1.6±0.14 µM, 0.6±0.03 µM 
and 0.12±0.05 µM, and against matriptase, with Ki values of 155±31 nM, 9±1 nM 
and 158±46 nM respectively. In contrast, MCoTI-II[A] and MCoTI-II[V] were only 
active against human leukocyte elastase (HLE) with Ki values of 32±13 nM, 21±7 
nM respectively, and appeared to be among the most potent HLE inhibitor in the 
series. MCoTI-II[AVP] was the only cyclotide in the series to show inhibitory 
activity against hepatitis C virus NS3/4A, though the inhibition was only slight (Ki 
> 50 µM). MCoTI-II[AKQ] and MCoTI-II[Q] were active against the cysteine 
protease (chymotrypsin-like fold) FMDV 3Cpro with Ki values of 56±35 µM and 
41±25 µM, respectively. 
 
According to the inhibitory activities of MCoTI cyclotides against the panel of 
serine proteases tested, it is clearly found that inhibitory activity can be re-directed 
towards an alternative protease via only replacing the single amino acid at the 
requisite P1 residue.  
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6.1.3 Size minimisation of MCoTIs 
 
Further investigations were performed to see whether it was possible to minimise 
the size of the MCoTI-II scaffold as it has been reported that inhibitor size is one of 
the most important factors affecting tryptase inhibitory activity (Scarpi et al., 2002; 
Scarpi et al., 2004). Minimized MCoTI-II was therefore synthesised by truncating 
some amino acids within the mobile loop, and the variants evaluated in terms of 
their inhibitory activities against trysin, tryptase and matriptase. Interestingly, all 
truncated MCoTI-II cyclotides were active against both trypsin and β-tryptase with 
Ki values in the range of nanomolar region. MCoTI-II[A24G, ∆SDGG] was found 
to be the most active inhibitor against tryptase in the series with a Ki value of 9±0.5 
nM. This potent inhibitory activity was attributed to result from minimised steric 
interaction (between the tryptase surface and inhibitor at Asp4, and an appropriately 
sized inhibitor that better fitted into the tryptase active site. 
 
The cyclic motif was found to contribute to protease inhibitory activity. Cyclic 
cysteine knot MCoEeTI showed greater protease inhibitory activities against 
trypsin, tryptase and matriptase compared to ck-MCoEeTI (linear cysteine knot) 
with Ki values of 45±5 nM, 33±7 nM and 380±3 nM, while the linear cysteine knot, 
ck-MCoEeTI showed lesser inhibitory activities against trypsin, tryptase and 
matriptase with Ki values of 99±9 nM, 110±9 nM and >2500 nM respectively. 
 
According to the structure elucidation of MCoTI-II[A24G, ∆SDGG], the great 
similarity of both TOCSY and NOESY spectra compared to MCoTI-II suggests 
that MCoTI-II[A24G, -SDGG] have retained a similar structure despite having four 
residues truncated.   
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7.1 Materials and Methods 
All general laboratory chemicals obtained from chemical suppliers (Novabiochem 
UK or Aldrich Chemical Co.) were used without further purification. Peptides were 
synthesised using an Advanced ChemTech Apex 396 multiple peptide synthesiser 
(Advanced Chemtech Europe, Cambridge, UK). Purification of crude peptides was 
performed on a Gilson semi-preparative RP-HPLC system (Anachem Ltd., Luton, 
UK) equipped with 306 pumps and a Gilson 155 UV/Vis detector. Analytical RP-
HPLC was performed on a Gilson analytical HPLC system (Anachem Ltd., Luton, 
UK) equipped with a Gilson 151 UV/Vis detector and Gilson 234 auto injector.  
For both HPLC systems, the peptide bond absorption was detected at 223 nm.  
 
Preloaded Wang resin, 4-Sulfamylbutyryl AM resin and 2-Chlorotrityl resin were 
purchased from Novabiochem UK. The resin substitution ratios were shown as 
follows: Fmoc-Lys(Boc)-Wang: 0.69 mmol/g; Fmoc-Phe-Wang: 0.74 mmol/g; 
Fmoc-Gln(Trt)-Wang: 0.62 mmol/g; Fmoc-Arg(Pbf)-Wang: 0.51 mmol/g; 2-
Chlorotrityl resin: 1.4 mmole/g; 4-Sulfamylbutyryl AM resin: 1.1 mmol/g  
 
N-α-9-Fluorenylmethoxycarbonyl (N-α-Fmoc) protected amino acid were obtained 
from Novabiochem UK with the following side chain protecting groups. Ala, 
Arg(Pbf), Asn(Trt), Asp(tBu), Cys(Trt), Gly, Ile, Leu, Lys(Boc), Pro, Ser(tBu), 
Tyr(tBu), Val and Fmoc-Asp(OtBu)-(Hmb)Gly-OH were purchased from 
Novabiochem UK.  
 
Peptide synthesis grade dimethylformamide (DMF) was purchased from Rathburn 
Chemicals UK and AGCT bioproducts. Benzotriazole-1-yl-oxy-tris-pyrrolidino-
phosphonium hexafluorophosphate (PyBop), 1,3 Dicyclohexylcarbodiimide (DCC), 
N-hydroxybenzotriazole (HOBt), diisopropylethylamine (DIPEA) and 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) were 
purchased from Novabiochem UK and Sigma Aldrich. Dry tetrahydrofuran (THF) 
and DMF, chloroform, dimethylsulfoxide (DMSO), dichloromethane (DCM),  
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methanol, piperidine, thioanisole, t-butylmethylether (TBME), trifluoroacetic acid 
(TFA), ethanedithiol (EDT), iodoacetonitrile, ethyl-3-mercapto propionate, sodium 
thiophenolate, monobasic and dibasic sodium phosphate, trimethylsilylisopropane 
(TIPS) were reagent grade from Sigma Aldrich.  
 
Immobilised TPCK-trypsin was purchased from Pierce bioscience,  
α-chymotrypsin (enzyme attached to carboxymethyl cellulose), human leukocyte 
elastase, subtilisin carlsberg, porcine pancreatic elastase were purchased from 
Sigma, β-tryptase was purchased from Promega products, NS3-NS4A (HCV) was 
purchased from Alexis chemicals and human matriptase was purchased from 
Axxora chemicals. 
 
7.1.1 Loading of Sulfamylbutylryl AM resin with Fmoc-Ala-OH and Fmoc-
Gly-OH 
 
Sulfamylbutyryl AM resin (250 mg, 0.172 mmol) was swelled in DMF (3 mL) for  
1 hr at ambient temperature. To this solution were added Fmoc-Ala-OH (268 mg, 
0.86 mmol) and DIPEA (264 µl, 1.6 mmol). The reaction mixture was left to stir for 
15 min followed by cooling to -20°C for 20 min. Then PyBOP (447 mg, 
0.86 mmol) was added and the reaction mixture stirred for 8 hrs at -20°C. The 
reaction mixture was then left to warm to ambient temperature overnight. The resin 
was recovered by filtration and washed with DMF (3 × 2 mL). The coupling was 
repeated using the same procedure and washed with DMF (3 × 2 mL), DCM (3 × 
2 mL) and MeOH (3 × 2 mL), respectively. The loaded resin was dried in vacuo. 
The coupling efficiency was assessed as follows: typically 2 mg of thoroughly-
dried resin (or peptidyl resin) was incubated with a solution of 1 mL of 20 % 
piperidine in DMF, and left for 1 hr. The solution was then filtered and the filtrate 
measured for its absorbance at 290 nm or 301 nm (ε290nm = 5800 M-1cm-1, ε301nm = 
7800 M-1cm-1) against a blank of 20 % piperidine in DMF. The loading efficiency 
was ~ 81 %. 
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7.1.2 Loading of 2-Chlorotrityl resin with Fmoc-Nva-OH 
Fmoc-Nva-OH (475 mg, 1.4 mmol, 2 eq) was dissolved by DCM (5 mL) following 
by the addition of DIPEA (478 µL, 2.8 mmol, 4 eq). To this solution was added by 
2-Chlorotrityl resins (500 mg, 0.7 mmol) under nitrogen atmosphere and stirred the 
reaction mixture for 120 min. The resin was washed with DMF (3×1 mL), DCM 
(3×1 mL) and diethyl ether (3×1 mL), respectively. The resin was dried in vacuo 
and the loading of resin was estimated by Fmoc test (Method 7.11). Loading 
efficiency was > 80 %. 
 
7.1.3 Deprotection Mixture Preparation Protocol 
A mixture of TFA:H2O:EDT:TIPS (94:2.5:2.5:1) was used for cleavage and 
deprotection steps. 
 
7.1.4 Solid Phase Peptide Synthesis 
Peptide synthesis was carried out in peptide synthesis grade DMF. Resin preloaded 
with the appropriate Fmoc-protected amino acid (25 µmole per well) was swelled in 
DMF for 60 min before coupling each cycle, N-α-amino acid was treated with 20 
% (v/v) piperidine in DMF for 15 min, with two further repetitions. A five fold 
excess of amino acid over resin (125 µmole, 250 µL of 0.5 M solution) was used 
for each coupling. In situ activation and coupling was carried out for 45 min with a 
mixture of HBTU/HOBt (125 µmole, 250 µL of 0.5 M solution) and DIPEA (125 
µmole, 250 µL of 0.5 M solution). The peptide was washed with DMF (3×1 mL) 
between each deprotection and coupling step. A typical cycle consisted of 
deprotection, DMF wash, coupling and a further DMF wash. The N-α-Fmoc 
protection at the final residue was removed at the end of the synthesis under the 
usual condition. After synthesis was completed, the fully protected peptide bound 
resin was removed from the synthesiser, washed several times (3×2 mL DMF, 3×2 
mL DCM, 3×2 mL MeOH) and dried in vacuo. For oc-MCoTI thioester syntheses, 
Asp21Gly20 was introduced as a dipeptide (Fmoc-Asp(OtBu)-(Hmb)Gly-OH) and 
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coupled for 2 hrs. Cys34 was introduced as Boc-Cys(Trt)-OH for oc-MCoTI 
thioester syntheses. 
 
7.1.5 Activation and Displacement from Sulfamyl Resin 
This synthetic procedure was adapted from (Backes & Ellman, 1999). 
 
Activation Protocol:  
Fully protected MCoTI bound to sulfamyl resin (25 µmole) was swelled in 1.5 mL 
of dry NMP for 1 hr. To this solution was added DIEPA (200 µL, 1.1 mmole) 
followed by excess iodoacetonitrile (180 µL, filtered through basic alumina prior to 
use). The reaction flask was shielded from light and agitated for 24 hrs at ambient 
temperature. The resin was washed with NMP (5×5 mL), DCM (5×5 mL), MeOH 
(5×5 mL) and dried in vacuo.  
 
Displacement Protocol:  
To the activated resin was added a small amount of sodium thiophenolate (1.6 mg), 
ethyl-3-mercaptoproprionate (160 µL, 1.25 mmol) and DMF (500 µL). The reaction 
mixture was agitated overnight at ambient temperature. The resin was filtered and 
the filtrate was evaporated to dryness in vacuo to yield fully protected MCoTI 
thioester, which was subsequently treated with deprotection mixture (2 mL) over 3 
hrs to give the corresponding oc-MCoTI thioester. Deprotection, precipitation and 
purification were described in Method 7.1.6 and 7.1.7. 
 
7.1.6 Deprotection and Cleavage from Wang resin 
Cleavage and deprotection of peptides were achieved by adding 1.5 mL of 
deprotection mixture to dry peptide bound Wang resin (25 µmole). The mixture 
was agitated on an orbital shaker for up to 3 hrs (30 min for 2-Chlorotrityl resin) 
and then filtered. The resin was washed twice with a small volume of TFA and the 
combinded washing and filtrated were precipitated with 10 mL ice cold tert-butyl 
methyl ether (TBME). The mixture was centrifuged at 3500 rpm for 20 min at 0°C, 
the supernatant discarded and the remaining peptide washed with a fresh aliquot of 
TBME. The process was repeated three times to ensure complete removal of all 
    
 Chapter 7 Experimental section 
199 
 
organic impurities. The crude product was dried in a desicator over silica gel to 
yield an off-white solid. 
 
7.1.7 Peptide Purification 
A small sample of crude peptide was analysed by analytical preparative RP-HPLC 
before purifying by preparative HPLC. The mobile phases contained 0.1 % HPLC-
grade TFA as an ion pairing agent and were degassed with Helium. Peptide 
purification was achieved by using preparative reverse-phase HPLC using a 
HICHROM C18 Column (250 × 21.2). Individual fractions from preparative 
reverse-phase HPLC were analysed by using analytical reverse-phase HPLC, and 
pure fractions combinded and diluted to < 10 % MeCN with deionised water. The 
peptide was obtained as a white solid after lyophilisation on a Christ Alpha 2-4 
freeze dryer (Osterode am Harz Germany). Mass identification by Matrix-Assisted 
Laser Desorption/Ionisation Time of Flight Mass Spectrometry (MALDI-TOF MS) 
was performed by using α-cyano-4-hydroxy cinnamic acid as matrix. The 
following elution methods were used: Method A: 20 to 50% MeCN in H2O over 
40 min; Method B: 0 to 85% MeCN in H2O over 40 min; Method C: 2 to 98% 
MeCN in H2O over 20 min. All peptides and reaction mixtures were analysed using 
Method B unless otherwise specified 
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7.2 The Cyclotide Synthesis: Thia-zip native chemical ligation pathway  
7.2.1 Synthesis of Peptidyl Thioesters 
oc-MCoTI-I, II thioesters and analogues syntheses were carried out as previously described in Section 7.1.4, 7.1.5 and 7.1.6.  
 
oc-MCoTI Thioesters 
Peptide sequence: H-CICRGNGYCG34S1GSDGGVCPX1ILX2X3CRRDSDCPGA-S(CH2)2COOEt 
Name 
 
X1 
 
X2 X3 Double coupled residues Yield (%) 
MALDI-MS 
(calculated) 
MALDI-MS (found) Retention time     
(Rt): Method B 
oc-MCoTI-I thioester K Q R Val7 5.6 3621 3622[M+H]+ 14.8 
oc-MCoTI-II thioester K K K Ile11, Lys10 and Val7 5.4 3593 3594[M+H]+, 1798[M+2H]2+ 14.35 
oc-MCoTI-II [R] thioester R K K Ile11, Arg10 6.8 3621 3622[M+H]+ 14.1 
oc-MCoTI-II [F] thioester F K K Ile11, Phe10 4 3612 3613[M+H]+, 1807[M+2H]2+ 15.4 
oc-MCoTI-II [Q] thioester Q K K Ile11, Gln10 4.2 3593 3593[M]+ 14.55 
oc-MCoTI-II [AKQ] thioester AKQ K K Ile13, Gln12, Lys11, Ala10 4.8 3792 3793[M+H]+, 1897[M+2H]2+ 14.44 
 
 
    
 Chapter 7 Experimental section 
201 
 
  
oc-MCoTI Thioesters 
Peptide sequence: H-CICRGNGYCG34S1GSDGGVCX1X2X3LKKCRRDSDCPGA-S(CH2)2COOEt 
Name 
 
X1 
 
X2 X3 Double coupled residues 
Yield 
(%) 
MALDI-MS 
(calculated) 
MALDI-MS (found) Retention time (Rt): 
Method B, C* 
oc-MCoTI-II [A] thioester P A I Ile11, Ala10 4.3 3536 3537[M+H]+, 1769[M+2H]2+ 14.77 
oc-MCoTI-II [V] thioester P V I Ile11, Val10  4.2 3565 3566[M+H]+, 1783[M+2H]2+ 14.60 
oc-MCoTI Thioesters 
Peptide sequence: H-CICRGNGYCG34S1GSDGGVCX1X2X3LKKCRRDSDCPGA-S(CH2)2COOMe 
oc-MCoTI-II [AVP] thioester A V P Pro11, Val10 4.8 3508 3509[M+H]+, 1754[M+2H]2+ 10.10* 
oc-MCoTI-II [PVP] thioester P V P Pro11, Val10 3.8 3534 3535[M+H]+, 1768[M+2H]2+ 10.16* 
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oc-truncated MCoTI Thioesters 
Peptide sequence: H-CICRGNGYCG34S1GSDGGVCPX1ILKKCRRDSDCPGG-S(CH2)2COOEt 
Name 
 
X1 
 
Double coupled residues Yield 
(%) 
MALDI-MS 
(calculated) 
MALDI-MS (found) Retention time     
(Rt): Method B, C* 
oc-MCoTI-II[A24G, ∆SDGG] thioester, or oc-MCoTI 
-II[A24G, ∆S3D4G5G6] thioester 
K Ile11, Lys10 3 3263 3264[M+H]+, 1632[M+2H]2+ 10.2* 
oc- MCoTI-II[A24G, ∆SDGG, K10R] thioester, or  
oc-MCoTI-II[A24G, ∆S3D4G5G6, K10R] thioester  
R Ile11, Arg10  4 3291 3292[M+H]+, 1647[M+2H]2+ 10.2* 
oc-MCoTI-II[A24G, ∆DG] thioester, or oc-MCoTI 
-II[A24G, ∆D4G5] thioester 
K Ile11, Lys10 2 3407 3407[M]+ 15 
oc-MCoTI-II[A24G, ∆SDGGV] thioester, or oc-MCoTI 
-II[A24G, ∆S3D4G5G6V7] thioester 
K Ile11, Lys10 5 3164 3165[M+H]+ 14 
oc-MCoTI-II[A24G, ∆GSDGGV] thioester, or oc-
MCoTI-II [A24G, ∆G2S3D4G5G6V7] thioester 
K Ile11, Lys10 0.5 3106 3107[M+H]+ 13 
Peptide sequence: H-CVCGPNGFCG34S1GVCPX1ILKKCRRDSDCLAG-S(CH2)2COOMe 
oc-MCoEeTI thioester K Ile7, Lys6, Val3 7 3189 3190[M+H]+, 1595[M+2H]2+ 10.9* 
Peptide sequence: H-CVCGPNGFCG34S1GVCPX1ILKKCRRDSDCLAG-S(CH2)2COOEt 
oc-MCoEeTI [R] thioester R Ile7, Arg6, Val3 3 3232 3233[M+H]+, 1616[M+2H]2+ 11.0* 
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7.2.2 Synthesis of MCoTI-I, II and analogues via Thia-zip NCL 
Glutathione (0.3 mg, 1 µmole) was dissolved in 1 mL of 0.1 M carbonate buffer. 
This solution was added to oc-MCoTI thioester (0.28 µmole), which was dissolved 
in 1 mL of acetonitrile and the reaction mixture was left for 24 hrs at room 
temperature. The reaction mixture was then diluted 2-fold in water and purified by 
preparative RP-HPLC using Method A. Fractions were collected and analysed by 
analytical HPLC using Method B, C*. Pure fractions were pooled and lyophilized 
to yield the cyclotide product. 
 
Synthesised cyclotides via Thia-zip NCL 
Cyclotides MALDI-MS 
(calculated) 
MALDI-MS (found) Yield 
(%) 
Retention time     
(Rt): Method B, C* 
MCoTI-I 3481 3482[M+H]+, 1741[M+2H]2+ 68 12.3 
MCoTI-II 3453 3454[M+H]+, 1727[M+2H]2+ 72 11.5 
MCoTI-II [R] 3482 3483[M+H]+, 1742[M+2H]2+ 72 11.8 
MCoTI-II [F] 3472 3473[M+H]+, 1737[M+2H]2+ 64 15.2 
MCoTI-II [Q] 3454 3455[M+H]+, 1727[M+2H]2+ 64 12.5 
MCoTI-II [AKQ] 3652 3653[M+H]+, 1827[M+2H]2+ 71 11.7 
MCoTI-II [A] 3397 3398[M+H]+, 1699[M+2H]2+ 63 10.15* 
MCoTI-II [V] 3426 3427[M+H]+, 1713[M+2H]2+ 64 10.25* 
MCoTI-II [AVP] 3383 3384[M+H]+ 65 10* 
MCoTI-II [PVP] 3408 3409[M+H]+ 76 10* 
MCoTI-II[A24G, 
∆DG] 
3267 3268[M+H]+ 58 11.28 
MCoTI-II[A24G, 
∆SDGG] 
3124 3125[M+H]+, 1563[M+2H]2+ 60 9.5* 
MCoTI-II[A24G, 
∆SDGGV] 
3024 3025[M+H]+ 70 10.7* 
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Synthesised cyclotides via Thia-zip NCL 
Cyclotides MALDI-MS 
(calculated) 
MALDI-MS (found) Yield 
(%) 
Retention time     
(Rt): Method B, C* 
MCoTI-II[A24G, 
∆GSDGGV] 
2966 2967[M+H]+ 69 11* 
MCoTI-II [A24G, 
∆SDGG, K10R] 
3151 3152[M+H]+, 1576[M+2H]2+ 67 9.5* 
MCoEeTI 3064 3065[M+H]+, 1533[M+2H]2+ 53 10.2* 
MCoEeTI [R] 3093 3094[M+H]+, 1548[M+2H]2+ 60 10.3* 
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7.3 The Cyclotide Synthesis: Immobilised protease assisted cyclisation pathway  
7.3.1 Synthesis of oc-MCoTI Acids 
oc-MCoTI-I, II acid and analogues syntheses were achieved as previously described in Section 7.1.4 and 7.1.6 
oc-MCoTI acids 
Peptide sequence: H-ILX2X3CRRDSDCPGACICRGNGYCG34S1GSDGGVCPX1-OH 
Name 
 
X1 
 
X2 X3 Double coupled residues Yield (%) 
MALDI-MS (found) MALDI-MS 
(calculated) 
Retention time     
(Rt): Method B, 
C* 
oc-MCoTI-I acid K Q R Ala24, Gly23 6.5 3507[M+H]+, 1754[M+2H]2+ 3506 12.36 
oc-MCoTI-II acid K K K Ala24, Gly23 and Ile11 12.7 3478[M+H]+ 3477 12.3 
oc-MCoTI-II [R] acid R K K Ala24, Gly23 and Ile11 7.4 3505[M]+ 3505 12.0 
oc-MCoTI-II [F] acid F K K Ala24, Gly23 and Ile11 10 3497[M+H]+ 3496 14.4 
oc-MCoTI-II [Q] acid Q K K Ala24, Gly23 and Ile11 4.6 3478[M+H]+, 1739[M+2H]2+ 3477 12.25 
oc-MCoTI-II [AKQ] acid AKQ K K Ala26, Gly25 and Ile13 4.6 3676[M]+ 3476 10.17 
oc-MCoEeTI acid 
Peptide sequence: H-VCPX1ILKKCRRDSDCLAGCVCGPNGFCG34S1G-OH 
oc-MCoEeTI acid K - - Ile7, Lys6, Val3 8 3088[M+H]+ 3087 10.45* 
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7.3.2 Synthesis of refolded MCoTIs 
oc-MCoTI acid was dissolved in 1 mL of 0.1 M carbonate buffer. To this solution 
was added by glutathione (0.3 mg, 1 µmole) which was dissolved in 1 mL of 
acetonitrile. The reaction mixture was allowed for overnight at room temperature, 
then diluted 2-fold in water and purified by preparative RP-HPLC using Method A. 
Fractions were collected, analysed by using Method B, C on the analytical HPLC, 
pooled and lyophilised, respectively.  
 
Refolded MCoTIs 
Sequence: H-ILX1X2CΙΙRRDSDCΙΙΙPGACΙVICVRGNGYCVΙGSGSDGGVCΙPX1-OH 
Cyclotides MALDI-MS 
(calculated) 
MALDI-MS (found) Yield 
(%) 
Retention time     
(Rt): Method B, C* 
rf-MCoTI-I 3499 3501[M+H]+ 72 10.5 
rf-MCoTI-II 3471 3472[M+H]+, 1737[M+2H]2+ 65 10.4 
rf-MCoTI-II[R] 3499 3500[M+H]+, 1751[M+2H]2+ 59 10.5 
rf-MCoTI-II[F] 3490 3491[M+H]+, 1746[M+2H]2+ 64 12.2 
rf-MCoTI-II[Q] 3472 3473[M+H]+, 1736[M+2H]2+ 60 10.63 
rf-MCoTI-II[PAKQ] 3670 3671[M+H]+ 36 12.3 
rf-MCoEeTI  3081 3082[M+H]+ 52 9.7* 
 
 
7.3.3 Immobilised protease assisted cyclotide syntheses  
 
Immobilised trypsin assisted cyclisation:  
Immobilised trypsin (500 µL of re-suspended beads) was washed with 0.1 M 
phosphate buffer (5×1 mL, pH 7.4) before use. rf-MCoTI peptide (0.03 µmole) was 
dissolved in 500 µL of 0.1 M phosphate buffer pH 7.4. To this solution was added 
with immobilised trypsin. The reaction mixture was incubated at 37°C for 15 min, 
mixed on a vortex mixture for 10 s and centrifuged at 14000 rpm for 5 min. The 
supernatant was removed from immobilised trypsin, which was subsequently 
washed with water (5×1 mL); the reaction mixture was mixed and centrifuged as 
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above at each washing. 0.1% TFA in water was added, and mixed on a vortex 
mixer and left to stand for 5 min. The supernatant was recovered, and this 
procedure was repeated (at least 2 times). The combined TFA washing were 
analysed by analytical HPLC and MALDI MS. 
 
Immobilised Chymotrypsin assisted cyclisation:  
The reaction was performed exactly as for immobilised trypsin, except that 25 mg 
immobilised chymotrypsin was weighted out and washed as above and the 
incubation time was typically 15 min. 
 
Sequence: H-ILKKCΙΙRRDSDCΙΙΙPGACΙVICVRGNGYCVΙGSGSDGGVCΙPX-OH 
Cyclotides  
Lys10 = [X] MALDI-MS 
Retention 
time     (Rt): 
Method B 
Yield (%) 
PST 
Cyclotides 
PSC 
Cyclotides 
MCoTI-I 3482[M+H]+ 12.3 93 - 
MCoTI-II 3454[M+H]+ 11.5 92 - 
MCoTI-II[R] 3481[M]+ 11.8 94 - 
MCoTI-II[F] 3474[M+H]+ 15.2 - 90 
 
    
 
 
7.4 MCoTI-II Synthesis: Immobilised protease assisted cyclisation pathway 
(with selective disulfide bond formation pathway) 
 
7.4.1 Synthesis of partially protected MCoTI-II acid 
 
H-ILKKCRRDSDC(Acm)PGAC(Acm)ICRGNGYC(Acm)GSGSDGGVC(Acm) 
PK-OH 
                                                   
 
Partially protected MCoTI-II acid (7.4.1) was synthesised as described previously 
in Section 7.1.4 and 7.1.6 and Fmoc-Cys(Acm)-OH was used if specified. 
 
(7.4.1) 
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7.4.2 Disulfide Bridge Formation (DMSO oxidation) between Cys(II)-Cys(V) 
 
H-ILKKC I IRRDSDC I I I (Acm)PGAC IV (Acm)ICVRGNGYCV I(Acm)GSGSDGG 
VC I(Acm)PK-OH  
    
                                          (7.4.2)  
                                                  
oc-partially protected MCoTI-II acid (7.4.1) oxidation was carried out by dissolving 
0.5 mg of oc-partially protected MCoTI-II acid (7.4.1) with 2 mL the solution of 
20% DMSO (v/v), 5% AcOH (v/v) at pH 6. The reaction mixture was left for 24 hrs 
at room temperature, diluted ten-fold with water and purified by RP-HPLC using 
Method A. Fractions were collected, analysed using Method B, pooled and 
lyophilised. The resulting product was obtained with excellent yield  
(> 80 %, Rt (Method B): 11.9, MALDI-MS (calculated): 3761, MALDI-MS 
(found): 3762[M+H]+). 
 
7.4.3 Disulfide Bridge Formation (Iodine oxidation) 
 
H-ILKKCΙΙRRDSDCΙΙΙPGACΙVICVRGNGYCVΙGSGSDGGVCΙPK-OH 
 
misfolded MCoTI-II acid (7.4.3) or misfolded rf-MCoTI-II 
 
 
2 mg of oc-partially protected MCoTI-II acid (7.4.2) was dissolved in 1 mL of 
AcOH: H2O (4:1) solution. To this solution was then added by iodine (1.35 mg, 10 
eq.) and stirred for 24 hrs at room temperature to yield misfolded MCoTI-II acid 
(7.4.3). The reaction mixture was quenched by adding 2-fold water and extracted I2 
with CHCl3 (× 6 times). The aqueous fraction was subsequently purified by 
preparative HPLC and lyophilized respectively, to give white solid of misfolded 
MCoTI-II acid with moderate yield (60%, Rt (Method B): 11.48, MALDI-MS 
(calculated): 3471, MALDI-MS (found): 3472[M+H]+ ). 
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7.4.4 The Synthesis of Correctly Folded MCoTI-II acid 
 
H-ILKKCΙΙRRDSDCΙΙΙPGACΙVICVRGNGYCVΙGSGSDGGVCΙPK-OH 
 
Correctly folded MCoTI-II acid (7.4.4): Cys(I)-Cys(IV), Cys(II)-Cys(V) and Cys(III)-Cys(VI) 
 
 
 
Misfolded MCoTI-II acid (20 mg, 5.8 µmole) was dissolved in 1 mL of 0.1 M 
carbonate buffer, which was dissolved by glutathione (0.3 mg, 1 µmole). The 
reaction mixture was allowed for overnight at room temperature, then diluted 2-fold 
in water and purified by preparative RP-HPLC using Method A. Fractions were 
collected, analysed by using Method B on the analytical HPLC, pooled and 
lyophilised, respectively. The correctly folded MCoTI-II acid was obtained with 
excellent yield (75%, Rt (Method B): 10.4, MALDI-MS (calculated): 3471, 
MALDI-MS (found): 3472[M+H]+). 
 
 
7.5 Synthesis of Hepatitis C Virus [HCV (NS3/4A)] Substrate  
 
The synthetic strategy of HCV (NS3/4A) substrate was adapted from that of (Zhang 
et al., 1999). 
 
Ac-DTEDVVPNva-OHMC (7.5) 
 
 
7.5.1 Synthesis of HCV (NS3/4A) Substrate  
 
H-D(tBu)T(tBu)E(tBu)D(tBu)VVPNva-O-Chlorotrityl resin (7.5.1) 
 
The peptide backbone synthesis was assembled as previously described in Section 
7.1.4 by using preloaded Fmoc-Nva-OH Trityl resin. The loading protocol was 
described in Section 7.1.2.  
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7.5.2 Acetic Anhydride Capping  
 
Ac-D(tBu)T(tBu)E(tBu)D(tBu)VVPNva-O-Chlorotrityl resin (7.5.2) 
 
Fully protected peptidyl resin (7.5.1) (25 µmol) was swelled with DMF for 60 min. 
Acetic anhydride (0.2 mL), DIPEA (0.1 mL) and DMF (0.7 mL) were added to the 
peptidyl-resin and left for 2 hrs. The solution was then filtered off. The capped 
peptidyl-resin was washed with DMF (3×1 mL), DCM (3×1 mL) and diethyl ether 
(3×1 mL), and dried in vacuo 
 
7.5.3 The Cleavage of Peptide from 2-Chlorotrityl resin 
 
Ac-D(tBu)T(tBu)E(tBu)D(tBu)VVPNva-OH (7.5.3) 
 
Fully protected peptidyl resin (7.5.2) was treated with 1 mL of deprotection mixture 
(1% TFA in DCM) and left the reaction for 30 min. The solution was filtered off 
and precipitated with water. The mixture was centrifuged at 3500 rpm for 20 min at 
4°C and washed with water (3×1 mL). The N-acetylated peptidyl acid (7.5.3) was 
dried by lyophilisation. The fully protected peptide (7.5.3) was obtained as white 
solid (20%, Rt (Method C): 14.63, MALDI-MS (calculated): 1139, MALDI-MS 
(found): 1162[M+Na]+). 
 
7.5.4 The Esterification of N-Acetylated Peptidyl Acid with 7-HMC 
 
  Ac-DTEDVVPNva-OHMC (7.5) 
 
Fully protected peptidyl acid (7.5.3) (5 mg, 4.4 µmole) was dissolved by anhydrous 
pyridine (100 µL). To this solution was added by 7-hydroxy-4-Methyl Coumarin 
(7.7 mg, 44 µmmole), a catalytic amount of p-toluene sulfonic acid (0.09 mg, 0.44 
µmole, 0.1 eq.) and dicyclohexylcarbodiimide (2.72 mg, 13.2 µmole, 3 eq.) and 
then left for overnight. The reaction mixture was evaporated to dryness and 
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precipitated with water. The reaction mixture was centrifuged at 3500 rpm for 20 
min at 4°C, washed with water (3×1 mL) and dried by lyophilsation, respectively.  
 
Esterified peptide was treated with 1.5 mL of deprotection mixture (95% TFA in 
DCM). The reaction mixture was evaporated to dryness, extracted with diethyl 
ether (3×2.5 mL) and purified by preparative RP-HPLC. Pure fractions were 
combined, pooled and lyophilised, respectively. The peptide (7.5) was obtained as a 
white solid (0.6 mg, 1.25 %, MALDI-MS (calculated): 1075, MALDI-MS (found): 
1098[M+Na]+). 
 
7.6 Protease concentration determination 
For Ki determination, proteases were determined an activity, prior to conducting 
enzyme assay. Trypsin and chymotrypsin activities have been calculated by active 
site titration by means of initial burst kinetics (Jaulent, 2004). p-Nitrophenyl acetate 
and p-nitrophenyl-p’-guanidinobenzoate were used as substrate for measuring 
chymotrypsin and trypsin activities, respectively where p-nitrophenol was released 
when trypsin and chymotrypsin were acylated. p-Nitrophenol concentration was 
corresponding to the active enzyme.  
 
Typical experimental procedure: 
50 µM of p-nitrophenol-p’-guanidinobenzoate (for trypsin assay) or 50 µM of p-
nitrophenyl acetate (for chymotrypsin) solution was prepared in DMF. A range of 
proteases (trypsin or chymotrypsin) was prepared in 0.1 M phosphate buffer at pH 8 
by varying concentration from 50 to 10 µM. 10 µL of substrate was added to 
protease solution (990 µL), mixed and measured the absorbance immediately at 410 
nm. 
  
    
 Chapter 7 Experimental section 
212 
 
 
7.7 Cyclotide concentration determination 
Cyclotide concentration did not determine directly from weighting. Titration with 
trypsin and standard addition method were used for measuring cyclotide 
concentration accurately. The measurement of absorbance at 280 nm was also 
employed for cyclotide concentration determination. The detail is shown as follows    
 
Titration with trypsin:  
This strategy was adapted from (Avrutina et al., 2005) 
 
The concentration determination of MCoTI-I, II and R was determined by using 
trypsin titration. The procedure is shown as follows; A range of cyclotide 
concentration (1 µM to 0.1 nM, 50 µL) in TBS pH 7.6 (Tris buffered saline: 50 mM 
Tris-HCl, 150 mM NaCl, 0.01% Tritron-X-100, 0.02% sodium azide) was 
incubated with trypsin (25 nM, 50 µL) for 30 min at 37°C in a 96-well plate 
(Falcon MicrotestTM 96). Carbobenzoxy-L-arginine-7-amino-4-methyl coumarin 
(75 µM, 100 µL) was added to this solution and the absorbance measured at room 
temperature with excitation and emission wavelengths at 360 and 465 nm, 
respectively. The concentration of active cyclotide was determined from the 
inhibition curves obtained in two separate experiments assuming a 1:1 interaction 
between inhibitor and trypsin. 
 
Measuring the absorbance at 280 nm: 
MCoTI possessing Trp, Tyr and disulfide bond can be calculated the concentration 
by measuring the absorbance at 280 nm, in quartz cuvette where the MCoTI 
concentration depends on the content of Trp, Tyr and disulfide bond. The molar 
extinction coefficient at 280 nm was reported as following: Trp (5500 M-1cm-1), Tyr 
(1490 M-1cm-1) and disulfide bond (125 M-1cm-1).  
 
A standard addition method:  
Certain MCoTI-IIs did not possess Trp and Tyr residues on the sequence and 
displayed a relatively low inhibition against trypsin. A standard addition method 
was applied to determine the cyclotide concentration by using analytical HPLC.  
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A standard addition graph from an exceptionally potent trypsin inhibition of 
MCoTI-I, II and [R] was then plotted by varying a range of cyclotide 
concentrations (200 µM to 10 µM) versus peak area measured at 223 nm and, by 
comparison of peak areas, used to determine the cyclotide concentration of MCoTI-
II [A], [V], [F], [Q] and [PAKQ], including truncated MCoTI-IIs. 
 
7.8 Inhibition Kinetics 
All inhibition kinetics were determined by competitive binding assays at 37°C on a 
Cytofluor series 400 microplate reader (Perseptive Biosystem, Warrington, UK), 
using Falcon microtestTM 96-well plates.  
 
7.8.1 Trypsin and Chymotrypsin Assays  
These assays were adapted from (Avrutina et al., 2005) 
 
50 mM TBS, 150 mM NaCl, 0.01 % Triton X-100, 0.01 % NaN3, pH 7.6 was 
prepared for trypsin and chymotrypsin assays. The equilibrium dissociation 
constant (Ki) for the complex between trypsin or chymotrypsin and the cyclotide 
was determined by using enzyme concentrations lower than Ki. Protease (0.005 nM, 
50 µL for trypsin or 0.5 nM, 50 µL for chymotrypsin) was thus incubated with a 
range of inhibitor concentrations (1 nM to 0.01 pM, 50 µL for trypsin and 70 nM to 
0.05 pM, 50 µL for chymotrypsin) in TBS for 1 hr. The measurement was started 
by the addition of substrate: N-p-tosyl-Gly-Pro-Arg-7-Amido-4-Methyl Coumarin 
(5 µM, 100 µL) for trypsin assay and Suc-Ala-Ala-Pro-Phe-7-Amido-4-Methyl 
Coumarin (10 µM, 100 µL) for chymotrypsin assay. The initial rate of substrate 
hydrolysis was monitored by the cleavage of AMC from substrate at an excitation 
of 360 nm and emission of 460 nm. Initial rate data were then fitted to determine Ki 
using the GraFit Software package (http://www.erithacus.com/grafit). All assays 
were reproduced 3 times with fresh solutions of all reagents, and the standard 
deviation is given where appropriate. 
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7.8.2 Tryptase Assay  
This assay was adapted from (Scarpi et al., 2004) 
 
0.05 M TBS, 0.15 M NaCl, Heparin 55 µgmL-1, pH 7.6 was prepared for tryptase 
assay. The equilibrium dissociation constant (Ki) was determined as trypsin and 
chymotrypsin assays. Tryptase (1 nM, 50 µL) was incubated with a range of 
inhibitor concentrations (5 µM to 0.1 nM, 50 µL) in TBS for 30 min. The 
measurement was started by the addition of N-p-tosyl-Gly-Pro-Arg-7-Amido-4-
Methyl Coumarin (7.5 µM, 100 µL). The initial rate of substrate hydrolysis was 
monitored by the cleavage of AMC from substrate at an excitation of 360 nm and 
emission of 460 nm. Initial rate data were then fitted to determine Ki using the 
GraFit Software package (http://www.erithacus.com/grafit). Assays were 
reproduced 3 times with fresh solutions of all reagents.  
 
7.8.3 Human Leukocyte Elastase (HLE) and Porcine Pancreatic Elastase 
(PPE) Assays:  
This assay was adapted from (McBride et al., 1999) 
 
0.10 M TBS, 0.5 M NaCl, pH 7.5 was prepared for HLE and PPE assays. The 
equilibrium dissociation constant (Ki) was determined as follows. HLE (1.25 nM, 
50 µL), or PPE (6.25 nM, 50 µL) was incubated with a range of inhibitor 
comcentrations (5 µM to 0.1 nM, 50 µL) in TBS for 1 hr. The measurement was 
started by the addition of MeO-Suc-Ala-Ala-Pro-Val-7-Amido-4-Methyl Coumarin 
(25 µM, 100 µL) for HLE assay, or Ac-Ala-Ala-Pro-Ala-7-Amido-4-Methyl 
Coumarin (25 µM, 100 µL) for PPE assay. The initial rate of substrate hydrolysis 
was mornitored by the cleavage of AMC from substrate at an excitation of 360 nm 
and emission of 460 nm. Initial rate data were then fitted to determine Ki using the 
GraFit Software package (http://www.erithacus.com/grafit). Assays were 
reproduced 3 times with fresh solutions of all reagents. 
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7.8.4 Thrombin and Subtilisin Assays: 
50 mM TBS, 150 mM NaCl, 0.01 % Triton X-100, 0.01 % NaN3, pH 7.6 was 
prepared for thrombin and subtilisin assays. The equilibrium dissociation constant 
(Ki) was determined by incubating protease (1 nM, 50 µL for thrombin or 12.5 nM, 
50 µL for subtilisin) with a range of inhibitor concentrations (50 µM to 5 nM, 50 
µL) in TBS for 1 hr. The measurement was started by the addition of substrate: N-
p-tosyl-Gly-Pro-Arg-7-Amido-4-Methyl Coumarin (5 µM, 100 µL) for thrombin 
assay and Suc-Ala-Ala-Pro-Phe-7-Amido-4-Methyl Coumarin (10 µM, 100 µL) for 
subtilisin assay. The initial rate of substrate hydrolysis was monitored by the 
cleavage of AMC from substrate at an excitation of 360 nm and emission of 460 
nm. Initial rate data were then fitted to determine Ki using the GraFit Software 
package (http://www.erithacus.com/grafit). All assays were reproduced 3 times 
with fresh solutions of all reagents. 
 
7.8.5 FMDV 3Cpro Assay  
This assay was adapted from (Jaulent et al., 2007) 
 
100 mM Phosphate buffer (Na2PO4:NaH2PO4), 1 mM TCEP, 1 mM EDTA, 5% 
glycerol was prepared for FMDV 3Cpro assay. The equilibrium dissociation constant 
(Ki) was determined by incubating FMDV 3Cpro (617 nM, 50 µL) with a range of 
inhibitor concentrations (125 µM to 100 nM, 50 µL) in Phosphate buffer for 30 
min. The measurement was started by the addition of substrate: DABCYL-Ala-Pro-
Ala-Lys-Qln-Leu-Leu-Asp(EDANS)-Phe-asp-Leu-Leu-Lys-OH (50 µM, 100 µL). 
The initial rate of substrate hydrolysis was monitored by the increasing of 
fluorescence at 460 nm. Initial rate data were fitted to determine Ki by using the 
GraFit Software package (http://www.erithacus.com/grafit). All assays were 
reproduced 3 times with fresh solutions of all reagents. 
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7.8.6 Matriptase Assay 
This assay was adapted from (Li et al., 2007) 
 
100 mM TBS, Bovine Serum Albumin (BSA) 100 mgmL-1, pH 8.5 was prepared 
for Matriptase assay. The equilibrium dissociation constant (Ki) was determined as 
follows. Matriptase (0.25 nM, 50 µL) was incubated with a range of inhibitor 
concentrations (10 µM to 0.1 nM, 50 µL) in TBS buffer for 30 min. The 
measurement was started by the addition of substrate: N-p-tosyl-Gly-Pro-Arg-7-
Amido-4-Methyl Coumarin (5 µM, 100 µL). The initial rate of substrate hydrolysis 
was monitored by the cleavage of AMC from substrate at an excitation of 360 nm 
and emission of 460 nm. All data were fitted to determine Ki by using the GraFit 
Software package (http://www.erithacus.com/grafit). All assays were reproduced 3 
times with fresh solutions of all reagents.  
 
7.8.7 Hepatits C virus (HCV) Assay 
This assay was adapted from (Zhang et al., 1999)  
 
25 mM Mops, 300 mM NaCl, 10% glycerol, 0.05% lauryl maltoside, 5 µM EDTA, 
and 5 µM DTT at pH 8.5 was prepared for HCV assay. The equilibrium 
dissociation constant (Ki) was determined as follows. HCV [NS3/NS4A] (3 nM, 50 
µL) was incubated with a range of inhibitor concentrations (7 µM to 7 nM, 50 µL) 
for 30 min. The measurement was started by the addition of substrate (7.5): Ac-
Asp-Thr-Glu-Asp-Val-Val-Pro-Nva-7-Hydroxy-4-Methyl Coumarin (37.5 µM, 100 
µL). The initial rate of substrate hydrolysis was monitored by the cleavage of AMC 
from substrate at an excitation of 360 nm and emission of 460 nm. All data were 
fitted to determine Ki by using the GraFit software package 
(http://www.erithacus.com/grafit). All assays were reproduced 3 times with fresh 
solutions of all reagents. 
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7.9 Structure Determination 
Samples prepared for NMR spectroscopy contained ~ 0.1 mM MCoTI-II (or 0.4 
mM of MCoTI-II[A24G, -SDGG] in 1:9 (H2O/D2O) with 0.1 % aqueous TFA at 
pH 3.3. 1 and 2D NMR spectra recorded at 293 K. 
 
7.10 MALDI sample preparation  
MALDI Matrix ingradient: MALDI Matrix was prepared by dissolving α-cyano-
4-hydroxycinnamic acid (10 mg) in ethanol (495 µL), acetonitrile (495 µL) and 
0.1% TFA (10 µL). All cyclotide samples were prepared by mixing 1 µl of sample 
solution with 1 µl of MALDI matrix and then spotted 1 µL of solution mixture to 
the MALDI plate. 
 
7.11 Fmoc Test  
The coupling efficiency was assessed as follows: typically 2 mg of thoroughly-
dried resin (or peptidyl resin) was incubated with a solution of 1 mL of 20 % 
piperidine in DMF, and left for 1 hr. The solution was then filtered and the filtrate 
measured for its absorbance at 290 nm or 301 mm (ε290nm = 5800 M-1cm-1, ε301nm  
= 7800 M-1cm-1) against a blank of 20% piperidine in DMF. 
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8.1 Amino Acid Nomenclature 
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8.1 Amino Acid Nomenclature (Continued) 
 
Lysine 
(Lys, K) 
Methionine 
(Met, M) 
Proline 
(Pro, P) 
Serine 
(Ser, S) 
Threonine 
(Thr, T) 
Phenylanine 
(Phe, F) 
Thyptophan 
(Trp, W) Tyrosine (Tyr, Y) 
Valine 
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Norvaline 
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  N° Residue No. 
Chemical shift (ppm) 
N° Residue No. 
Chemical shift (αH) 
NH Hα Others (Hβ, Hγ, Hδ and Hε) NH Hα Others (Hβ, Hγ, Hδ and Hε) 
1 Ser 8.73 4.44 3.86(Hβ) 18 Asp 9.37 4.06 2.87(Hβ) 
2 Gly 9.03 4.35, 
3.81 
- 19 Ser 8.12 4.21 3.76-4.06(Hβ) 
3 Ser  8.59 4.41 3.83(Hβ) 20 Asp 7.62 4.56 2.93(Hβ) 
4 Asp  8.51 4.76 2.91(Hβ) 21 Cys 8.03 5.01 2.6-2.73(Hβ) 
5 Gly  8.14 4.03, 3.76 - 
22 Pro Not observed - 
6 Gly  8.01 3.83 - 23 Gly 8.41 3.71 - 
7 Val  8.39 3.95 1.91(Hβ), 0.8(γCH3) 24 Ala 8.35 4.44 1.26(Hβ) 
8 Cys  8.61 5.12 2.78(Hβ) 25 Cys 8.23 4.53 3.13(Hβ) 
9 Pro  Not observed - 26 Ile 8.98 4.33 1.8(Hβ), 0.8(γCH3 and δCH3) 
10 Lys  Not observed - 27 Cys Not observed - 
11 Ile  7.65 4.31 1.72(Hβ), 1.3-1.5(Hγ), 0.9(γCH3),  0.7 (δCH3) 
28 Arg 8.02 4.28 1.7(Hβ), 1.35(Hγ), 3.08(Hδ) 
12 Leu  8.55 4.26 1.6(Hβ), 1.45(Hγ), 0.86(δCH3) 29 Gly 8.82 3.87 - 
13 Lys 8.82 4.51 1.5(Hβ), 1.33(Hγ), 1.67(Hδ) 30 Asn 7.73 4.61 2.81-3.28(Hβ) 
14 Lys  8.49 4.88 1.5(Hβ), 1.4(Hγ), 2.42(Hδ) 31 Gly 8.33 3.6-3.9 - 
15 Cys  8.35 4.81 3.11(Hβ) 32 Tyr 7.21 5.18 2.54-3.12(Hβ), 6.6(3,5H), 6.8(2,6H) 
16 Arg  9.22 4.38 1.82(Hβ), 1.56(Hγ), 3.1(Hδ) 33 Cys 8.74 5.33 2.72-2.99(Hβ) 
17 Arg  7.98 4.66 1.5(Hβ), 1.35(Hγ), 3.08(Hδ) 34 Gly 9.69 4.5-3.9 - 
 
  
 
 
 
 
 
 
 
8.1 1H chemical shifts of MCoTI-II 
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N° Residue No. 
Chemical shift (ppm) 
N° Residue No. 
Chemical shift (αH) 
NH Hα Others (Hβ, Hγ, Hδ and Hε) NH Hα Others (Hβ, Hγ, Hδ and Hε) 
1 Ser 8.60 4.15 3.58(Hβ) 18 Asp 9.21 4.02 2.73(Hβ) 
2 Gly 
Truncated 
region 
 19 Ser 8.19 3.97 3.73(Hβ) 
3 Ser   20 Asp 7.64 4.53 2.75-3.18(Hβ) 
4 Asp   21 Cys 8.08 4.59 2.97-3.32(Hβ) 
5 Gly   22 Pro Not observed - 
6 Gly   23 Gly Not observed - 
7 Val  8.55 4.23 1.75(Hβ), 0.72(γCH3) 24 Gly 8.24 4.29 - 
8 Cys  8.43 4.20 4.1-3.97(Hβ) 25 Cys Not observed - 
9 Pro  Not observed  26 Ile Not observed - 
10 Lys  Not observed  27 Cys 8.86 4.77 2.42-2.70(Hβ) 
11 Ile  7.49 4.23 1.67(Hβ), 1.52(Hγ), 0.72(γCH3), 1.0(δCH3)  
28 Arg 7.94 4.96 2.36(Hβ), 1.55(Hγ), 4.23(Hδ) 
12 Leu  8.45 4.33 1.46(Hβ), 1.34(Hγ), 0.59(δCH3)  29 Gly 8.8 3.8 - 
13 Lys 8.71 4.48 1.30(Hβ), 1.51(Hγ), 1.66(Hδ) 30 Asn 7.82 4.66 3.05-3.45(Hβ) 
14 Lys  8.52 4.23 1.20(Hβ), 1.3(Hγ), 1.5(Hδ) 31 Gly 8.28 3.58, 3.88 - 
15 Cys  8.33 4.76 2.87-3.09(Hβ) 32 Tyr 7.21 5.18 2.5-2.9(Hβ) 
16 Arg  9.32 4.30 1.52-1.63(Hβ), 1.78(Hγ), 3.09(Hδ) 33 Cys 8.79 5.18 2.89-3.0(Hβ) 
17 Arg  7.95 4.62 1.33-1.44(Hβ), 1.69(Hγ), 3.18(Hδ) 34 Gly 9.62 3.89, 4.29 - 
 
  
 
 
  
 
 
 
8.1 (continued) 1H chemical shifts of MCoTI-II[A24G, ∆SDGG] 
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